Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
(12S)hydroperoxy-5,8-cis-10-trans-13-cis-eicosatetraenoic acid + O2
(5S,12S)-dihydroperoxy-5,8-cis-10-trans-13-cis-eicosatetraenoic acid
-
22% of the activity with arachidonic acid
-
?
(15S)-hydroperoxy-5,8,11-cis-13-trans-eicosatetraenoic acid + O2
(5S,15S)-dihydroperoxy-5,8,11-cis-13-trans-eicosatetraenoic acid
-
30% of the activity with arachidonic acid
-
?
(5S,6E,8Z,11Z,14Z)-5-hydroperoxyicosa-6,8,11,14-tetraenoate
(5S,6S,7E,9E,11Z,14Z)-5,6-epoxyicosa-7,9,11,14-tetraenoate + H2O
(5Z,8Z,10E,12S,14Z)-12-hydroxyicosa-5,8,10,14-tetraenoic acid + O2
?
-
-
-
-
?
(6E,8Z,11Z,14Z)-(5S)-5-hydroperoxyeicosa-6,8,11,14-tetraenoate
leukotriene A4 + H2O
(6E,8Z,11Z,14Z)-(5S)-hydroperoxyicosa-6,8,11,14-tetraenoate + O2
leukotriene A4
1-linoleoyl lysophosphatidic acid + O2
(S)-hydroperoxy 1-linoleoyl lysophosphatidic acid
-
i.e. linoleoyl-lysoPA
major product
-
?
1-linoleoyl lysophosphatidylcholine + O2
(S)-hydroperoxy 1-linoleoyl lysophosphatidylcholine
-
i.e. linoleoyl-lysoPC
major product
-
?
11,14,17-eicosatrienoic acid + O2
?
-
-
-
-
?
15S-hydroperoxyeicosatetraenoic acid + O2
lipoxin A4
-
-
-
?
2',7'-dichlorodihydrofluorescein diacetate + O2
2',7'-dichlorofluorescein
-
-
-
-
?
2',7'-dichlorodihydrofluorescein diacetate + O2
?
-
development of a fluorescence assay for 5-LOX, overview
-
-
?
5,8,11,14,17-eicosapentaenoic acid + O2
?
5,8,11-eicosatrienoic acid + O2
?
-
almost as active as arachidonic acid
-
-
?
5-hydroperoxyeicosatetraenoic acid
leukotriene A4 + H2O
-
-
is unstable and metabolized to leukotriene B4
-
?
7,7-d2-arachidonate + O2
7-d-(5S,6S,7E,9E,11Z,14Z)-5,6-epoxyicosa-7,9,11,14-tetraenoate + H2O
analysis of the product distribution reveals that 5-LOX displays a reversal of selectivity to bypass abstracting the deuterium atom from C7
-
-
?
8,11,14-eicosatrienoic acid + O2
?
arachidonate + O2
(5S,6E,8Z,11Z,14Z)-5-hydroperoxyicosa-6,8,11,14-tetraenoate
arachidonate + O2
(5S,6S,7E,9E,11Z,14Z)-5,6-epoxyicosa-7,9,11,14-tetraenoate + H2O
arachidonate + O2
(5Z,8Z,11Z,13E)-(5S)-5-hydroperoxyicosa-5,8,11,13-tetraenoate
-
-
-
?
arachidonate + O2
(6E,8Z,11Z,14Z)-(5S)-5-hydroperoxyicosa-6,8,11,14-tetraenoate
arachidonate + O2
(6E,8Z,11Z,14Z)-(5S)-hydroperoxyicosa-6,8,11,14-tetraenoate
arachidonic acid + O2
(5S,6E,8Z,11Z,14Z)-5-hydroperoxyeicosa-6,8,11,14-tetraenoate
-
-
-
-
?
arachidonic acid + O2
(6E,8Z,11Z,14Z)-(5S)-5-hydroperoxyeicosa-6,8,11,14-tetraenoate
arachidonic acid + O2
5-hydroperoxyeicosatetraenoic acid
-
-
-
-
?
bishomo-gamma-linolenic acid + O2
?
-
-
-
-
?
docosahexaenoic acid + O2
?
-
-
-
-
?
homo-gamma-linolenic acid + O2
8-L-hydroxy-9,11,14-eicosatrienoic acid
-
-
-
?
linoleic acid + O2
(9Z,11E)-(13S)-13-hydroperoxyoctadeca-9,11-dienoate
-
-
-
-
?
linoleic acid + O2
9-hydroperoxyoctadecadienoic acid
additional information
?
-
(5S,6E,8Z,11Z,14Z)-5-hydroperoxyicosa-6,8,11,14-tetraenoate
(5S,6S,7E,9E,11Z,14Z)-5,6-epoxyicosa-7,9,11,14-tetraenoate + H2O
epoxidation
-
-
?
(5S,6E,8Z,11Z,14Z)-5-hydroperoxyicosa-6,8,11,14-tetraenoate
(5S,6S,7E,9E,11Z,14Z)-5,6-epoxyicosa-7,9,11,14-tetraenoate + H2O
-
epoxidation
-
-
?
(5S,6E,8Z,11Z,14Z)-5-hydroperoxyicosa-6,8,11,14-tetraenoate
(5S,6S,7E,9E,11Z,14Z)-5,6-epoxyicosa-7,9,11,14-tetraenoate + H2O
epoxidation
-
-
?
(6E,8Z,11Z,14Z)-(5S)-5-hydroperoxyeicosa-6,8,11,14-tetraenoate
leukotriene A4 + H2O
-
-
is unstable and metabolized to leukotriene B4
-
?
(6E,8Z,11Z,14Z)-(5S)-5-hydroperoxyeicosa-6,8,11,14-tetraenoate
leukotriene A4 + H2O
-
-
684399, 684672, 685926, 687035, 688246, 688512, 688751, 689841, 689844, 689872, 711134, 711633, 711661, 712666 -
-
?
(6E,8Z,11Z,14Z)-(5S)-5-hydroperoxyeicosa-6,8,11,14-tetraenoate
leukotriene A4 + H2O
-
a conjugated epoxide intermediate in leukotriene biosynthesis, is unstable and enzymatically metabolized to leukotriene B4 or by spontaneous hydrolysis
-
?
(6E,8Z,11Z,14Z)-(5S)-5-hydroperoxyeicosa-6,8,11,14-tetraenoate
leukotriene A4 + H2O
-
-
is unstable and metabolized to leukotriene B4
-
?
(6E,8Z,11Z,14Z)-(5S)-5-hydroperoxyeicosa-6,8,11,14-tetraenoate
leukotriene A4 + H2O
-
-
is unstable and metabolized to leukotriene B4 via stereospecific hydration by LTA4 hydrolase, LTA4 induces VEGF transcription in malignant mesothelial cells, the enzyme is upregulated in cancer cells and is pro-angiogenic
-
?
(6E,8Z,11Z,14Z)-(5S)-5-hydroperoxyeicosa-6,8,11,14-tetraenoate
leukotriene A4 + H2O
-
-
is unstable and metabolized to leukotriene B4, has no effect on on the spontaneous and lipopolysaccharide-stimulated growth of leukemic blasts
-
?
(6E,8Z,11Z,14Z)-(5S)-5-hydroperoxyeicosa-6,8,11,14-tetraenoate
leukotriene A4 + H2O
-
stereospecific removal of the pro-R hydrogen at C10 resulting in epoxide formation
-
-
?
(6E,8Z,11Z,14Z)-(5S)-5-hydroperoxyeicosa-6,8,11,14-tetraenoate
leukotriene A4 + H2O
-
efficient LTA4 formation of 5LO requires both phosphatidyl choline and coactosin-like protein
-
-
?
(6E,8Z,11Z,14Z)-(5S)-5-hydroperoxyeicosa-6,8,11,14-tetraenoate
leukotriene A4 + H2O
-
-
is unstable and metabolized to leukotriene B4
-
?
(6E,8Z,11Z,14Z)-(5S)-5-hydroperoxyeicosa-6,8,11,14-tetraenoate
leukotriene A4 + H2O
-
-
-
-
?
(6E,8Z,11Z,14Z)-(5S)-5-hydroperoxyeicosa-6,8,11,14-tetraenoate
leukotriene A4 + H2O
-
-
-
?
(6E,8Z,11Z,14Z)-(5S)-5-hydroperoxyeicosa-6,8,11,14-tetraenoate
leukotriene A4 + H2O
-
-
-
-
?
(6E,8Z,11Z,14Z)-(5S)-5-hydroperoxyeicosa-6,8,11,14-tetraenoate
leukotriene A4 + H2O
-
-
-
?
(6E,8Z,11Z,14Z)-(5S)-5-hydroperoxyeicosa-6,8,11,14-tetraenoate
leukotriene A4 + H2O
-
-
a conjugated epoxide intermediate in leukotriene biosynthesis, is unstable and enzymatically metabolized to leukotriene B4 or by spontaneous hydrolysis
-
?
(6E,8Z,11Z,14Z)-(5S)-5-hydroperoxyeicosa-6,8,11,14-tetraenoate
leukotriene A4 + H2O
-
is unstable and metabolized to leukotriene B4
-
?
(6E,8Z,11Z,14Z)-(5S)-5-hydroperoxyeicosa-6,8,11,14-tetraenoate
leukotriene A4 + H2O
-
-
is unstable and metabolized to leukotriene B4
-
?
(6E,8Z,11Z,14Z)-(5S)-5-hydroperoxyeicosa-6,8,11,14-tetraenoate
leukotriene A4 + H2O
-
is unstable and metabolized to leukotriene B4
-
?
(6E,8Z,11Z,14Z)-(5S)-5-hydroperoxyeicosa-6,8,11,14-tetraenoate
leukotriene A4 + H2O
-
-
is unstable and metabolized to leukotriene B4 by leukotriene A4 hydrolase, which binds to its specific receptor
-
?
(6E,8Z,11Z,14Z)-(5S)-5-hydroperoxyeicosa-6,8,11,14-tetraenoate
leukotriene A4 + H2O
-
is unstable and metabolized to leukotriene B4
-
?
(6E,8Z,11Z,14Z)-(5S)-5-hydroperoxyeicosa-6,8,11,14-tetraenoate
leukotriene A4 + H2O
-
-
is unstable and metabolized to leukotriene B4 by leukotriene A4 hydrolase, which binds to its specific receptor
-
?
(6E,8Z,11Z,14Z)-(5S)-5-hydroperoxyeicosa-6,8,11,14-tetraenoate
leukotriene A4 + H2O
-
is unstable and metabolized to leukotriene B4
-
?
(6E,8Z,11Z,14Z)-(5S)-5-hydroperoxyeicosa-6,8,11,14-tetraenoate
leukotriene A4 + H2O
-
-
-
-
?
(6E,8Z,11Z,14Z)-(5S)-5-hydroperoxyeicosa-6,8,11,14-tetraenoate
leukotriene A4 + H2O
-
-
-
?
(6E,8Z,11Z,14Z)-(5S)-5-hydroperoxyeicosa-6,8,11,14-tetraenoate
leukotriene A4 + H2O
-
-
a conjugated epoxide intermediate in leukotriene biosynthesis, is unstable and enzymatically metabolized to leukotriene B4 or by spontaneous hydrolysis
-
?
(6E,8Z,11Z,14Z)-(5S)-5-hydroperoxyeicosa-6,8,11,14-tetraenoate
leukotriene A4 + H2O
-
is unstable and metabolized to leukotriene B4
-
?
(6E,8Z,11Z,14Z)-(5S)-5-hydroperoxyeicosa-6,8,11,14-tetraenoate
leukotriene A4 + H2O
-
-
-
-
?
(6E,8Z,11Z,14Z)-(5S)-hydroperoxyicosa-6,8,11,14-tetraenoate + O2
leukotriene A4
-
-
-
?
(6E,8Z,11Z,14Z)-(5S)-hydroperoxyicosa-6,8,11,14-tetraenoate + O2
leukotriene A4
-
-
-
?
5,8,11,14,17-eicosapentaenoic acid + O2
?
-
-
-
-
?
5,8,11,14,17-eicosapentaenoic acid + O2
?
-
-
-
-
?
5,8,11,14,17-eicosapentaenoic acid + O2
?
-
-
-
-
?
8,11,14-eicosatrienoic acid + O2
?
-
-
-
-
?
8,11,14-eicosatrienoic acid + O2
?
-
4% of the activity with 5,8,11,14,17-eicosapentaenoic acid
-
-
?
8,11,14-eicosatrienoic acid + O2
?
-
-
-
-
?
arachidonate + O2
(5S,6E,8Z,11Z,14Z)-5-hydroperoxyicosa-6,8,11,14-tetraenoate
-
-
-
?
arachidonate + O2
(5S,6E,8Z,11Z,14Z)-5-hydroperoxyicosa-6,8,11,14-tetraenoate
hydroperoxidation
-
-
?
arachidonate + O2
(5S,6E,8Z,11Z,14Z)-5-hydroperoxyicosa-6,8,11,14-tetraenoate
-
hydroperoxidation
-
-
?
arachidonate + O2
(5S,6E,8Z,11Z,14Z)-5-hydroperoxyicosa-6,8,11,14-tetraenoate
hydroperoxidation
-
-
?
arachidonate + O2
(5S,6E,8Z,11Z,14Z)-5-hydroperoxyicosa-6,8,11,14-tetraenoate
-
-
-
-
?
arachidonate + O2
(5S,6S,7E,9E,11Z,14Z)-5,6-epoxyicosa-7,9,11,14-tetraenoate + H2O
-
-
-
?
arachidonate + O2
(5S,6S,7E,9E,11Z,14Z)-5,6-epoxyicosa-7,9,11,14-tetraenoate + H2O
-
-
-
-
?
arachidonate + O2
(5S,6S,7E,9E,11Z,14Z)-5,6-epoxyicosa-7,9,11,14-tetraenoate + H2O
-
-
-
?
arachidonate + O2
(5S,6S,7E,9E,11Z,14Z)-5,6-epoxyicosa-7,9,11,14-tetraenoate + H2O
-
-
-
-
?
arachidonate + O2
(5S,6S,7E,9E,11Z,14Z)-5,6-epoxyicosa-7,9,11,14-tetraenoate + H2O
-
-
-
?
arachidonate + O2
(5S,6S,7E,9E,11Z,14Z)-5,6-epoxyicosa-7,9,11,14-tetraenoate + H2O
-
-
-
-
?
arachidonate + O2
(5S,6S,7E,9E,11Z,14Z)-5,6-epoxyicosa-7,9,11,14-tetraenoate + H2O
-
-
-
?
arachidonate + O2
(5S,6S,7E,9E,11Z,14Z)-5,6-epoxyicosa-7,9,11,14-tetraenoate + H2O
-
-
-
-
?
arachidonate + O2
(5S,6S,7E,9E,11Z,14Z)-5,6-epoxyicosa-7,9,11,14-tetraenoate + H2O
-
-
-
?
arachidonate + O2
(5S,6S,7E,9E,11Z,14Z)-5,6-epoxyicosa-7,9,11,14-tetraenoate + H2O
-
-
-
-
?
arachidonate + O2
(5S,6S,7E,9E,11Z,14Z)-5,6-epoxyicosa-7,9,11,14-tetraenoate + H2O
-
-
-
?
arachidonate + O2
(5S,6S,7E,9E,11Z,14Z)-5,6-epoxyicosa-7,9,11,14-tetraenoate + H2O
overall reaction
-
-
?
arachidonate + O2
(5S,6S,7E,9E,11Z,14Z)-5,6-epoxyicosa-7,9,11,14-tetraenoate + H2O
product generation is both regiospecific and stereospecific, the S-isomer is produced
-
-
?
arachidonate + O2
(6E,8Z,11Z,14Z)-(5S)-5-hydroperoxyicosa-6,8,11,14-tetraenoate
-
higher affinity of arachidonate than linoleic acid for the ferrous form of lipoxygenase-1. Hydrogen abstraction step displays high kinetic isotope effects on kcat due to tunneling contributions. Lack of solvent-dependent rate-limiting steps at lower temperatures with arachidonate as substrate
-
-
?
arachidonate + O2
(6E,8Z,11Z,14Z)-(5S)-5-hydroperoxyicosa-6,8,11,14-tetraenoate
-
-
-
-
?
arachidonate + O2
(6E,8Z,11Z,14Z)-(5S)-5-hydroperoxyicosa-6,8,11,14-tetraenoate
-
-
-
-
?
arachidonate + O2
(6E,8Z,11Z,14Z)-(5S)-hydroperoxyicosa-6,8,11,14-tetraenoate
-
i.e. 5,8,11,14-eicosatetraenoic acid
-
?
arachidonate + O2
(6E,8Z,11Z,14Z)-(5S)-hydroperoxyicosa-6,8,11,14-tetraenoate
-
i.e. 5,8,11,14-eicosatetraenoic acid
-
?
arachidonate + O2
(6E,8Z,11Z,14Z)-(5S)-hydroperoxyicosa-6,8,11,14-tetraenoate
-
i.e. 5,8,11,14-eicosatetraenoic acid
-
?
arachidonate + O2
(6E,8Z,11Z,14Z)-(5S)-hydroperoxyicosa-6,8,11,14-tetraenoate
-
i.e. 5,8,11,14-eicosatetraenoic acid
-
?
arachidonate + O2
(6E,8Z,11Z,14Z)-(5S)-hydroperoxyicosa-6,8,11,14-tetraenoate
-
-
672591, 672680, 673996, 675270, 675744, 676811, 676924, 711100, 711134, 711633, 711661, 712666 -
-
?
arachidonate + O2
(6E,8Z,11Z,14Z)-(5S)-hydroperoxyicosa-6,8,11,14-tetraenoate
-
72% of the activity with 5,8,11,14,17-eicosapentaenoic acid
-
?
arachidonate + O2
(6E,8Z,11Z,14Z)-(5S)-hydroperoxyicosa-6,8,11,14-tetraenoate
-
i.e. 5,8,11,14-eicosatetraenoic acid
-
?
arachidonate + O2
(6E,8Z,11Z,14Z)-(5S)-hydroperoxyicosa-6,8,11,14-tetraenoate
-
i.e. 5,8,11,14-eicosatetraenoic acid
-
?
arachidonate + O2
(6E,8Z,11Z,14Z)-(5S)-hydroperoxyicosa-6,8,11,14-tetraenoate
-
i.e. 5,8,11,14-eicosatetraenoic acid
-
?
arachidonate + O2
(6E,8Z,11Z,14Z)-(5S)-hydroperoxyicosa-6,8,11,14-tetraenoate
-
i.e. 5,8,11,14-eicosatetraenoic acid
-
?
arachidonate + O2
(6E,8Z,11Z,14Z)-(5S)-hydroperoxyicosa-6,8,11,14-tetraenoate
-
i.e. 5,8,11,14-eicosatetraenoic acid
-
?
arachidonate + O2
(6E,8Z,11Z,14Z)-(5S)-hydroperoxyicosa-6,8,11,14-tetraenoate
-
i.e. 5,8,11,14-eicosatetraenoic acid
-
?
arachidonate + O2
(6E,8Z,11Z,14Z)-(5S)-hydroperoxyicosa-6,8,11,14-tetraenoate
-
i.e. 5,8,11,14-eicosatetraenoic acid
-
?
arachidonate + O2
(6E,8Z,11Z,14Z)-(5S)-hydroperoxyicosa-6,8,11,14-tetraenoate
-
i.e. 5,8,11,14-eicosatetraenoic acid
-
?
arachidonate + O2
(6E,8Z,11Z,14Z)-(5S)-hydroperoxyicosa-6,8,11,14-tetraenoate
-
i.e. 5,8,11,14-eicosatetraenoic acid
-
?
arachidonate + O2
(6E,8Z,11Z,14Z)-(5S)-hydroperoxyicosa-6,8,11,14-tetraenoate
-
i.e. 5,8,11,14-eicosatetraenoic acid
-
?
arachidonate + O2
(6E,8Z,11Z,14Z)-(5S)-hydroperoxyicosa-6,8,11,14-tetraenoate
-
i.e. 5,8,11,14-eicosatetraenoic acid
-
?
arachidonate + O2
(6E,8Z,11Z,14Z)-(5S)-hydroperoxyicosa-6,8,11,14-tetraenoate
-
i.e. 5,8,11,14-eicosatetraenoic acid
-
?
arachidonate + O2
(6E,8Z,11Z,14Z)-(5S)-hydroperoxyicosa-6,8,11,14-tetraenoate
-
i.e. 5,8,11,14-eicosatetraenoic acid
-
?
arachidonate + O2
(6E,8Z,11Z,14Z)-(5S)-hydroperoxyicosa-6,8,11,14-tetraenoate
-
i.e. 5,8,11,14-eicosatetraenoic acid
-
?
arachidonate + O2
(6E,8Z,11Z,14Z)-(5S)-hydroperoxyicosa-6,8,11,14-tetraenoate
-
i.e. 5,8,11,14-eicosatetraenoic acid
-
?
arachidonate + O2
(6E,8Z,11Z,14Z)-(5S)-hydroperoxyicosa-6,8,11,14-tetraenoate
-
i.e. 5,8,11,14-eicosatetraenoic acid
-
?
arachidonate + O2
(6E,8Z,11Z,14Z)-(5S)-hydroperoxyicosa-6,8,11,14-tetraenoate
-
i.e. 5,8,11,14-eicosatetraenoic acid
-
?
arachidonate + O2
(6E,8Z,11Z,14Z)-(5S)-hydroperoxyicosa-6,8,11,14-tetraenoate
-
i.e. 5,8,11,14-eicosatetraenoic acid
+ minor amounts of the double oxygenation products
?
arachidonate + O2
(6E,8Z,11Z,14Z)-(5S)-hydroperoxyicosa-6,8,11,14-tetraenoate
-
i.e. 5,8,11,14-eicosatetraenoic acid
5(S)-hydroperoxy-6-trans-8,11,14-cis-eicosatetraenoic acid + 6-trans-leukotriene B4 + 12-epi-6-trans-leukotriene B4
?
arachidonate + O2
(6E,8Z,11Z,14Z)-(5S)-hydroperoxyicosa-6,8,11,14-tetraenoate
-
i.e. 5,8,11,14-eicosatetraenoic acid
-
?
arachidonate + O2
(6E,8Z,11Z,14Z)-(5S)-hydroperoxyicosa-6,8,11,14-tetraenoate
-
-
-
-
?
arachidonate + O2
(6E,8Z,11Z,14Z)-(5S)-hydroperoxyicosa-6,8,11,14-tetraenoate
-
i.e. 5,8,11,14-eicosatetraenoic acid
-
?
arachidonate + O2
(6E,8Z,11Z,14Z)-(5S)-hydroperoxyicosa-6,8,11,14-tetraenoate
-
i.e. 5,8,11,14-eicosatetraenoic acid
-
?
arachidonate + O2
(6E,8Z,11Z,14Z)-(5S)-hydroperoxyicosa-6,8,11,14-tetraenoate
-
-
-
-
?
arachidonate + O2
(6E,8Z,11Z,14Z)-(5S)-hydroperoxyicosa-6,8,11,14-tetraenoate
-
i.e. 5,8,11,14-eicosatetraenoic acid
-
?
arachidonate + O2
(6E,8Z,11Z,14Z)-(5S)-hydroperoxyicosa-6,8,11,14-tetraenoate
-
i.e. 5,8,11,14-eicosatetraenoic acid
-
?
arachidonate + O2
(6E,8Z,11Z,14Z)-(5S)-hydroperoxyicosa-6,8,11,14-tetraenoate
-
i.e. 5,8,11,14-eicosatetraenoic acid
-
?
arachidonate + O2
(6E,8Z,11Z,14Z)-(5S)-hydroperoxyicosa-6,8,11,14-tetraenoate
-
-
-
-
?
arachidonate + O2
(6E,8Z,11Z,14Z)-(5S)-hydroperoxyicosa-6,8,11,14-tetraenoate
-
i.e. 5,8,11,14-eicosatetraenoic acid
-
?
arachidonate + O2
(6E,8Z,11Z,14Z)-(5S)-hydroperoxyicosa-6,8,11,14-tetraenoate
-
i.e. 5,8,11,14-eicosatetraenoic acid
-
?
arachidonate + O2
(6E,8Z,11Z,14Z)-(5S)-hydroperoxyicosa-6,8,11,14-tetraenoate
-
i.e. 5,8,11,14-eicosatetraenoic acid
-
?
arachidonate + O2
(6E,8Z,11Z,14Z)-(5S)-hydroperoxyicosa-6,8,11,14-tetraenoate
-
i.e. 5,8,11,14-eicosatetraenoic acid
-
?
arachidonate + O2
(6E,8Z,11Z,14Z)-(5S)-hydroperoxyicosa-6,8,11,14-tetraenoate
-
i.e. 5,8,11,14-eicosatetraenoic acid
-
?
arachidonate + O2
(6E,8Z,11Z,14Z)-(5S)-hydroperoxyicosa-6,8,11,14-tetraenoate
-
i.e. 5,8,11,14-eicosatetraenoic acid
-
?
arachidonate + O2
(6E,8Z,11Z,14Z)-(5S)-hydroperoxyicosa-6,8,11,14-tetraenoate
-
i.e. 5,8,11,14-eicosatetraenoic acid
-
?
arachidonate + O2
(6E,8Z,11Z,14Z)-(5S)-hydroperoxyicosa-6,8,11,14-tetraenoate
-
i.e. 5,8,11,14-eicosatetraenoic acid
-
?
arachidonate + O2
(6E,8Z,11Z,14Z)-(5S)-hydroperoxyicosa-6,8,11,14-tetraenoate
-
i.e. 5,8,11,14-eicosatetraenoic acid
-
?
arachidonate + O2
(6E,8Z,11Z,14Z)-(5S)-hydroperoxyicosa-6,8,11,14-tetraenoate
-
i.e. 5,8,11,14-eicosatetraenoic acid
-
?
arachidonate + O2
(6E,8Z,11Z,14Z)-(5S)-hydroperoxyicosa-6,8,11,14-tetraenoate
-
i.e. 5,8,11,14-eicosatetraenoic acid
-
?
arachidonate + O2
(6E,8Z,11Z,14Z)-(5S)-hydroperoxyicosa-6,8,11,14-tetraenoate
-
i.e. 5,8,11,14-eicosatetraenoic acid
-
?
arachidonate + O2
(6E,8Z,11Z,14Z)-(5S)-hydroperoxyicosa-6,8,11,14-tetraenoate
-
i.e. 5,8,11,14-eicosatetraenoic acid
-
?
arachidonate + O2
(6E,8Z,11Z,14Z)-(5S)-hydroperoxyicosa-6,8,11,14-tetraenoate
-
i.e. 5,8,11,14-eicosatetraenoic acid
-
?
arachidonate + O2
(6E,8Z,11Z,14Z)-(5S)-hydroperoxyicosa-6,8,11,14-tetraenoate
-
i.e. 5,8,11,14-eicosatetraenoic acid
formation of leukotriene A4 without release of the intermediate (6E,8Z,11Z,14Z)-(5S)-hydroperoxyicosa-6,8,11,14-tetraenoate
?
arachidonate + O2
(6E,8Z,11Z,14Z)-(5S)-hydroperoxyicosa-6,8,11,14-tetraenoate
-
i.e. 5,8,11,14-eicosatetraenoic acid
-
?
arachidonate + O2
(6E,8Z,11Z,14Z)-(5S)-hydroperoxyicosa-6,8,11,14-tetraenoate
-
i.e. 5,8,11,14-eicosatetraenoic acid
-
?
arachidonate + O2
(6E,8Z,11Z,14Z)-(5S)-hydroperoxyicosa-6,8,11,14-tetraenoate
-
i.e. 5,8,11,14-eicosatetraenoic acid
5-hydroperoxyeicosatetraenoic acid + 11(S)-hydroperoxyeicosatetraenoic acid + 15-hydroperoxyeicosatetraenoic acid + 5(S),12(S)-dihydroperoxy-6,8,10,14-eicosatetraenoic acid + 6-trans-leukotriene B4 + 12-epi-6-trans-leukotiene B4
?
arachidonate + O2
(6E,8Z,11Z,14Z)-(5S)-hydroperoxyicosa-6,8,11,14-tetraenoate
-
i.e. 5,8,11,14-eicosatetraenoic acid
5(S)-hydroperoxyeicosatetraenoic acid is the most abundant primary oxygenation product, representing 60% of the total hydroperoxyeicosatetraenoic acids, followed by 8(S)-hydroperoxyeicosatetraenoic acid, 9-hydroperoxyeicosatetraenoic acid, 11(S)-hydroperoxyeicosatetraenoic acid, 12-hydroperoxyeicosatetraenoic acid, and 15-hydroperoxyeicosatetraenoic acid in decreasing order of abundance, all possible diH(P)ETEs are detected
?
arachidonate + O2
(6E,8Z,11Z,14Z)-(5S)-hydroperoxyicosa-6,8,11,14-tetraenoate
-
i.e. 5,8,11,14-eicosatetraenoic acid
-
?
arachidonate + O2
(6E,8Z,11Z,14Z)-(5S)-hydroperoxyicosa-6,8,11,14-tetraenoate
-
i.e. 5,8,11,14-eicosatetraenoic acid
-
?
arachidonate + O2
(6E,8Z,11Z,14Z)-(5S)-hydroperoxyicosa-6,8,11,14-tetraenoate
-
i.e. 5,8,11,14-eicosatetraenoic acid
-
?
arachidonate + O2
(6E,8Z,11Z,14Z)-(5S)-hydroperoxyicosa-6,8,11,14-tetraenoate
-
i.e. 5,8,11,14-eicosatetraenoic acid
-
?
arachidonate + O2
(6E,8Z,11Z,14Z)-(5S)-hydroperoxyicosa-6,8,11,14-tetraenoate
-
i.e. 5,8,11,14-eicosatetraenoic acid
(5S,6R)-dihydroperoxy-7,9,11,14-eicosatetraenoic acid is produced as major product especially when the incubation is performed on ice rather than at room temperature, 6R-oxygenase activity
?
arachidonate + O2
(6E,8Z,11Z,14Z)-(5S)-hydroperoxyicosa-6,8,11,14-tetraenoate
-
i.e. 5,8,11,14-eicosatetraenoic acid
+ minor products: 5-hydroxy-6,8,11,14-eicosatetraenoic acid, 6-trans-leukotriene B4 and 5,6-dihydroxy-7,9,11,14-eicosatetraenoic acid
?
arachidonate + O2
(6E,8Z,11Z,14Z)-(5S)-hydroperoxyicosa-6,8,11,14-tetraenoate
-
i.e. 5,8,11,14-eicosatetraenoic acid
+ leukotriene A4
?
arachidonate + O2
(6E,8Z,11Z,14Z)-(5S)-hydroperoxyicosa-6,8,11,14-tetraenoate
-
i.e. 5,8,11,14-eicosatetraenoic acid
the enzyme is rather specific for the insertion of O2 at the fifth carbon on arachidonic acid
?
arachidonic acid + O2
(6E,8Z,11Z,14Z)-(5S)-5-hydroperoxyeicosa-6,8,11,14-tetraenoate
-
-
-
-
?
arachidonic acid + O2
(6E,8Z,11Z,14Z)-(5S)-5-hydroperoxyeicosa-6,8,11,14-tetraenoate
-
-
684399, 684672, 685926, 686278, 687035, 688246, 688512, 688751, 689841, 689844, 689872 -
-
?
arachidonic acid + O2
(6E,8Z,11Z,14Z)-(5S)-5-hydroperoxyeicosa-6,8,11,14-tetraenoate
-
-
-
?
arachidonic acid + O2
(6E,8Z,11Z,14Z)-(5S)-5-hydroperoxyeicosa-6,8,11,14-tetraenoate
-
first committed step in the synthesis of leukotrienes
-
-
?
arachidonic acid + O2
(6E,8Z,11Z,14Z)-(5S)-5-hydroperoxyeicosa-6,8,11,14-tetraenoate
-
stereospecific abstraction of the pro-S hydrogen at C7, followed by insertion of molecular O2 at C5
-
-
?
arachidonic acid + O2
(6E,8Z,11Z,14Z)-(5S)-5-hydroperoxyeicosa-6,8,11,14-tetraenoate
-
-
-
-
?
arachidonic acid + O2
(6E,8Z,11Z,14Z)-(5S)-5-hydroperoxyeicosa-6,8,11,14-tetraenoate
-
-
-
-
?
arachidonic acid + O2
(6E,8Z,11Z,14Z)-(5S)-5-hydroperoxyeicosa-6,8,11,14-tetraenoate
-
-
-
?
arachidonic acid + O2
(6E,8Z,11Z,14Z)-(5S)-5-hydroperoxyeicosa-6,8,11,14-tetraenoate
-
-
-
-
?
arachidonic acid + O2
(6E,8Z,11Z,14Z)-(5S)-5-hydroperoxyeicosa-6,8,11,14-tetraenoate
-
-
-
?
arachidonic acid + O2
(6E,8Z,11Z,14Z)-(5S)-5-hydroperoxyeicosa-6,8,11,14-tetraenoate
-
-
-
?
arachidonic acid + O2
(6E,8Z,11Z,14Z)-(5S)-5-hydroperoxyeicosa-6,8,11,14-tetraenoate
-
-
-
-
?
arachidonic acid + O2
(6E,8Z,11Z,14Z)-(5S)-5-hydroperoxyeicosa-6,8,11,14-tetraenoate
-
-
-
?
arachidonic acid + O2
(6E,8Z,11Z,14Z)-(5S)-5-hydroperoxyeicosa-6,8,11,14-tetraenoate
-
-
-
-
?
arachidonic acid + O2
(6E,8Z,11Z,14Z)-(5S)-5-hydroperoxyeicosa-6,8,11,14-tetraenoate
-
-
-
?
arachidonic acid + O2
(6E,8Z,11Z,14Z)-(5S)-5-hydroperoxyeicosa-6,8,11,14-tetraenoate
-
-
-
-
?
linoleic acid + O2
9-hydroperoxyoctadecadienoic acid
-
-
-
-
?
linoleic acid + O2
9-hydroperoxyoctadecadienoic acid
-
-
-
-
?
linoleic acid + O2
9-hydroperoxyoctadecadienoic acid
-
-
-
?
linoleic acid + O2
?
-
lower affinity of linoleic acid than arachidonic acid for the ferrous form of lipoxygenase-1. Hydrogen abstraction step displays high kinetic isotope effects on kcat due to tunneling contributions
-
-
?
linoleic acid + O2
?
-
-
-
-
?
additional information
?
-
-
key enzyme in leukotriene biosynthesis, catalyzes the initial steps in the conversion of arachidonic acid to biologically active leukotrienes. Leukotrienes are considered as potent mediators of inflammatory and allergic reactions
-
-
?
additional information
?
-
-
key enzyme in leukotriene biosynthesis, catalyzes the initial steps in the conversion of arachidonic acid to biologically active leukotrienes. Leukotrienes are considered as potent mediators of inflammatory and allergic reactions
-
-
?
additional information
?
-
-
key enzyme in leukotriene biosynthesis, catalyzes the initial steps in the conversion of arachidonic acid to biologically active leukotrienes. Leukotrienes are considered as potent mediators of inflammatory and allergic reactions
-
-
?
additional information
?
-
-
key enzyme in leukotriene biosynthesis, catalyzes the initial steps in the conversion of arachidonic acid to biologically active leukotrienes. Leukotrienes are considered as potent mediators of inflammatory and allergic reactions
-
-
?
additional information
?
-
-
the purified protein expresses both 5-oxygenase and leukotriene A4 synthase activities in the ratio of 6:1
-
-
?
additional information
?
-
-
enzyme of leukotriene biosynthetic pathway
-
-
?
additional information
?
-
-
key enzyme in leukotriene metabolism, in human mast cells glucocorticoids effectively and selectively upregulate the expression
-
-
?
additional information
?
-
-
key enzyme in leukotriene biosynthesis, catalyzes the initial steps in the conversion of arachidonic acid to biologically active leukotrienes. Leukotrienes are considered as potent mediators of inflammatory and allergic reactions
-
-
?
additional information
?
-
-
key enzyme in the biosynthesis of proinflammatory leukotrienes
-
-
?
additional information
?
-
-
5-lipoxygenase/cyclooxygenase-2 cross-talk through cysteinyl leukotriene receptor 2 in endothelial cells, overview
-
-
?
additional information
?
-
-
ALOX5-derived lipid mediators leukotrienes and lipoxins have regulatory functions in inflammation by modulating activities of immune cells and cytokine production, host control of Mycobacterium tuberculosis is regulated by 5-lipoxygenase
-
-
?
additional information
?
-
-
inhibition of COX pathways does not increase the transformation of arachidonic acid by the 5-LOX pathway
-
-
?
additional information
?
-
-
key enzyme in biosynthesis of leukotrienes, overview. Upon cell activation, cytosolic and nuclear enzyme translocates the nuclear envelope, where it interacts with phospholipase A2, making free arachidonate available for 5-LO, and with 5-LO activating protein, i.e. FLAP. 5-LO regulates cancer cell survival and interferes with the mechanismtumor suppression, and increases cancer cell chemoresistance, overview
-
-
?
additional information
?
-
key enzyme in the leukotriene biosynthesis, pathway overview, the 5-LO pathway is linked to the development of cardiovascular disease and other diseases, regulatory mechanisms underlying the expression and control of 5-LO activity, overview
-
-
?
additional information
?
-
-
no significant effect of LTB4, 12-hydroperoxyeicosatetraenoic acid or 15-hydroperoxyeicosatetraenoic acid on leukemic blast growth and on their apoptose rate, overview
-
-
?
additional information
?
-
-
the enzyme is involved in survival of Epstein-Barr virus-converted B lymphoma cells via function of 5-hydroperoxyeicosatetraenoic acid, overview
-
-
?
additional information
?
-
-
the enzyme is the key enzyme in biosynthesis of biologically active leukotrienes
-
-
?
additional information
?
-
-
the enzyme, catalyzing the key step in leukotriene biosynthesis, interacts with methyl jasmonate, which is probably involved in the anticarcinogenic activity of methyl jasmonate inducing apoptosis, overview
-
-
?
additional information
?
-
the enzyme catalyzes the dioxygenation of polyunsaturated fatty acids
-
-
?
additional information
?
-
5-LOX catalyzes a 2-step reaction where arachidonic acid (AA) is oxygenated, resulting in formation of 5(S)-hydroperoxy-(6E,8Z,11Z,14Z)-eicosatetraenoic acid (5-HPETE), with subsequent formation of leukotriene A4 (LTA4). Active site structure and binding of substrate arachidonate involving residues F421, F177, Q363, L414 and L368 during the reaction, model, overview
-
-
?
additional information
?
-
-
5-LOX catalyzes a 2-step reaction where arachidonic acid (AA) is oxygenated, resulting in formation of 5(S)-hydroperoxy-(6E,8Z,11Z,14Z)-eicosatetraenoic acid (5-HPETE), with subsequent formation of leukotriene A4 (LTA4). Active site structure and binding of substrate arachidonate involving residues F421, F177, Q363, L414 and L368 during the reaction, model, overview
-
-
?
additional information
?
-
detectable 5-LO products derived from conversion of arachidonate are quantified by HPLC and comprise 5-H(p)ETE (a mixture of 5-HETE (5S-hydroxy-6,8,11,14(E,Z,Z,Z)-eicosatetraenoic acid) and 5-HpETE (5S-hydroperoxy-6,8,11,14(E,Z,Z,Z)-eicosatetraenoic acid)) and the non-enzymatic hydrolysis products of leukotriene A4, 6-trans-leukotriene B4 (5S,12R-dihydroxy-6,8,10,14(E,E,E,Z)-eicosatetraenoic acid) and 6-trans-12-epi-LTB4 (5S,12S-dihydroxy-6,8,10,14-(E,E,E,Z)-eicosatetraenoic acid)
-
-
?
additional information
?
-
-
detectable 5-LO products derived from conversion of arachidonate are quantified by HPLC and comprise 5-H(p)ETE (a mixture of 5-HETE (5S-hydroxy-6,8,11,14(E,Z,Z,Z)-eicosatetraenoic acid) and 5-HpETE (5S-hydroperoxy-6,8,11,14(E,Z,Z,Z)-eicosatetraenoic acid)) and the non-enzymatic hydrolysis products of leukotriene A4, 6-trans-leukotriene B4 (5S,12R-dihydroxy-6,8,10,14(E,E,E,Z)-eicosatetraenoic acid) and 6-trans-12-epi-LTB4 (5S,12S-dihydroxy-6,8,10,14-(E,E,E,Z)-eicosatetraenoic acid)
-
-
?
additional information
?
-
no substrate: 5S,15S-dihydroperoxyeicosatetraenoic acid
-
-
-
additional information
?
-
-
no substrate: 5S,15S-dihydroperoxyeicosatetraenoic acid
-
-
-
additional information
?
-
-
arachidonate 5-lipoxygenase and leukotriene A5 synthase are identical
-
-
?
additional information
?
-
-
key enzyme in leukotriene biosynthesis, catalyzes the initial steps in the conversion of arachidonic acid to biologically active leukotrienes. Leukotrienes are considered as potent mediators of inflammatory and allergic reactions
-
-
?
additional information
?
-
5-LO inhibition in obese mice downregulates genes involved in hepatic fatty acid uptake, i.e. L-FABP and FAT/CD36, and normalizes PPARalpha and acyl-CoA oxidase expression, whereas the expression of lipogenic genes, i.e. FASN and SREBP-1c, remains unaltered. The 5-LO inhibition restores hepatic microsomal triglyceride transfer protein, MTP, activity in parallel with a stimulation of hepatic VLDL-TG and ApoB secretion in obese mice, overview
-
-
?
additional information
?
-
-
5-LO inhibition in obese mice downregulates genes involved in hepatic fatty acid uptake, i.e. L-FABP and FAT/CD36, and normalizes PPARalpha and acyl-CoA oxidase expression, whereas the expression of lipogenic genes, i.e. FASN and SREBP-1c, remains unaltered. The 5-LO inhibition restores hepatic microsomal triglyceride transfer protein, MTP, activity in parallel with a stimulation of hepatic VLDL-TG and ApoB secretion in obese mice, overview
-
-
?
additional information
?
-
inhibition of 5-lipoxygenase does not affect cardiac ischemia-reperfusion injury but the post-ischemic inflammatory response, overview
-
-
?
additional information
?
-
-
key enzyme in the leukotriene biosynthesis, pathway overview, regulatory mechanisms underlying the expression and control of 5-LO activity, overview
-
-
?
additional information
?
-
5-LO inhibition in obese mice downregulates genes involved in hepatic fatty acid uptake, i.e. L-FABP and FAT/CD36, and normalizes PPARalpha and acyl-CoA oxidase expression, whereas the expression of lipogenic genes, i.e. FASN and SREBP-1c, remains unaltered. The 5-LO inhibition restores hepatic microsomal triglyceride transfer protein, MTP, activity in parallel with a stimulation of hepatic VLDL-TG and ApoB secretion in obese mice, overview
-
-
?
additional information
?
-
-
key enzyme in leukotriene biosynthesis, catalyzes the initial steps in the conversion of arachidonic acid to biologically active leukotrienes. Leukotrienes are considered as potent mediators of inflammatory and allergic reactions
-
-
?
additional information
?
-
-
key enzyme in the biosynthesis of proinflammatory leukotrienes
-
-
?
additional information
?
-
5-LOX is the key enzyme in the biosynthesis of leukotrienes through catalyzing the initial two steps in conversion of arachidonic acid to leukotrienes
-
-
?
additional information
?
-
-
key enzyme in the leukotriene biosynthesis, pathway overview, regulatory mechanisms underlying the expression and control of 5-LO activity, overview
-
-
?
additional information
?
-
-
stereo-selectivity in LOX-catalyzed oxygenation of lysophospholipids, overview
-
-
?
additional information
?
-
-
5-lipoxygenase has a two-domain structure, the small N-terminal beta-barrel domain and a larger catalytic domain containing a single atom of non-heme iron coordinating with His525, His530, His716 and Ile864
-
-
?
additional information
?
-
-
the enzyme exhibits 6R-oxygenase activity with (5S)-hydroxy and (5S)-hydroperoxy acids as substrates
-
-
?
additional information
?
-
-
the enzyme is involved in lipoxin synthesis from 5,15-dihydroxyperoxyeicosatetraenoic acid via 5,6-epoxide
-
-
?
additional information
?
-
-
key enzyme in leukotriene biosynthesis, catalyzes the initial steps in the conversion of arachidonic acid to biologically active leukotrienes. Leukotrienes are considered as potent mediators of inflammatory and allergic reactions
-
-
?
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
(5S,6E,8Z,11Z,14Z)-5-hydroperoxyicosa-6,8,11,14-tetraenoate
(5S,6S,7E,9E,11Z,14Z)-5,6-epoxyicosa-7,9,11,14-tetraenoate + H2O
(5Z,8Z,10E,12S,14Z)-12-hydroxyicosa-5,8,10,14-tetraenoic acid + O2
?
-
-
-
-
?
(6E,8Z,11Z,14Z)-(5S)-5-hydroperoxyeicosa-6,8,11,14-tetraenoate
leukotriene A4 + H2O
5-hydroperoxyeicosatetraenoic acid
leukotriene A4 + H2O
-
-
is unstable and metabolized to leukotriene B4
-
?
arachidonate + O2
(5S,6E,8Z,11Z,14Z)-5-hydroperoxyicosa-6,8,11,14-tetraenoate
arachidonate + O2
(5S,6S,7E,9E,11Z,14Z)-5,6-epoxyicosa-7,9,11,14-tetraenoate + H2O
arachidonate + O2
(6E,8Z,11Z,14Z)-(5S)-hydroperoxyicosa-6,8,11,14-tetraenoate
arachidonic acid + O2
(6E,8Z,11Z,14Z)-(5S)-5-hydroperoxyeicosa-6,8,11,14-tetraenoate
arachidonic acid + O2
5-hydroperoxyeicosatetraenoic acid
-
-
-
-
?
additional information
?
-
(5S,6E,8Z,11Z,14Z)-5-hydroperoxyicosa-6,8,11,14-tetraenoate
(5S,6S,7E,9E,11Z,14Z)-5,6-epoxyicosa-7,9,11,14-tetraenoate + H2O
epoxidation
-
-
?
(5S,6E,8Z,11Z,14Z)-5-hydroperoxyicosa-6,8,11,14-tetraenoate
(5S,6S,7E,9E,11Z,14Z)-5,6-epoxyicosa-7,9,11,14-tetraenoate + H2O
-
epoxidation
-
-
?
(5S,6E,8Z,11Z,14Z)-5-hydroperoxyicosa-6,8,11,14-tetraenoate
(5S,6S,7E,9E,11Z,14Z)-5,6-epoxyicosa-7,9,11,14-tetraenoate + H2O
epoxidation
-
-
?
(6E,8Z,11Z,14Z)-(5S)-5-hydroperoxyeicosa-6,8,11,14-tetraenoate
leukotriene A4 + H2O
-
-
is unstable and metabolized to leukotriene B4
-
?
(6E,8Z,11Z,14Z)-(5S)-5-hydroperoxyeicosa-6,8,11,14-tetraenoate
leukotriene A4 + H2O
-
-
-
-
?
(6E,8Z,11Z,14Z)-(5S)-5-hydroperoxyeicosa-6,8,11,14-tetraenoate
leukotriene A4 + H2O
-
a conjugated epoxide intermediate in leukotriene biosynthesis, is unstable and enzymatically metabolized to leukotriene B4 or by spontaneous hydrolysis
-
?
(6E,8Z,11Z,14Z)-(5S)-5-hydroperoxyeicosa-6,8,11,14-tetraenoate
leukotriene A4 + H2O
-
-
is unstable and metabolized to leukotriene B4
-
?
(6E,8Z,11Z,14Z)-(5S)-5-hydroperoxyeicosa-6,8,11,14-tetraenoate
leukotriene A4 + H2O
-
-
is unstable and metabolized to leukotriene B4 via stereospecific hydration by LTA4 hydrolase, LTA4 induces VEGF transcription in malignant mesothelial cells, the enzyme is upregulated in cancer cells and is pro-angiogenic
-
?
(6E,8Z,11Z,14Z)-(5S)-5-hydroperoxyeicosa-6,8,11,14-tetraenoate
leukotriene A4 + H2O
-
-
is unstable and metabolized to leukotriene B4, has no effect on on the spontaneous and lipopolysaccharide-stimulated growth of leukemic blasts
-
?
(6E,8Z,11Z,14Z)-(5S)-5-hydroperoxyeicosa-6,8,11,14-tetraenoate
leukotriene A4 + H2O
-
efficient LTA4 formation of 5LO requires both phosphatidyl choline and coactosin-like protein
-
-
?
(6E,8Z,11Z,14Z)-(5S)-5-hydroperoxyeicosa-6,8,11,14-tetraenoate
leukotriene A4 + H2O
-
-
is unstable and metabolized to leukotriene B4
-
?
(6E,8Z,11Z,14Z)-(5S)-5-hydroperoxyeicosa-6,8,11,14-tetraenoate
leukotriene A4 + H2O
-
-
-
-
?
(6E,8Z,11Z,14Z)-(5S)-5-hydroperoxyeicosa-6,8,11,14-tetraenoate
leukotriene A4 + H2O
-
-
a conjugated epoxide intermediate in leukotriene biosynthesis, is unstable and enzymatically metabolized to leukotriene B4 or by spontaneous hydrolysis
-
?
(6E,8Z,11Z,14Z)-(5S)-5-hydroperoxyeicosa-6,8,11,14-tetraenoate
leukotriene A4 + H2O
-
is unstable and metabolized to leukotriene B4
-
?
(6E,8Z,11Z,14Z)-(5S)-5-hydroperoxyeicosa-6,8,11,14-tetraenoate
leukotriene A4 + H2O
-
-
is unstable and metabolized to leukotriene B4
-
?
(6E,8Z,11Z,14Z)-(5S)-5-hydroperoxyeicosa-6,8,11,14-tetraenoate
leukotriene A4 + H2O
-
is unstable and metabolized to leukotriene B4
-
?
(6E,8Z,11Z,14Z)-(5S)-5-hydroperoxyeicosa-6,8,11,14-tetraenoate
leukotriene A4 + H2O
-
-
is unstable and metabolized to leukotriene B4 by leukotriene A4 hydrolase, which binds to its specific receptor
-
?
(6E,8Z,11Z,14Z)-(5S)-5-hydroperoxyeicosa-6,8,11,14-tetraenoate
leukotriene A4 + H2O
-
is unstable and metabolized to leukotriene B4
-
?
(6E,8Z,11Z,14Z)-(5S)-5-hydroperoxyeicosa-6,8,11,14-tetraenoate
leukotriene A4 + H2O
-
-
is unstable and metabolized to leukotriene B4 by leukotriene A4 hydrolase, which binds to its specific receptor
-
?
(6E,8Z,11Z,14Z)-(5S)-5-hydroperoxyeicosa-6,8,11,14-tetraenoate
leukotriene A4 + H2O
-
is unstable and metabolized to leukotriene B4
-
?
(6E,8Z,11Z,14Z)-(5S)-5-hydroperoxyeicosa-6,8,11,14-tetraenoate
leukotriene A4 + H2O
-
-
-
-
?
(6E,8Z,11Z,14Z)-(5S)-5-hydroperoxyeicosa-6,8,11,14-tetraenoate
leukotriene A4 + H2O
-
-
a conjugated epoxide intermediate in leukotriene biosynthesis, is unstable and enzymatically metabolized to leukotriene B4 or by spontaneous hydrolysis
-
?
(6E,8Z,11Z,14Z)-(5S)-5-hydroperoxyeicosa-6,8,11,14-tetraenoate
leukotriene A4 + H2O
-
is unstable and metabolized to leukotriene B4
-
?
(6E,8Z,11Z,14Z)-(5S)-5-hydroperoxyeicosa-6,8,11,14-tetraenoate
leukotriene A4 + H2O
-
-
-
-
?
arachidonate + O2
(5S,6E,8Z,11Z,14Z)-5-hydroperoxyicosa-6,8,11,14-tetraenoate
-
-
-
?
arachidonate + O2
(5S,6E,8Z,11Z,14Z)-5-hydroperoxyicosa-6,8,11,14-tetraenoate
hydroperoxidation
-
-
?
arachidonate + O2
(5S,6E,8Z,11Z,14Z)-5-hydroperoxyicosa-6,8,11,14-tetraenoate
hydroperoxidation
-
-
?
arachidonate + O2
(5S,6S,7E,9E,11Z,14Z)-5,6-epoxyicosa-7,9,11,14-tetraenoate + H2O
-
-
-
?
arachidonate + O2
(5S,6S,7E,9E,11Z,14Z)-5,6-epoxyicosa-7,9,11,14-tetraenoate + H2O
-
-
-
-
?
arachidonate + O2
(5S,6S,7E,9E,11Z,14Z)-5,6-epoxyicosa-7,9,11,14-tetraenoate + H2O
-
-
-
?
arachidonate + O2
(5S,6S,7E,9E,11Z,14Z)-5,6-epoxyicosa-7,9,11,14-tetraenoate + H2O
-
-
-
-
?
arachidonate + O2
(5S,6S,7E,9E,11Z,14Z)-5,6-epoxyicosa-7,9,11,14-tetraenoate + H2O
-
-
-
?
arachidonate + O2
(5S,6S,7E,9E,11Z,14Z)-5,6-epoxyicosa-7,9,11,14-tetraenoate + H2O
-
-
-
-
?
arachidonate + O2
(5S,6S,7E,9E,11Z,14Z)-5,6-epoxyicosa-7,9,11,14-tetraenoate + H2O
-
-
-
?
arachidonate + O2
(5S,6S,7E,9E,11Z,14Z)-5,6-epoxyicosa-7,9,11,14-tetraenoate + H2O
-
-
-
-
?
arachidonate + O2
(5S,6S,7E,9E,11Z,14Z)-5,6-epoxyicosa-7,9,11,14-tetraenoate + H2O
-
-
-
?
arachidonate + O2
(5S,6S,7E,9E,11Z,14Z)-5,6-epoxyicosa-7,9,11,14-tetraenoate + H2O
-
-
-
-
?
arachidonate + O2
(5S,6S,7E,9E,11Z,14Z)-5,6-epoxyicosa-7,9,11,14-tetraenoate + H2O
-
-
-
?
arachidonate + O2
(5S,6S,7E,9E,11Z,14Z)-5,6-epoxyicosa-7,9,11,14-tetraenoate + H2O
overall reaction
-
-
?
arachidonate + O2
(6E,8Z,11Z,14Z)-(5S)-hydroperoxyicosa-6,8,11,14-tetraenoate
-
-
-
-
?
arachidonate + O2
(6E,8Z,11Z,14Z)-(5S)-hydroperoxyicosa-6,8,11,14-tetraenoate
-
-
-
-
?
arachidonic acid + O2
(6E,8Z,11Z,14Z)-(5S)-5-hydroperoxyeicosa-6,8,11,14-tetraenoate
-
-
-
-
?
arachidonic acid + O2
(6E,8Z,11Z,14Z)-(5S)-5-hydroperoxyeicosa-6,8,11,14-tetraenoate
-
-
-
-
?
arachidonic acid + O2
(6E,8Z,11Z,14Z)-(5S)-5-hydroperoxyeicosa-6,8,11,14-tetraenoate
-
-
-
?
arachidonic acid + O2
(6E,8Z,11Z,14Z)-(5S)-5-hydroperoxyeicosa-6,8,11,14-tetraenoate
-
first committed step in the synthesis of leukotrienes
-
-
?
arachidonic acid + O2
(6E,8Z,11Z,14Z)-(5S)-5-hydroperoxyeicosa-6,8,11,14-tetraenoate
-
-
-
-
?
arachidonic acid + O2
(6E,8Z,11Z,14Z)-(5S)-5-hydroperoxyeicosa-6,8,11,14-tetraenoate
-
-
-
-
?
arachidonic acid + O2
(6E,8Z,11Z,14Z)-(5S)-5-hydroperoxyeicosa-6,8,11,14-tetraenoate
-
-
-
?
arachidonic acid + O2
(6E,8Z,11Z,14Z)-(5S)-5-hydroperoxyeicosa-6,8,11,14-tetraenoate
-
-
-
-
?
arachidonic acid + O2
(6E,8Z,11Z,14Z)-(5S)-5-hydroperoxyeicosa-6,8,11,14-tetraenoate
-
-
-
?
arachidonic acid + O2
(6E,8Z,11Z,14Z)-(5S)-5-hydroperoxyeicosa-6,8,11,14-tetraenoate
-
-
-
?
arachidonic acid + O2
(6E,8Z,11Z,14Z)-(5S)-5-hydroperoxyeicosa-6,8,11,14-tetraenoate
-
-
-
-
?
arachidonic acid + O2
(6E,8Z,11Z,14Z)-(5S)-5-hydroperoxyeicosa-6,8,11,14-tetraenoate
-
-
-
?
arachidonic acid + O2
(6E,8Z,11Z,14Z)-(5S)-5-hydroperoxyeicosa-6,8,11,14-tetraenoate
-
-
-
-
?
arachidonic acid + O2
(6E,8Z,11Z,14Z)-(5S)-5-hydroperoxyeicosa-6,8,11,14-tetraenoate
-
-
-
?
arachidonic acid + O2
(6E,8Z,11Z,14Z)-(5S)-5-hydroperoxyeicosa-6,8,11,14-tetraenoate
-
-
-
-
?
additional information
?
-
-
key enzyme in leukotriene biosynthesis, catalyzes the initial steps in the conversion of arachidonic acid to biologically active leukotrienes. Leukotrienes are considered as potent mediators of inflammatory and allergic reactions
-
-
?
additional information
?
-
-
key enzyme in leukotriene biosynthesis, catalyzes the initial steps in the conversion of arachidonic acid to biologically active leukotrienes. Leukotrienes are considered as potent mediators of inflammatory and allergic reactions
-
-
?
additional information
?
-
-
key enzyme in leukotriene biosynthesis, catalyzes the initial steps in the conversion of arachidonic acid to biologically active leukotrienes. Leukotrienes are considered as potent mediators of inflammatory and allergic reactions
-
-
?
additional information
?
-
-
key enzyme in leukotriene biosynthesis, catalyzes the initial steps in the conversion of arachidonic acid to biologically active leukotrienes. Leukotrienes are considered as potent mediators of inflammatory and allergic reactions
-
-
?
additional information
?
-
-
enzyme of leukotriene biosynthetic pathway
-
-
?
additional information
?
-
-
key enzyme in leukotriene metabolism, in human mast cells glucocorticoids effectively and selectively upregulate the expression
-
-
?
additional information
?
-
-
key enzyme in leukotriene biosynthesis, catalyzes the initial steps in the conversion of arachidonic acid to biologically active leukotrienes. Leukotrienes are considered as potent mediators of inflammatory and allergic reactions
-
-
?
additional information
?
-
-
key enzyme in the biosynthesis of proinflammatory leukotrienes
-
-
?
additional information
?
-
-
5-lipoxygenase/cyclooxygenase-2 cross-talk through cysteinyl leukotriene receptor 2 in endothelial cells, overview
-
-
?
additional information
?
-
-
ALOX5-derived lipid mediators leukotrienes and lipoxins have regulatory functions in inflammation by modulating activities of immune cells and cytokine production, host control of Mycobacterium tuberculosis is regulated by 5-lipoxygenase
-
-
?
additional information
?
-
-
inhibition of COX pathways does not increase the transformation of arachidonic acid by the 5-LOX pathway
-
-
?
additional information
?
-
-
key enzyme in biosynthesis of leukotrienes, overview. Upon cell activation, cytosolic and nuclear enzyme translocates the nuclear envelope, where it interacts with phospholipase A2, making free arachidonate available for 5-LO, and with 5-LO activating protein, i.e. FLAP. 5-LO regulates cancer cell survival and interferes with the mechanismtumor suppression, and increases cancer cell chemoresistance, overview
-
-
?
additional information
?
-
key enzyme in the leukotriene biosynthesis, pathway overview, the 5-LO pathway is linked to the development of cardiovascular disease and other diseases, regulatory mechanisms underlying the expression and control of 5-LO activity, overview
-
-
?
additional information
?
-
-
no significant effect of LTB4, 12-hydroperoxyeicosatetraenoic acid or 15-hydroperoxyeicosatetraenoic acid on leukemic blast growth and on their apoptose rate, overview
-
-
?
additional information
?
-
-
the enzyme is involved in survival of Epstein-Barr virus-converted B lymphoma cells via function of 5-hydroperoxyeicosatetraenoic acid, overview
-
-
?
additional information
?
-
-
the enzyme is the key enzyme in biosynthesis of biologically active leukotrienes
-
-
?
additional information
?
-
-
the enzyme, catalyzing the key step in leukotriene biosynthesis, interacts with methyl jasmonate, which is probably involved in the anticarcinogenic activity of methyl jasmonate inducing apoptosis, overview
-
-
?
additional information
?
-
the enzyme catalyzes the dioxygenation of polyunsaturated fatty acids
-
-
?
additional information
?
-
-
key enzyme in leukotriene biosynthesis, catalyzes the initial steps in the conversion of arachidonic acid to biologically active leukotrienes. Leukotrienes are considered as potent mediators of inflammatory and allergic reactions
-
-
?
additional information
?
-
5-LO inhibition in obese mice downregulates genes involved in hepatic fatty acid uptake, i.e. L-FABP and FAT/CD36, and normalizes PPARalpha and acyl-CoA oxidase expression, whereas the expression of lipogenic genes, i.e. FASN and SREBP-1c, remains unaltered. The 5-LO inhibition restores hepatic microsomal triglyceride transfer protein, MTP, activity in parallel with a stimulation of hepatic VLDL-TG and ApoB secretion in obese mice, overview
-
-
?
additional information
?
-
-
5-LO inhibition in obese mice downregulates genes involved in hepatic fatty acid uptake, i.e. L-FABP and FAT/CD36, and normalizes PPARalpha and acyl-CoA oxidase expression, whereas the expression of lipogenic genes, i.e. FASN and SREBP-1c, remains unaltered. The 5-LO inhibition restores hepatic microsomal triglyceride transfer protein, MTP, activity in parallel with a stimulation of hepatic VLDL-TG and ApoB secretion in obese mice, overview
-
-
?
additional information
?
-
inhibition of 5-lipoxygenase does not affect cardiac ischemia-reperfusion injury but the post-ischemic inflammatory response, overview
-
-
?
additional information
?
-
-
key enzyme in the leukotriene biosynthesis, pathway overview, regulatory mechanisms underlying the expression and control of 5-LO activity, overview
-
-
?
additional information
?
-
5-LO inhibition in obese mice downregulates genes involved in hepatic fatty acid uptake, i.e. L-FABP and FAT/CD36, and normalizes PPARalpha and acyl-CoA oxidase expression, whereas the expression of lipogenic genes, i.e. FASN and SREBP-1c, remains unaltered. The 5-LO inhibition restores hepatic microsomal triglyceride transfer protein, MTP, activity in parallel with a stimulation of hepatic VLDL-TG and ApoB secretion in obese mice, overview
-
-
?
additional information
?
-
-
key enzyme in leukotriene biosynthesis, catalyzes the initial steps in the conversion of arachidonic acid to biologically active leukotrienes. Leukotrienes are considered as potent mediators of inflammatory and allergic reactions
-
-
?
additional information
?
-
-
key enzyme in the biosynthesis of proinflammatory leukotrienes
-
-
?
additional information
?
-
5-LOX is the key enzyme in the biosynthesis of leukotrienes through catalyzing the initial two steps in conversion of arachidonic acid to leukotrienes
-
-
?
additional information
?
-
-
key enzyme in the leukotriene biosynthesis, pathway overview, regulatory mechanisms underlying the expression and control of 5-LO activity, overview
-
-
?
additional information
?
-
-
the enzyme is involved in lipoxin synthesis from 5,15-dihydroxyperoxyeicosatetraenoic acid via 5,6-epoxide
-
-
?
additional information
?
-
-
key enzyme in leukotriene biosynthesis, catalyzes the initial steps in the conversion of arachidonic acid to biologically active leukotrienes. Leukotrienes are considered as potent mediators of inflammatory and allergic reactions
-
-
?
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
(1-difluoromethyl-2-oxo-1,2-dihydropyridin-3-yl)acetic acid
-
-
(1-difluoromethyl-2-oxo-1,2-dihydropyridin-4-yl)acetic acid
-
-
(1-[2-[4-(trifluoromethyl)phenyl]ethyl]-1H-1,2,3-triazol-4-yl)methyl (2E)-3-(3,4-dihydroxyphenyl)prop-2-enoate
compound forms pi-pi interactions with residues Phe177, His367 and coordinates iron
-
(10E,12E)-octadeca-10,12-dien-8-ynoic acid
-
-
(11E)-octadec-11-en-9-ynoic acid
-
-
(15S)-hydroperoxy-5,8,11,13-eicosatetraenoyl lysophosphatidylcholine
-
-
(17S)-hydroperoxy-4,7,10,13,15,19-docosahexaenoyl lysophosphatidylcholine
-
-
(1E)-1-((1-[(1Z)-prop-1-en-1-yldisulfanyl]propyl)sulfinyl)prop-1-ene
-
-
(1E)-1-(2,5-dihydroxyphenyl)-5-phenylpent-1-en-3-one
inhibits leukotriene biosynthesis in isolated human neutrophils and in whole blood
-
(1E)-1-(3,4-dihydroxyphenyl)-6-phenylhex-1-en-3-one
inhibits leukotriene biosynthesis in isolated human neutrophils and in whole blood
-
(1E)-1-(4-hydroxy-3,5-dimethoxyphenyl)-5-phenylpent-1-en-3-one
inhibits leukotriene biosynthesis in isolated human neutrophils and in whole blood, retains 50% of inhibitory activity after up to one hour of incubation
-
(2,4-dihydroxyphenyl)[3-(1-[hydroxy[(3,4,5-trihydroxyphenyl)methyl]amino]ethyl)phenyl]methanone
-
(2,4-dihydroxyphenyl)[3-(1-[hydroxy[(4-hydroxyphenyl)methyl]amino]ethyl)phenyl]methanone
-
(2E)-1-(2-hydroxy-4-methoxyphenyl)-3-(2,4,5-trimethoxyphenyl)prop-2-en-1-one
-
-
(2E)-1-(2-hydroxy-4-methoxyphenyl)-3-(3,4,5-trimethoxyphenyl)prop-2-en-1-one
-
-
(2E)-1-(2-hydroxy-4-methoxyphenyl)-3-(4-hydroxyphenyl)prop-2-en-1-one
-
-
(2E)-1-(2-hydroxy-4-methoxyphenyl)-3-(4-methoxyphenyl)prop-2-en-1-one
-
-
(2E)-1-(2-hydroxy-4-methoxyphenyl)-3-[3-methoxy-4-(3-phenoxypropoxy)phenyl]prop-2-en-1-one
-
-
(2E)-1-(2-hydroxy-4-methoxyphenyl)-3-[4-(morpholin-4-ylcarbonyl)phenyl]prop-2-en-1-one
-
-
(2E)-1-(2-hydroxy-4-methoxyphenyl)-3-[4-(piperidin-1-ylcarbonyl)phenyl]prop-2-en-1-one
-
-
(2E)-1-(2-hydroxy-4-methoxyphenyl)-3-[4-(pyrrolidin-1-ylcarbonyl)phenyl]prop-2-en-1-one
-
-
(2E)-1-(2-hydroxy-4-methoxyphenyl)-3-[4-[(4-methylpiperazin-1-yl)carbonyl]phenyl]prop-2-en-1-one
-
-
(2E)-3-(3,4-dihydroxyphenyl)-1-(2,4-dimethoxyphenyl)prop-2-en-1-one
-
-
(2E)-3-(3,4-dihydroxyphenyl)prop-2-enoic acid
-
-
(2E)-3-[3-(2-ethoxyethoxy)phenyl]-1-(2-hydroxy-4-methoxyphenyl)prop-2-en-1-one
-
-
(2E)-3-[4-(2-ethoxyethoxy)phenyl]-1-(2-hydroxy-4-methoxyphenyl)prop-2-en-1-one
-
-
(2E)-3-[4-(3-ethoxypropoxy)-3-methoxyphenyl]-1-(2-hydroxy-4-methoxyphenyl)prop-2-en-1-one
-
-
(2E)-3-[4-(benzyloxy)-3-bromo-5-methoxyphenyl]-1-(2-hydroxy-4-methoxyphenyl)prop-2-en-1-one
-
-
(2E)-3-[4-(benzyloxy)phenyl]-1-(2-hydroxy-4-methoxyphenyl)prop-2-en-1-one
-
-
(2E)-3-[4-[(1E)-3-[[(2E)-3-(2,3-dihydroxyphenyl)prop-2-enoyl]oxy]prop-1-en-1-yl]phenyl]prop-2-en-1-yl (2E)-3-(3,4-dihydroxyphenyl)prop-2-enoate
caffeic acid phenylethyl ester analogue, IC50 value for inhibition of 5-Lox product synthesis in transfected HEK-293 cells is 0.00061 mM. Compound is a good radical scavenger
-
(2E,2'E)-(1,1'-(2,2-bis((4-(((E)-3-(3,4-dihydroxyphenyl)acryloyloxy)methyl)-1H-1,2,3-triazol-1-yl)methyl)propane-1,3-diyl)bis(1H-1,2,3-triazole-4,1-diyl))bis(methylene) bis(3-(3,4-dihydroxyphenyl)acrylate)
-
potent inhibition by 92%
(2E,2'E)-(1,1'-(2,2-bis((4-(cinnamoyloxymethyl)-1H-1,2,3-triazol-1-yl)methyl)propane-1,3-diyl)bis(1H-1,2,3-triazole-4,1-diyl))bis(methylene) bis(3-phenylacrylate)
-
shows less inhibitory activity than the corresponding clusters bearing the caffeic acid moiety
(2E,2'E)-(1,1'-(2-((4-(((E)-3-(3,4-dihydroxyphenyl)acryloyloxy)methyl)-1H-1,2,3-triazol-1-yl)methyl)-2-(hydroxymethyl)propane-1,3-diyl)bis(1H-1,2,3-triazole-4,1-diyl))bis(methylene) bis(3-(3,4-dihydroxyphenyl)acrylate)
-
potent inhibition by 91%
(2E,2'E)-(1,1'-(2-((4-(cinnamoyloxymethyl)-1H-1,2,3-triazol-1-yl)methyl)-2-(hydroxymethyl)propane-1,3-diyl)bis(1H-1,2,3-triazole-4,1-diyl))bis(methylene) bis(3-phenylacrylate)
-
shows less inhibitory activity than the corresponding clusters bearing the caffeic acid moiety
(2E,2'E)-2,2'-(4,4'-(2,2-bis(((1-(2-((E)-3-(3,4-dihydroxyphenyl)acryloyloxy)ethyl)-1H-1,2,3-triazol-4-yl)methoxy)methyl)propane-1,3-diyl)bis(oxy)bis(methylene)bis(1H-1,2,3-triazole-4,1-diyl))bis(ethane-2,1-diyl) bis(3-(3,4-dihydroxyphenyl)acrylate)
-
-
(2E,2'E)-2,2'-(4,4'-(2,2-bis(((1-(2-(cinnamoyloxy)ethyl)-1H-1,2,3-triazol-4-yl)methoxy)methyl)propane-1,3-diyl)bis(oxy)bis(methylene)bis(1H-1,2,3-triazole-4,1-diyl))bis(ethane-2,1-diyl) bis(3-phenylacrylate)
-
shows less inhibitory activity than the corresponding clusters bearing the caffeic acid moiety
(2E,5E)-5-[(2E)-3-(furan-2-yl)prop-2-en-1-ylidene]-3-phenyl-2-(phenylimino)-1,3-thiazolidin-4-one
-
-
(2E,6E,10E)-13-((R)-6-hydroxy-2,5,7,8-tetramethylchroman-2-yl)-N-(4-methoxybenzyl)-2,6,10-trimethyltrideca-2,6,10-trienamide
significant inhibitory activity in both cell-free and cell-based assays, inhibits leukotriene biosynthesis by human primary polymorphonuclear leukocytes, IC50 value 250 nM
-
(2E,6E,10E)-13-((R)-6-hydroxy-2,8-dimethylchroman-2-yl)-N-(4-methoxybenzyl)-2,6,10-trimethyltrideca-2,6,10-trienamide
significant inhibitory activity in both cell-free and cell-based assays, inhibits leukotriene biosynthesis by human primary polymorphonuclear leukocytes, IC50 value 184 nM
-
(2E,6E,10E)-13-(6-hydroxy-2,8-dimethylchroman-2-yl)-2,6,10-trimethyl-N-(pyridin-3-ylmethyl)trideca-2,6,10-trienamide
inhibits leukotriene biosynthesis by human primary polymorphonuclear leukocytes, IC50 value 415 nM
-
(2E,6E,10E)-N-benzyl-13-((R)-6-hydroxy-2,5,7,8-tetramethylchroman-2-yl)-2,6,10-trimethyltrideca-2,6,10-trienamide
significant inhibitory activity in both cell-free and cell-based assays, inhibits leukotriene biosynthesis by human primary polymorphonuclear leukocytes, IC50 value 173 nM
-
(2E,6E,10E)-N-benzyl-13-((R)-6-hydroxy-2,8-dimethylchroman-2-yl)-2,6,10-trimethyltrideca-2,6,10-trienamide
inhibits leukotriene biosynthesis by human primary polymorphonuclear leukocytes, IC50 value 303 nM
-
(2Z)-2-[4-(acetylamino)phenyl]-3-[4-(methylsulfonyl)phenyl]prop-2-enoic acid
-
-
(5E)-2-(3-acetylphenyl)-5-(4-methoxybenzylidene)-1,3-thiazol-4(5H)-one
-
-
(5E)-2-(3-fluorophenyl)-5-(4-methoxybenzylidene)-1,3-thiazol-4(5H)-one
-
-
(5E)-2-(4-acetylphenyl)-5-(4-methoxybenzylidene)-1,3-thiazol-4(5H)-one
-
-
(5E)-2-(4-aminophenyl)-5-(4-methoxybenzylidene)-1,3-thiazol-4(5H)-one
-
-
(5E)-2-(4-chlorophenyl)-5-(4-hydroxybenzylidene)-1,3-thiazol-4(5H)-one
-
-
(5E)-2-(4-chlorophenyl)-5-(4-methoxybenzylidene)-1,3-thiazol-4(5H)-one
-
-
(5E)-2-(4-hydroxyphenyl)-5-(4-methoxybenzylidene)-1,3-thiazol-4(5H)-one
-
-
(5E)-2-(4-methylphenyl)-5-(3,4,5-trimethoxybenzylidene)-1,3-thiazol-4(5H)-one
-
-
(5E)-5-(2,4-dimethoxybenzylidene)-2-(4-methylphenyl)-1,3-thiazol-4(5H)-one
-
-
(5E)-5-(2-hydroxy-3-methoxybenzylidene)-2-(4-methylphenyl)-1,3-thiazol-4(5H)-one
-
-
(5E)-5-(2-hydroxy-3-methoxybenzylidene)-2-phenyl-1,3-thiazol-4(5H)-one
-
-
(5E)-5-(3,5-dimethoxybenzylidene)-2-(4-methylphenyl)-1,3-thiazol-4(5H)-one
-
-
(5E)-5-(3-chloro-4-hydroxy-5-methoxybenzylidene)-2-(4-methylphenyl)-1,3-thiazol-4(5H)-one
-
-
(5E)-5-(3-chloro-4-hydroxy-5-methoxybenzylidene)-2-phenyl-1,3-thiazol-4(5H)-one
-
-
(5E)-5-(3-chloro-5-ethoxy-4-hydroxybenzylidene)-2-(4-methylphenyl)-1,3-thiazol-4(5H)-one
-
-
(5E)-5-(3-chlorobenzylidene)-2-(4-methylphenyl)-1,3-thiazol-4(5H)-one
-
-
(5E)-5-(4-hydroxy-3-methoxy-5-nitrobenzylidene)-2-phenyl-1,3-thiazol-4(5H)-one
-
-
(5E)-5-(4-methoxybenzylidene)-2-(4-methoxyphenyl)-1,3-thiazol-4(5H)-one
-
-
(5E)-5-(4-methoxybenzylidene)-2-(4-methylphenyl)-1,3-thiazol-4(5H)-one
-
-
(5E)-5-(4-methoxybenzylidene)-2-phenyl-1,3-thiazol-4(5H)-one
-
-
(5E)-5-(4-tert-butylbenzylidene)-2-phenyl-1,3-thiazol-4(5H)-one
-
-
(5E)-5-(4-[(methylperoxy)acetyl]benzylidene)-2-(4-methylphenyl)-1,3-thiazol-4(5H)-one
-
-
(5E)-5-(5-chloro-2-hydroxy-3-methoxybenzylidene)-2-phenyl-1,3-thiazol-4(5H)-one
-
-
(5E)-5-(anthracen-9-ylmethylidene)-2-phenyl-1,3-thiazol-4(5H)-one
-
-
(5E)-5-4-[(methylperoxy)acetyl]benzylidene
-
-
(5E)-5-benzylidene-2-(4-methylphenyl)-1,3-thiazol-4(5H)-one
-
-
(5E)-5-[4-(dimethylamino)benzylidene]-2-(piperidin-1-yl)-1,3-thiazol-4(5H)-one
-
-
(5S,6S,7E,9E,11Z,14Z)-5,6-epoxyicosa-7,9,11,14-tetraenoate
product inhibition
(5Z)-2-(cyclohexylamino)-5-(4-propoxybenzylidene)-1,3-thiazol-4(5H)-one
-
-
(5Z)-5-(4-methoxybenzylidene)-2-(pyrrolidin-1-yl)-1,3-thiazol-4(5H)-one
-
-
(5Z)-5-(4-methylbenzylidene)-2-(naphthalen-2-ylamino)-1,3-thiazol-4(5H)-one
-
-
(5Z)-5-benzylidene-2-(phenylamino)-1,3-thiazol-4(5H)-one
-
-
(6E,8Z,11Z,14Z)-(5S)-hydroperoxyicosa-6,8,11,14-tetraenoate
-
inhibits reaction with arachidonate
(E)-N-hydroxy-N-(3-(3-phenoxyphenyl)-allyl)acetamide
-
BWA4C
(R)-N-((3-(3-fluoro-4-morpholinophenyl)-2-oxooxazolidin-5-yl) methyl)-N-hydroxyheptanamide
-
-
(R)-N-((3-(3-fluoro-4-morpholinophenyl)-2-oxooxazolidin-5-yl) methyl)-N-hydroxyoctanamide
-
-
(R)-N-((3-(3-fluoro-4-morpholinophenyl)-2-oxooxazolidin-5-yl)methyl)-N-hydroxypentanamide
-
-
(R)-N-(2-(diphenylamino)ethyl)-3-(3-(1-hydroxyureido)but-1-yn-1-yl)benzamide
dual 5-LOX/soluble epoxide hydrolase inhibitor
-
(R)-N-(3,3-bis(4-fluorophenyl)propyl)-3-(3-(1-hydroxyureido)but-1-yn-1-yl)benzamide
dual 5-LOX/soluble epoxide hydrolase inhibitor
-
([3-chloro-5-(2,3-dihydro-1H-inden-4-ylamino)phenyl]sulfanyl)acetic acid
-
-
([4-chloro-6-[(2,3-dimethylphenyl)amino]pyrimidin-2-yl]sulfanyl)(naphthalen-1-yl)acetic acid
-
-
1,10-phenanthroline
-
0.01 mM, 34% inhibition
1,4a-dimethyl-7-(propan-2-yl)-1-(prop-1-en-2-yl)-1,2,3,4,4a,4b,5,6,10,10a-decahydrophenanthrene (non-preferred name)
-
-
1-(2,4-difluorophenyl)-3-(3,5a,10-trimethyl-2-oxo-2,3,3a,4,5,5a,6,10,10a,10b-decahydrofuro[3',2':7,8]naphtho[2,3-d][1,3]thiazol-8-yl)urea
-
-
1-(2,4-dihydroxyphenyl)-2-(naphthalen-2-yl)ethanone
-
-
1-(3,4-dichlorobenzyl)-3-(2-morpholin-4-yl-2-oxoethyl)-1H-indole
82% inhibition at 0.005 mM
1-(3,4-dichlorobenzyl)-3-(3-morpholin-4-yl-3-oxopropyl)-1H-indole
38.5% inhibition at 0.005 mM
1-(3,4-difluorophenyl)-1,2,4-triazinan-3-one
-
-
1-(3-bromophenyl)-1,2,4-triazinan-3-one
-
-
1-(3-chlorophenyl)-1,2,4-triazinan-3-one
-
-
1-(3-ethylphenyl)-1,2,4-triazinan-3-one
-
-
1-(3-hydroxyphenyl)-3-[4-(methylsulfonyl)phenyl]prop-2-yn-1-one
1-(3-[5-(hydroxyureido)methyl-2-methoxyphenoxy]propyl)-3-[4-(trifluoromethoxy)phenyl]urea
KM55, a multitarget ligand and dual 5-lipoxygenase (5-LO)/soluble epoxide hydrolase (sEH) inhibitor. KM55 potently inhibits both enzymes in vitro and attenuates the formation of leukotrienes in human whole blood. It significantly inhibits the LPS-induced adhesion of leukocytes to endothelial cells by blocking leukocyte activation. Compound synthesis and evaluation, overview. KM55 inhibits the formation of leukotriene B4 and 5-hydroxyeicosatrienoic acid, while the formation of 12-hydroperoxyicosatetraenoate and 15-hydroperoxyicosatetraenoate are unaffected. KM55 blocks leukocyte-endothelial cell interaction by impairing leukocyte activation, whereas endothelial cells are not affected
1-(4-aminosulfonylphenyl)-5-(2-chloropyridin-4-yl)-3-trifluoromethyl-1H-pyrazole
-
-
1-(4-aminosulfonylphenyl)-5-[4-(1-difluoromethyl-1,2-dihydropyrid-2-one)]-3-trifluoromethyl-1H-pyrazole
-
-
1-(4-chlorobenzyl)-2-[2,2-dimethyl-3-(1H-tetrazol-5-yl)propyl]-4-methyl-6-[2-(5-phenylpyridin-2-yl)ethyl]-2,2a,4,5-tetrahydro-1H-thiopyrano[2,3,4-cd]indole
-
-
1-(4-chlorophenoxy)-3-(2-morpholin-4-yl-2-oxoethyl)-1H-indole
22% inhibition at 0.005 mM
1-(4-chlorophenoxy)-3-(3-morpholin-4-yl-3-oxopropyl)-1H-indole
26% inhibition at 0.005 mM
1-(4-chlorophenoxy)-5-methoxy-2-methyl-3-(4-morpholin-4-yl-4-oxobutyl)-1H-indole
70% inhibition at 0.005 mM
1-(4-methanesulfonylphenyl)-5-(2-chloropyridin-4-yl)-3-trifluoromethyl-1H-pyrazole
-
-
1-(4-methanesulfonylphenyl)-5-[4-(1-difluoromethyl-1,2-dihydropyrid-2-one)]-3-trifluoromethyl-1H-pyrazole
-
-
1-(4-methylbenzyl)-3-(2-morpholin-4-yl-2-oxoethyl)-1H-indole
35% inhibition at 0.005 mM
1-(4-methylbenzyl)-3-(3-morpholin-4-yl-3-oxopropyl)-1H-indole
55% inhibition at 0.005 mM
1-(6-methylpyridin-2-yl)-1,2,4-triazinan-3-one
-
-
1-(7-tert-butyl-3,3-dimethyl-2,3-dihydro-1-benzofuran-5-yl)butan-1-one
-
-
1-(8-tert-butyl-4,4-dimethyl-3,4-dihydro-2H-chromen-6-yl)-4-cyclopropylbutan-1-one
-
-
1-(benzyloxy)hept-2-yn-4-ol
-
forms three hydrogen bonds with 5-lipoxygenase
1-(difluoromethyl)-5-[[2-(methylsulfonyl)phenyl]ethynyl]pyridin-2(1H)-one
-
-
1-benzyl-3-(2-morpholin-4-yl-2-oxoethyl)-1H-indole
41% inhibition at 0.005 mM
1-benzyl-3-(3,5a,10-trimethyl-2-oxo-2,3,3a,4,5,5a,6,10,10a,10b-decahydrofuro[3',2':7,8]naphtho[2,3-d][1,3]thiazol-8-yl)urea
-
-
1-benzyl-3-(3-morpholin-4-yl-3-oxopropyl)-1H-indole
64% inhibition at 0.005 mM
1-benzyl-3-(4-morpholin-4-ylbutyl)-1H-indole
42% inhibition at 0.005 mM
1-benzyl-3-(4-oxo-4-piperazin-1-ylbutyl)-1H-indole
95% inhibition at 0.005 mM
1-benzyl-3-[2-[3-fluoro-5-(4-methoxytetrahydro-2H-pyran-4-yl)phenoxy]ethyl]-1H-indole
32% inhibition at 0.005 mM
1-benzyl-3-[3-[3-fluoro-5-(4-methoxytetrahydro-2H-pyran-4-yl)phenoxy]propyl]-5-methoxy-2-methyl-1H-indole
46.5% inhibition at 0.005 mM
1-benzyl-5-chloro-2-methyl-3-(4-morpholin-4-yl-4-oxobutyl)-1H-indole
80% inhibition at 0.005 mM
1-benzyl-5-methoxy-2-methyl-3-(4-morpholin-4-yl-4-oxobutyl)-1H-indole
54% inhibition at 0.005 mM
1-benzyl-5-methoxy-2-methyl-3-(4-oxo-4-piperazin-1-ylbutyl)-1H-indole
65% inhibition at 0.005 mM
1-hydroxy-1-[1-(5-methoxy-1-methyl-1H-indol-2-yl)ethyl]urea
-
-
1-O-dodecyl 2,3-O-isopropylidene-5,6-dideoxy-5-N-[4-(2-hydroxy-2-oxoethyl) phenylaminocarbonyl] amino-beta-L-gulofuranoside sodium salt
-
competitive inhibitor, IC50: 0.0035 mM with recombinant enzyme, IC50: 0.005 mM with native enzyme
1-phenyl-5-(propan-2-yl)-1,2,4-triazinan-3-one
-
-
1-[(4methylbenzyl)oxy]hept-2-yn-4-ol
-
is more potent than 1-(benzyloxy)hept-2-yn-4-ol to 5-lipoxygenase
1-[1-(6-tert-butyl-1-benzothiophen-2-yl)ethyl]-1-hydroxyurea
-
-
1-[3-(benzyloxy)phenyl]-1,2,4-triazinan-3-one
-
-
1-[3-(methylsulfanyl)phenyl]-3-(3,5a,10-trimethyl-2-oxo-2,3,3a,4,5,5a,6,10,10a,10b-decahydrofuro[3',2':7,8]naphtho[2,3-d][1,3]thiazol-8-yl)urea
-
-
1-[4-([3-fluoro-5-[4-(methylsulfinyl)tetrahydro-2H-pyran-4-yl]phenoxy]methyl)phenyl]-2-methyl-1H-imidazole
-
-
1-[4-([3-fluoro-5-[4-(methylsulfonyl)tetrahydro-2H-pyran-4-yl]phenoxy]methyl)phenyl]-2-methyl-1H-imidazole
-
-
10,17(S)-dihydroxydocosahexaenoic acid
-
IC50: 0.017 mM
10-nitro-oleic acid
inhibition of the 5-LO product formation of intact human polymorphonuclear leukocytes, IC50 value 0.0015 mM
-
11,14,17-Eicosatrienoic acid
11alpha,13-dihydrohelenalin acetate
-
enzyme from polymorphonuclear leukocyte
15-hydroperoxy-6,8,11,13-eicosatetraenoic acid
-
IC50: 0.0048 mM
2,3,4',5-tetrahydroxystilbene-2-O-D-glucoside
-
polymorphonuclear leukocyte
2,3-dichlorophenyl 3,5-dinitrobenzoate
-
2,5-dimethoxy-3-tridecylbenzene-1,4-diol
-
2-(1-difluoromethyl-2-oxo-1,2-dihydropyridin-3-yl)propanoic acid
-
-
2-(1-difluoromethyl-2-oxo-1,2-dihydropyridin-4-yl)phenylacetic acid
-
micromolar 5-LOX inhibitory activity
2-(1-difluoromethyl-2-oxo-1,2-dihydropyridin-4-yl)propanoic acid
-
-
2-(1-difluoromethyl-2-oxo-1,2-dihydropyridin-5-yl)acetic acid
-
-
2-(1-difluoromethyl-2-oxo-1,2-dihydropyridin-5-yl)propanoic acid
-
-
2-(2,2-dimethyl-6-(4-nitrophenyl)-7-phenyl-2,3-dihydro-1H-pyrrolizin-5-yl)acetic acid
-
-
2-(2,2-dimethyl-7-phenyl-6-(4-(trifluoromethyl)phenyl)-2,3-dihydro-1H-pyrrolizin-5-yl)acetic acid
-
-
2-(2,4-dihydroxyphenyl)-8,8-dimethyl-3-(3-methylbut-2-en-1-yl)-4H,8H-pyrano[2,3-f]chromen-4-one
-
-
2-(2-methoxyphenyl)-N-(3,5a,10-trimethyl-2-oxo-2,3,3a,4,5,5a,6,10,10a,10b-decahydrofuro[3',2':7,8]naphtho[2,3-d][1,3]thiazol-8-yl)acetamide
-
-
2-(2-[ethyl(hydroxy)amino]ethyl)dibenzo[b,e]oxepin-11(6H)-one
-
-
2-(3,4,5-trihydroxyphenyl)-3,4-dihydro-2H-chromene-3,5,7-triol
-
-
2-(3,4-dihydroxyphenyl)-3,4-dihydro-2H-chromene-3,5,7-triol
-
-
2-(3,4-dihydroxyphenyl)-3,5,7-trihydroxy-4H-chromen-4-one
-
-
2-(3-acetylphenyl)propanoic acid
-
2-(3-benzoylphenyl)propanoic acid
-
2-(3-methylbut-2-en-1-yl)-6H-[1]benzofuro[3,2-c]chromene-3,6,9-triol
-
-
2-(3-phenoxyphenyl)propanoic acid
-
2-(3-[hydroxy(methyl)amino]propyl)dibenzo[b,e]oxepin-11(6H)-one
-
-
2-(4-(biphenyl-4-ylamino)-6-chloropyrimidine-2-ylthio)octanoic acid
-
-
2-(4-(biphenyl-4-ylmethylamino)-6-chloropyrimidin-2-ylthio)octanoic acid
-
-
2-(4-chloro-6-(2,3-dimethylphenylamino)pyrimidin-2-ylthio)acetic acid
-
-
2-(4-chloro-6-(4'-cyanobiphenyl-4-ylamino)pyrimidin-2-ylthio)octanoic acid
-
-
2-(4-chloro-6-(5-methoxy-2-methylbiphenyl-4-ylamino)pyrimidin-2-ylthio)octanoic acid
-
-
2-(4-methylphenyl)-5-(2-phenylethenylidene)-1,3-thiazol-4(5H)-one
-
-
2-(5,8-dimethyl-7-propoxy-1,2,3,4-tetrahydronaphthalen-2-yl)-N-(5-methyl-1,3-thiazol-2-yl)propanamide
-
-
2-(5,8-dimethyl-7-propoxy-1,2,3,4-tetrahydronaphthalen-2-yl)-N-1,3-thiazol-2-ylpropanamide
-
-
2-(5,8-dimethyl-7-propoxy-1,2,3,4-tetrahydronaphthalen-2-yl)-N-pyridin-2-ylpropanamide
-
-
2-(5,8-dimethyl-7-propoxy-1,2,3,4-tetrahydronaphthalen-2-yl)-N-thiophen-3-ylpropanamide
-
-
2-(6-(4-chlorophenyl)-2,2-dimethyl-7-phenyl-2,3-dihydro-1H-pyrrolizin-5-yl)-N-(methylsulfonyl)acetamide
-
-
2-(6-(4-chlorophenyl)-2,2-dimethyl-7-phenyl-2,3-dihydro-1H-pyrrolizin-5-yl)-N-(phenylsulfonyl)acetamide
-
-
2-(6-(4-chlorophenyl)-2,2-dimethyl-7-phenyl-2,3-dihydro-1H-pyrrolizin-5-yl)-N-tosylacetamide
-
-
2-(6-(4-chlorophenyl)-2,2-dimethyl-7-phenyl-2,3-dihydro-1Hpyrrolizin-5-yl)-N-tosylpropanamide
-
-
2-(6-(4-chlorophenyl)-7-phenyl-2,3-dihydro-1H-pyrrolizin-5-yl)acetic acid
-
-
2-(6-(4-tert-butylphenyl)-2,2-dimethyl-7-phenyl-2,3-dihydro-1H-pyrrolizin-5-yl)acetic acid
-
-
2-(7-methoxy-5,8-dimethyl-1,2,3,4-tetrahydronaphthalen-2-yl)-N-(thiophen-2-ylmethyl)propanamide
-
-
2-(7-methoxy-5,8-dimethyl-1,2,3,4-tetrahydronaphthalen-2-yl)-N-1,3-thiazol-2-ylpropanamide
-
-
2-(7-methoxy-5,8-dimethyl-1,2,3,4-tetrahydronaphthalen-2-yl)-N-pyridin-2-ylpropanamide
-
-
2-(dibenzo[b,d]furan-3-yl)-5-hydroxycyclohexa-2,5-diene-1,4-dione
-
-
2-([4-chloro-6-[(2,3-dimethylphenyl)amino]pyrimidin-2-yl]sulfanyl)octanoic acid
-
-
2-benzyl-5-hydroxycyclohexa-2,5-diene-1,4-dione
-
-
2-hexyl-5-hydroxycyclohexa-2,5-diene-1,4-dione
-
-
2-hydroxy-5-(3-nitrophenyl)cyclohexa-2,5-diene-1,4-dione
-
-
2-hydroxy-5-(naphthalen-2-ylmethyl)cyclohexa-2,5-diene-1,4-dione
-
-
2-hydroxy-5-methoxy-3-(naphthalen-2-ylmethyl)cyclohexa-2,5-diene-1,4-dione
-
-
2-methoxy-5-(naphthalen-2-yloxy)cyclohexa-2,5-diene-1,4-dione
-
-
2-methyl-3-[(morpholine-4-carbonyl)amino]-3-oxopropanoic acid
-
2-phenylethyl (2E)-3-(2,5-dihydroxyphenyl)prop-2-enoate
-
2-phenylethyl (2E)-3-(4-hydroxy-3,5-dimethoxyphenyl)prop-2-enoate
inhibits leukotriene biosynthesis in isolated human neutrophils and in whole blood
-
2-[(1-hydroxy-6-oxo-1,6-dihydropyridin-3-yl)ethynyl]benzenesulfonamide
-
-
2-[(4-[[3,5-bis(2,2,2-trifluoroethoxy)phenyl]amino]-6-chloropyrimidin-2-yl)sulfanyl]octanoic acid
-
-
2-[2-(1-difluoromethyl-2-oxo-1,2-dihydropyridin-4-yl)phenyl]propanoic acid
-
micromolar 5-LOX inhibitory activity
2-[2-[(2-methyl-1H-benzimidazol-1-yl)methyl]phenoxy]acetamide
a BRP-7 derivative
2-[2-[(2-[1-[4-(2-methylpropyl)phenyl]ethyl]-1H-benzimidazol-1-yl)methyl]phenoxy]acetamide
a BRP-7 derivative
2-[3-(1-difluoromethyl-2-oxo-1,2-dihydropyridin-4-yl)phenyl]propanoic acid
-
micromolar 5-LOX inhibitory activity
2-[3-(2-methylpropanoyl)phenyl]propanoic acid
-
2-[3-(morpholine-4-carbonyl)phenyl]propanoic acid
-
2-[3-[(4-hydroxyphenyl)carbamoyl]phenyl]propanoic acid
-
2-[3-[hydroxy(phenyl)amino]phenyl]propanoic acid
-
2-[4'-(iso-propylphenyl)-amino]-5,6-dimethyl-1,4-benzoquinone
-
potent inhibitor, IC50: 0.006 mM
2-[4'-[(morpholin-4-yl)sulfanyl][1,1'-biphenyl]-3-yl]propanoic acid
-
2-[4-(1-difluoromethyl-2-oxo-1,2-dihydropyridin-4-yl)phenyl]propanoic acid
-
micromolar 5-LOX inhibitory activity
2-[4-(morpholine-4-carbonyl)phenyl]propanoic acid
-
2-[4-([[(2E)-3-phenylprop-2-enoyl]oxy]methyl)-1H-1,2,3-triazol-1-yl]ethyl (2E)-3-(3,4-dihydroxyphenyl)prop-2-enoate
-
-
2-[5,8-dimethyl-7-(2-morpholin-4-ylethoxy)-1,2,3,4-tetrahydronaphthalen-2-yl]-N-1,3-thiazol-2-ylpropanamide
-
-
2-[6-(4-chlorophenyl)-2,2-dimethyl-7-phenyl-2,3-dihydro-1H-pyrrolizin-5-yl]acetic acid
-
-
2-[7-[2-(dimethylamino)ethoxy]-5,8-dimethyl-1,2,3,4-tetrahydronaphthalen-2-yl]-N-1,3-thiazol-2-ylpropanamide
-
-
2-[7-[2-(dimethylamino)ethoxy]-5,8-dimethyl-1,2,3,4-tetrahydronaphthalen-2-yl]-N-pyridin-2-ylpropanamide
-
-
2-[[5-fluoro-6-(4-fluorophenoxy)-1H-benzimidazol-2-yl]sulfanyl]-2-methylpropanoic acid
-
additionally inhibts soluble epoxide hydrolase. Compound shows potent anti-inflammatory activity and significant inhibition of edema at a dose of 100 mg/kg
-
3'-nitrobiphenyl-2,4-diol
-
-
3,4,5-trimethoxy-N-(3,5a,10-trimethyl-2-oxo-2,3,3a,4,5,5a,6,10,10a,10b-decahydrofuro[3',2':7,8]naphtho[2,3-d][1,3]thiazol-8-yl)benzamide
-
-
3,4,6-trimethoxy-5-undecylcyclohexa-2,4-dien-1-one
-
3-((naphthalene-1-yloxy)carbonyl)benzoic acid
-
3-(1,10-dihydroxydecyl)-2,5-dimethoxycyclohexa-2,5-diene-1,4-dione
-
3-(1-acetoxy-10-hydroxydecyl)-2,5-dimethoxycyclohexa-2,5-diene-1,4-dione
-
3-(1-carboxyethyl)benzoic acid
-
3-(1-difluoromethyl-2-oxo-1,2-dihydropyridin-4-yl)phenylacetic acid
-
micromolar 5-LOX inhibitory activity
3-(10-hydroxydecyl)-2,5-dimethoxycyclohexa-2,5-diene-1,4-dione
-
3-(10-hydroxydecyl)-4,5-dimethoxycyclohexa-3,5-diene-1,2-dione
-
3-(11-hydroxyundecyl)-2,5-dimethoxycyclohexa-2,5-diene-1,4-dione
-
3-(11-hydroxyundecyl)-4,5-dimethoxycyclohexa-3,5-diene-1,2-dione
-
3-(2-(2-[(4-chlorophenyl)sulfanyl]ethoxy)-3-methoxy-5-[5-(3,4,5-trimethoxyphenyl)tetrahydrofuran-2-yl]benzyl)-1-hydroxy-1-methylurea
-
-
3-(2-morpholin-4-yl-2-oxoethyl)-1-phenoxy-1H-indole
21% inhibition at 0.005 mM
3-(2-morpholin-4-yl-2-oxoethyl)-1H-indole
16% inhibition at 0.005 mM
3-(3-(1-hydroxyureido)but-1-yn-1-yl)-N-(2-(trifluoromethyl)-benzyl)benzamide
dual 5-LOX/soluble epoxide hydrolase inhibitor
-
3-(3-(1-hydroxyureido)but-1-yn-1-yl)-N-(3-phenyl-3-(4-(trifluoromethoxy)phenyl)propyl)benzamide
dual 5-LOX/soluble epoxide hydrolase inhibitor
-
3-(3-(1-hydroxyureido)but-1-yn-1-yl)-N-(4-methoxy-2-(trifluoromethyl)benzyl)-benzamide
dual 5-LOX/soluble epoxide hydrolase inhibitor
-
3-(3-(1-hydroxyureido)hex-1-yn-1-yl)-N-(2-(trifluoromethyl)-benzyl)benzamide
dual 5-LOX/soluble epoxide hydrolase inhibitor
-
3-(3-morpholin-4-yl-3-oxopropyl)-1-phenoxy-1H-indole
23% inhibition at 0.005 mM
3-(3-morpholin-4-yl-3-oxopropyl)-1H-indole
33% inhibition at 0.005 mM
3-(4,5-dihydroxy-2-methyl-9,10-dioxo-4a,9,9a,10-tetrahydroanthracen-1-yl)-2-hydroxy-4,6-dimethoxybenzoic acid
-
-
3-(4-morpholin-4-yl-4-oxobutyl)-1H-indole
62% inhibition at 0.005 mM
3-(6-(4-chlorphenyl)-2,2-dimethyl-7-phenyl-2,3-dihydro-1H-pyrrolizin-5-yl)propionic acid
-
-
3-(8-hydroxyoctyl)-2,5-dimethoxycyclohexa-2,5-diene-1,4-dione
-
3-(8-hydroxyoctyl)-4,5-dimethoxycyclohexa-3,5-diene-1,2-dione
-
3-(benzyloxycarbonyl)benzoic acid
-
3-(cyclohexylmethyl)-2,5-dihydroxycyclohexa-2,5-diene-1,4-dione
-
-
3-(decahydronaphthalen-2-ylmethyl)-2,5-dihydroxycyclohexa-2,5-diene-1,4-dione
-
-
3-(naphhthalen-1-ylcarbmoyl)benzoic acid
-
3-(phenylcarbamoyl)benzoic acid
-
3-acetyl-11-keto-beta-boswellic acid
allosteric inhibitor from frankincense, wedges between the membrane-binding and catalytic domains of 5-LOX, some 30 A from the catalytic iron. Binding promotes a shift in the regiospecificity, i.e. a significant increase in the formation of 12-hydroxyeicosatetraenoic acid with the most prominent effect at 10 microM
3-benzyl-2-hydroxy-5-methoxycyclohexa-2,5-diene-1,4-dione
-
-
3-dodecyl-4,5-dimethoxybenzene-1,2-diol
-
3-dodecyl-4,5-dimethoxycyclohexa-3,5-diene-1,2-dione
-
3-ethoxy-11-oxours-12-en-23-oic acid
-
-
3-n-pentadecylcatechol
-
-
3-propylphenyl 3,5-dinitrobenzoate
-
3-tolyl 3,5-dinitrobenzoate
-
3-tridecyl-4,5-dimethoxybenzene-1,2-diol
shows anti-inflammatory effectiveness
3-undecyl-4,5-dimethoxybenzene-1,2-diol
-
3-[(10E)-pentadec-10'-en-1-yl]-catechol
-
-
3-[(10Z)-pentadec-10'-en-1-yl]-catechol
-
-
3-[2-[3-fluoro-5-(4-methoxytetrahydro-2H-pyran-4-yl)phenoxy]ethyl]-1H-indole
64% inhibition at 0.005 mM
3-[4-(3-[[(2E)-3-(2,3-dihydroxyphenyl)prop-2-enoyl]oxy]prop-1-yn-1-yl)phenyl]prop-2-yn-1-yl (2E)-3-(3,4-dihydroxyphenyl)prop-2-enoate
caffeic acid phenylethyl ester analogue, IC50 value for inhibition of 5-Lox product synthesis in transfected HEK-293 cells is 0.00036 mM. Compound is a good radical scavenger
-
3-[4-(methylsulfonyl)phenyl]-1-[4-(propan-2-yl)phenyl]prop-2-yn-1-one
-
-
3-[5-[(2E)-3,7-dimethylocta-2,6-dien-1-yl]-2,4-dihydroxyphenyl]-5,7-dihydroxy-2,3-dihydro-4H-chromen-4-one
-
-
3-[[3-fluoro-5-(4-methoxytetrahydro-2H-pyran-4-yl)phenoxy]methyl]-1-[4-(methylsulfonyl)phenyl]-5-phenyl-1H-pyrazole
-
-
4,4'-(2,3-dimethyl)-1,4-butanediylbis-1,2-benzenediol
-
-
4,5-bis(4-chlorophenyl)-1,2-selenazole
-
44% inhibition at 0.01 mM
4,5-bis(4-methoxyphenyl)-1,2-selenazole
-
58% inhibition at 0.01 mM
4,5-dimethoxy-3-tridecylcyclohexa-3,5-diene-1,2-dione
shows anti-inflammatory effectiveness
4,5-dimethoxy-3-undecylcyclohexa-3,5-diene-1,2-dione
-
4,7,10,13,16,19-docosahexaenoic acid
-
IC50: 0.0013 mM
4,9-dimethoxy-3-methyl-9,10-dihydrophenanthrene-2,7-diol
-
-
4-((3,4-dichlorobenzyl)-1H-indol-3-yl)-1-morpholinobutan-1-one
27% inhibition at 0.005 mM
4-((4-chlorobenzoyl)-1H-indol-3-yl)-1-morpholinobutan-1-one
32% inhibition at 0.005 mM
4-(1-(4-methylbenzyl)-1H-indol-3-yl)-1-morpholinobutan-1-one
34% inhibition at 0.005 mM
4-(1-benzothiophen-3-yl)benzene-1,3-diol
-
-
4-(1-benzoyl-1H-indol-3-yl)-1-morpholinobutan-1-one
58% inhibition at 0.005 mM
4-(1-benzyl-1H-indol-3-yl)-1-morpholinobutan-1-one
26% inhibition at 0.005 mM
4-(1-difluoromethyl-2-oxo-1,2-dihydropyridin-4-yl)phenylacetic acid
-
micromolar 5-LOX inhibitory activity
4-(3-(1-hydroxyureido)but-1-yn-1-yl)-N-(2-(trifluoromethyl)-benzyl)benzamide
dual 5-LOX/soluble epoxide hydrolase inhibitor, displays cellular activity in human polymorphonuclear leukocytes, oral bioavailability, and target engagement in vivo and demonstrates anti-inflammatory and anti-fibrotic efficiency in a kidney injury model caused by unilateral ureteral obstruction in mice
-
4-(3-fluoro-5-[[4-(2-methyl-1H-imidazol-1-yl)benzyl]oxy]phenyl)-N-methyltetrahydro-2H-pyran-4-carboxamide
-
-
4-(3-fluoro-5-[[4-(2-methyl-1H-imidazol-1-yl)benzyl]oxy]phenyl)tetrahydro-2H-pyran-4-ol
-
-
4-(3-fluoro-5[[4-(2-methyl-1H-imidazol-1-yl)benzyl]oxy]phenyl)tetrahydro-2H-pyran-4-carboxylic acid
-
-
4-(4-(4-chlorophenyl)thiazol-2-ylimino)cyclohexa-2,5-dienone
ST-1905
4-(4-chlorophenyl)-5-(4-methoxyphenyl)-1,2-selenazole
-
53% inhibition at 0.01 mM
4-(4-chlorophenyl)-5-p-tolyl-1,2-selenazole
-
45% inhibition at 0.01 mM
4-(4-chlorophenyl)-7-([3-fluoro-5-[2,2,2-trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]phenyl]sulfanyl)-2H-chromen-2-one
-
IC50: 180 nM
4-(4-fluorophenyl)-5-(4-(methylsulfonyl)phenyl)-1,2-selenazole
-
60% inhibition at 0.01 mM
4-(4-fluorophenyl)-7-([3-fluoro-5-[2,2,2-trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]phenoxy]methyl)-2H-chromen-2-one
-
IC50: 55 nM
4-(4-fluorophenyl)-7-([3-fluoro-5-[2,2,2-trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]phenyl]sulfanyl)-2H-chromen-2-one
-
IC50: 27 nM
4-(6-methoxynaphthalen-2-yl)butan-2-one
-
-
4-(acetyloxy)-2-[4-(acetyloxy)-6-methylhept-5-en-2-yl]cyclohexyl (2Z)-2-methylbut-2-enoate
-
-
4-(dibenzo[b,d]furan-3-yl)benzene-1,3-diol
-
-
4-(furan-3-yl)-7-[[2-(tetrahydro-2H-pyran-4-yl)pyridin-4-yl]methoxy]naphthalene-2-carbonitrile
-
-
4-(furan-3-yl)-7-[[6-(4-hydroxytetrahydro-2H-pyran-4-yl)pyridin-2-yl]methoxy]naphthalene-2-carbonitrile
-
-
4-(furan-3-yl)-7-[[7-(tetrahydro-2H-pyran-4-yl)-1,2,3,4-tetrahydroquinolin-2-yl]oxy]naphthalene-2-carbonitrile
-
-
4-(naphthalen-2-ylmethyl)benzene-1,3-diol
-
-
4-(thianthren-2-yl)benzene-1,3-diol
-
-
4-([[5-fluoro-6-(1H-1,2,4-triazol-1-yl)-1H-benzimidazol-2-yl]sulfanyl]methyl)benzoic acid
-
additionally inhibts soluble epoxide hydrolase. Compound shows potent anti-inflammatory activity and significant inhibition of edema at a dose of 100 mg/kg
-
4-([[5-fluoro-6-(4-fluorophenoxy)-1H-benzimidazol-2-yl]sulfanyl]methyl)benzoic acid
-
additionally inhibts soluble epoxide hydrolase. Compound shows potent anti-inflammatory activity and significant inhibition of edema at a dose of 100 mg/kg
-
4-([[6-(4-chlorophenoxy)-5-fluoro-1H-benzimidazol-2-yl]sulfanyl]methyl)benzoic acid
-
additionally inhibts soluble epoxide hydrolase. Compound shows potent anti-inflammatory activity and significant inhibition of edema at a dose of 100 mg/kg
-
4-benzylbenzene-1,3-diol
-
-
4-chloro-N-([4-[(2E)-3-(2,4-dichlorophenyl)prop-2-enoyl]phenyl]carbamoyl)benzenesulfonamide
-
IC50: 0.00042 mM
4-chloro-N-([4-[(2E)-3-phenylprop-2-enoyl]phenyl]carbamoyl)benzenesulfonamide
-
IC50: 0.00083 mM
4-hexylbenzene-1,3-diol
-
-
4-methoxy-4-[3-(naphthalen-2-ylmethoxy)phenyl]tetrahydro-2H-pyran
-
-
4-methoxy-N-(3,5a,10-trimethyl-2-oxo-2,3,3a,4,5,5a,6,10,10a,10b-decahydrofuro[3',2':7,8]naphtho[2,3-d][1,3]thiazol-8-yl)benzamide
-
-
4-methyl-N-(3,5a,10-trimethyl-2-oxo-2,3,3a,4,5,5a,6,10,10a,10b-decahydrofuro[3',2':7,8]naphtho[2,3-d][1,3]thiazol-8-yl)-1,2,3-thiadiazole-5-carboxamide
-
-
4-methyl-N-([4-[(2E)-3-(2,3,4-trimethylphenyl)prop-2 enoyl]phenyl]carbamoyl)benzenesulfonamide
-
IC50: 0.00045 mM
4-methyl-N-([4-[(2E)-3-phenylprop-2-enoyl]phenyl]carbamoyl)benzenesulfonamide
-
IC50: 0.00089 mM
4-methylesculetin
-
polymorphonuclear leukocyte
4-[(1E)-3-(2-hydroxy-4-methoxyphenyl)-3-oxoprop-1-en-1-yl]-N-(2-hydroxy-5-nitrophenyl)benzamide
-
-
4-[(1E)-3-(2-hydroxy-4-methoxyphenyl)-3-oxoprop-1-en-1-yl]-N-(2-hydroxyphenyl)benzamide
-
-
4-[(1E)-3-(2-hydroxy-4-methoxyphenyl)-3-oxoprop-1-en-1-yl]-N-(2-methoxyphenyl)benzamide
-
-
4-[(1E)-3-(2-hydroxy-4-methoxyphenyl)-3-oxoprop-1-en-1-yl]-N-(2-phenylethyl)benzamide
-
-
4-[(1E)-3-(2-hydroxy-4-methoxyphenyl)-3-oxoprop-1-en-1-yl]-N-(propan-2-yl)benzamide
-
-
4-[(1E)-3-(2-hydroxy-4-methoxyphenyl)-3-oxoprop-1-en-1-yl]-N-methyl-N-phenylbenzamide
-
-
4-[(1E)-3-(2-hydroxy-4-methoxyphenyl)-3-oxoprop-1-en-1-yl]-N-propylbenzamide
-
-
4-[(1E)-3-(3-phenylpropoxy)prop-1-en-1-yl]benzene-1,2-diol
caffeic acid phenylethyl ester analogue, IC50 value for inhibition of 5-Lox product synthesis in transfected HEK-293 cells is 0.00018 mM. Compound is a good radical scavenger
-
4-[(1E)-3-(benzyloxy)prop-1-en-1-yl]benzene-1,2-diol
caffeic acid phenylethyl ester analogue, IC50 value for inhibition of 5-Lox product synthesis in transfected HEK-293 cells is 0.00043 mM. Compound is a good radical scavenger
-
4-[(4-cyclohexyl-5-methyl-1,3-thiazol-2-yl)amino]-2,6-dimethylphenol
lead compound, in vitro pharmacokinetic profile, shows no cytotoxicity, overview
4-[(hydroxy[1-[3'-(morpholin-4-yl)[1,1'-biphenyl]-3-yl]ethyl]amino)methyl]phenol
-
4-[([5-fluoro-6-[4-(1H-imidazol-1-yl)phenoxy]-1H-benzimidazol-2-yl]sulfanyl)methyl]benzoic acid
-
additionally inhibts soluble epoxide hydrolase. Compound shows potent anti-inflammatory activity and significant inhibition of edema at a dose of 100 mg/kg
-
4-[1-(4-chlorobenzyl)-4-methyl-6-[(5-phenylpyridin-2-yl)methoxy]-2,2a,4,5-tetrahydro-1H-thiopyrano[2,3,4-cd]indol-2-yl]-3,3-dimethyl-N-(methylsulfonyl)butanamide
-
-
4-[4-(4-fluoro-phenyl)-thiazol-2-ylamino]-2,6-dimethylphenol
-
KR-33749, the compound exhibits a more than 1000fold selectivity for 5-LO against 12-LO and 15-LO
4-[5-(1H-indol-3-yl)-3-(trifluoromethyl)-4,5-dihydro-1H-pyrazol-1-yl]benzenesulfonamide
-
-
4-[5-(1H-indol-3-yl)-3-trifluoromethyl-4,5-dihydropyrazol-1-yl]-benzenesulfonamide
4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide
-
-
4-[5-(6-chloro-1H-indol-3-yl)-3-trifluoromethyl-4,5-dihydropyrazol-1-yl]-benzenesulfonamide
4-[5-(7-chloro-1H-indol-3-yl)-3-trifluoromethyl-4,5-dihydropyrazol-1-yl]-benzenesulfonamide
4-[[4-(2,4-dichlorophenyl)-5-methyl-1,3-thiazol-2-yl]amino]-2,6-dimethylphenol
lead compound, in vitro pharmacokinetic profile, shows no cytotoxicity, overview
4-[[4-(4-chlorophenyl)-1,3-thiazol-2-yl]amino]phenol
-
4-[[4-(4-chlorophenyl)-1,3-thiazol-2-yl]imino]cyclohexa-2,5-dien-1-one
-
4-[[hydroxy(2-methyl-1-[3-[(morpholin-4-yl)oxy]phenyl]propyl)amino]methyl]phenol
-
5,5'-di(prop-2-en-1-yl)biphenyl-2,2'-diol
-
-
5,5-dimethyl-1-phenyl-1,2,4-triazinan-3-one
-
-
5,6-Dehydroarachidonate
-
irreversible
5,6-Methano-leukotriene A4
-
-
5,8,11,13-eicosatetraynoic acid
-
IC50: 0.028 mM
5,8,11,14,17-eicosapentaenoic acid
-
-
5-(2-[[3-(trifluoromethyl)phenyl]amino]phenyl)-1,3,4-oxadiazole-2(3H)-thione
-
-
5-(3,5-di-tert-butyl-4-hydroxybenzylidene)thiazolidin-2,4-dione
-
effective inhibitor of 5-LOX in vivo
5-(4-chlorophenyl)-4-(4-methoxyphenyl)-1,2-selenazole
-
42% inhibition at 0.01 mM
5-(4-chlorophenyl)-4-p-tolyl-1,2-selenazole
-
67% inhibition at 0.01 mM
5-(4-fluorophenyl)-1-[4-(methylsulfonyl)phenyl]-3-(trifluoromethyl)-1H-pyrazole
-
-
5-(4-methoxyphenyl)-4-p-tolyl-1,2-selenazole
-
64% inhibition at 0.01 mM
5-(7-tert-butyl-3,3-dimethyl-2,3-dihydro-1-benzofuran-5-yl)-5-oxopentanenitrile
-
-
5-amino-2-hydroxy-N-(propan-2-yl)benzamide
-
5-aminosalicylic acid derivative, additionally inhibits cyclooxygenases Cox-1 and Cox-2
-
5-amino-N-cyclohexyl-2-hydroxybenzamide
-
5-aminosalicylic acid derivative, additionally inhibits cyclooxygenases Cox-1 and Cox-2
-
5-amino-N-hexyl-2-hydroxybenzamide
-
5-aminosalicylic acid derivative, additionally inhibits cyclooxygenases Cox-1 and Cox-2
-
5-butyl-1-phenyl-1,2,4-triazinan-3-one
-
-
5-chloro-1-(4-chlorophenoxy)-2-methyl-3-(4-morpholin-4-yl-4-oxobutyl)-1H-indole
38% inhibition at 0.005 mM
5-chloro-2-methyl-3-(4-morpholin-4-yl-4-oxobutyl)-1H-indole
71% inhibition at 0.005 mM
5-ethyl-1-phenyl-1,2,4-triazinan-3-one
-
-
5-hydroperoxy-6,8,11,14-eicosatetraenoic acid
-
-
5-methoxy-2-methyl-1-(4-methylbenzyl)-3-(4-morpholin-4-yl-4-oxobutyl)-1H-indole
26% inhibition at 0.005 mM
5-methoxy-2-methyl-3-(4-morpholin-4-yl-4-oxobutyl)-1H-indole
73% inhibition at 0.005 mM
5-methoxy-3-tridecylbenzene-1,2,4-triol
-
5-[(E)-2-(4-hydroxyphenyl)ethenyl]benzene-1,3-diol
-
-
5-[[(2,5-dihydroxyphenyl)methyl]amino]-2-hydroxy-N-(4-methylphenyl)benzamide
-
5-aminosalicylic acid derivative, additionally inhibits cyclooxygenases Cox-1 and Cox-2
-
5-[[hydroxy(2-methyl-1-[3-[(morpholin-4-yl)oxy]phenyl]propyl)amino]methyl]benzene-1,2,3-triol
-
6-(trideca-1,4,7-triene-1-sulfinyl)-hex-5-enoic acid
-
-
6-ethenesulfinyl-hex-5-enoic acid
-
-
6-ethenesulfinyl-hex-5-enoic acid amide
-
-
6-hept-1-ene-1-sulfinyl-hex-5-enoic acid
-
-
6-hept-1-enylsulfanyl-hex-5-enoic acid
-
-
6-hydroxy-3,4-dimethoxy-5-undecylcyclohexa-2,4-dien-1-one
-
6-vinylsulfanyl-hex-5-enoic acid
-
-
6-vinylsulfanyl-hex-5-enoic acid amide
-
-
6-[(4-hydroxy-3,6-dioxocyclohexa-1,4-dien-1-yl)methyl]naphthalene-2-carboxylic acid
-
-
6-[[3-fluoro-5-(4-methoxytetrahydro-2H-pyran-4-yl)phenoxy]methyl]-1-methylquinolin-2(1H)-one
-
-
7,17(S)-dihydroxydocosahexaenoic acid
-
IC50: 0.007 mM
7,8-dihydroxy-2H-chromen-2-one
-
-
7-(4-methylphenyl)-6-[4-(methylsulfonyl)phenyl]-2,3-dihydro-1H-pyrrolizine
-
-
7-([3-fluoro-5-[(1R)-1-hydroxy-1-pyridin-2-ylpropyl]phenoxy]methyl)-4-furan-3-yl-2H-chromen-2-one
-
IC50: 175 nM
7-([3-fluoro-5-[(1R,3R,5S)-3-hydroxy-6,8-dioxabicyclo[3.2.1]oct-3-yl]phenoxy]methyl)-4-(4-fluorophenyl)-2H-chromen-2-one
-
-
7-([3-fluoro-5-[(1R,3R,5S)-3-hydroxy-6,8-dioxabicyclo[3.2.1]oct-3-yl]phenoxy]methyl)-4-furan-3-yl-2H-chromen-2-one
-
IC50: 200 nM
7-([3-fluoro-5-[(1R,3R,5S)-3-hydroxy-6,8-dioxabicyclo[3.2.1]oct-3-yl]phenoxy]methyl)-4-phenyl-2H-chromen-2-one
-
IC50: 300 nM
7-([3-fluoro-5-[(1S)-1-hydroxy-1-(1,3-thiazol-2-yl)propyl]phenoxy]methyl)-4-(4-fluorophenyl)-2H-chromen-2-one
-
IC50: 175 nM
7-([3-fluoro-5-[2,2,2-trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]phenyl]sulfanyl)-4-furan-3-yl-2H-chromen-2-one
-
IC50: 9 nM
7-([3-fluoro-5-[2,2,2-trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]phenyl]sulfanyl)-4-phenyl-2H-chromen-2-one
-
IC50: 26 nM
7-tert-butyl-N-ethyl-N,3,3-trimethyl-2,3-dihydro-1-benzofuran-5-carboxamide
-
-
7-thiaarachidonic acid
-
-
7-[[3-(1-ethyl-1-hydroxypropyl)-5-fluorophenoxy]methyl]-4-furan-3-yl-2H-chromen-2-one
-
IC50: 15 nM
7-[[3-(4-methoxytetrahydro-2H-pyran-4-yl)benzyl]oxy]-4-phenylnaphtho[2,3-c]furan-1(3H)-one
-
-
7-[[3-fluoro-5-(3-hydroxy-6,8-dioxabicyclo[3.2.1]oct-3-yl)phenoxy]methyl]-4-(furan-3-yl)quinoline-2-carbonitrile
-
-
8,11,13-cis-icosatrienoic acid
-
-
8,11,14-eicosatrienoic acid
8-hydroxyquinoline
-
0.01 mM, 59% inhibition
ABT 761
-
CAS: 154355-76-7
acetonylacetone bisphenylhydrazone
-
IC50 for reaction with linoleic acid: 0.015 mM, IC50 for reaction with arachidonic acid: 0.0039 mM
arachidonate
substrate inhibition
arachidonoyl lysophosphatidylcholine
-
-
benzaldehyde phenylhydrazone
-
IC50 for reaction with linoleic acid: 0.0345 mM, IC50 for reaction with arachidonic acid: 0.0014 mM
benzyl 2-(3-chlorobenzyl)-5-hydroxy-1H-benzo[g]indole-3-carboxylate
-
-
benzyl 2-(4-chlorobenzyl)-5-hydroxy-1H-benzo[g]indole-3-carboxylate
-
-
beta-hydroxyacteoside
-
enzyme from polymorphonuclear leukocyte
biphenyl-3-yl 3,5-dinitrobenzoate
-
biphenyl-4-yl 3,5-dinitrobenzoate
-
BRP-7
benzimidazole derivative BRP-7 inhibits leukotriene biosynthesis in vitro and in vivo by targeting 5-lipoxygenase-activating protein (FLAP). BRP-7 blocks 5-LOX co-localization with FLAP at the nuclear envelope in neutrophils. No complete inhibition up to 0.01 mM
caffeic acid phenethyl ester
capsaicin
-
enzyme from polymorphonuclear leukocyte
catechol
-
IC50: 0.062 mM
chalcone
inhibition of the 5-LO product formation of intact human polymorphonuclear leukocytes, IC50 value 0.006 mM
cholesterol
-
addition to a membrane preperation in vitro reduces 5-lipoxygenase activity by half. Cholesterol sulfate can inhibit 5-lipoxygenase in intact cells
curcumin
inhibition of the 5-LO product formation of intact human polymorphonuclear leukocytes, IC50 value 0.0016 mM
cyrhetrenyl carboxylic acid
the compound is a good ROS generator
-
daidzein
-
noncompetitive
daphnetin
-
polymorphonuclear leukocyte
delphinidin 3-O-galactoside
-
from Vaccinium myrtillus berries, strong inhibitor, in a concentration-dependent manner
delphinidin 3-O-glucoside
-
from Vaccinium myrtillus berries, strong inhibitor, in a concentration-dependent manner
delta-garcinoic acid
i.e. an omega-oxidized tocotrienol, inhibits leukotriene biosynthesis by human primary polymorphonuclear leukocytes, IC50 value 345 nM
-
delta-tocopherol-13'-carboxychromanol
competitive, compound decreases leukotriene B4 from stimulated neutrophil-like cells without affecting translocation of 5-Lox from cytosol to the nucleus. Compound additionally inhibits cyclooxygenases Cox-1 and Cox-2
-
delta-tocotrienol
competitive, compound decreases leukotriene B4 from stimulated neutrophil-like cells without affecting translocation of 5-Lox from cytosol to the nucleus. Compound additionally inhibits cyclooxygenases Cox-1 and Cox-2
delta-tocotrienol-13'-carboxychromanol
competitive, compound decreases leukotriene B4 from stimulated neutrophil-like cells without affecting translocation of 5-Lox from cytosol to the nucleus. Compound additionally inhibits cyclooxygenases Cox-1 and Cox-2
-
Diamide
in 5-LO/FLAP-transfected HeLa cells, treatment with the thiol-oxidizing agent diamide which promotes glutathionylation at surface Cys residues leads to a decreased leukotriene synthesis by wild-type 5-LO
diphenyldisulfide
-
IC50: 0.002-0.005
docosahexaenoic acid
-
substrate inhibition
ebselen
-
54% inhibition at 0.01 mM
epinephrine
-
IC50: 0.98 mM
ethyl 1-benzyl-2-(4-chlorobenzyl)-5-hydroxy-1H-benzo[g]indole-3-carboxylate
-
-
ethyl 2-((2,4-difluorophenylthio)methyl)-5-hydroxy-1-methyl-1H-indole-3-carboxylate
-
ethyl 2-((2,6-dichlorophenylthio)methyl)-5-hydroxy-1-methyl-1H-indole-3-carboxylate
-
ethyl 2-((2,6-dimethylphenylthio)methyl)-5-hydroxy-1-methyl-1H-indole-3-carboxylate
-
ethyl 2-((3,5-dimethylphenylthio)methyl)-5-hydroxy-1-methyl-1H-indole-3-carboxylate
-
ethyl 2-((3-chlorophenylthio)methyl)-5-hydroxy-1-methyl-1H-indole-3-carboxylate
-
ethyl 2-((4-fluorophenylthio)methyl)-5-hydroxy-1-methyl-1H-indole-3-carboxylate
-
ethyl 2-(2-chlorobenzyl)-5-hydroxy-1H-benzo[g]indole-3-carboxylate
-
-
ethyl 2-(2-chlorobenzyl)-5-hydroxy-1H-indole-3-carboxylate
-
-
ethyl 2-(3-bromobenzyl)-5-hydroxy-1H-benzo[g]indole-3-carboxylate
-
-
ethyl 2-(3-chlorobenzyl)-5-hydroxy-1H-benzo[g]indole-3-carboxylate
ethyl 2-(3-chlorobenzyl)-5-hydroxy-1H-indole-3-carboxylate
-
-
ethyl 2-(3-chlorobenzyl)-5-hydroxy-1H-pyrrolo[2,3-f]quinoline-3-carboxylate
-
-
ethyl 2-(3-chlorobenzyl)-5-hydroxy-6-phenyl-1H-indole-3-carboxylate
-
-
ethyl 2-(3-chlorobenzyl)-5-methoxy-1-methyl-1H-benzo[g]-indole-3-carboxylate
-
-
ethyl 2-(3-chlorobenzyl)-5-phenyl-1H-benzo[g]indole-3-carboxylate
-
-
ethyl 2-(3-chlorobenzyl)-7,8-dimethoxy-5-hydroxy-1H-benzo[g]indole-3-carboxylate
-
-
ethyl 2-(3-chlorophenyl)-5-hydroxy-1H-benzo[g]indole-3-carboxylate
-
-
ethyl 2-(3-chlorophenyl)-5-hydroxy-1H-indole-3-carboxylate
-
-
ethyl 2-(3-fluorobenzyl)-5-hydroxy-1H-benzo[g]indole-3-carboxylate
-
-
ethyl 2-(3-methoxybenzyl)-5-hydroxy-1H-benzo[g]indole-3-carboxylate
-
-
ethyl 2-(4-bromobenzyl)-5-hydroxy-1H-benzo[g]indole-3-carboxylate
-
-
ethyl 2-(4-chlorobenzyl)-5-hydroxy-1H-benzo[g]indole-3-carboxylate
-
-
ethyl 2-(4-chlorobenzyl)-5-hydroxy-1H-indole-3-carboxylate
-
-
ethyl 2-(4-chlorophenyl)-5-hydroxy-1H-benzo[g]indole-3-carboxylate
-
-
ethyl 2-(4-chlorophenyl)-5-hydroxy-1H-indole-3-carboxylate
-
-
ethyl 2-(4-fluorobenzyl)-5-hydroxy-1H-benzo[g]indole-3-carboxylate
-
-
ethyl 2-(4-methoxybenzyl)-5-hydroxy-1H-benzo[g]indole-3-carboxylate
-
-
ethyl 2-(4-trifluoromethylbenzyl)-5-hydroxy-1H-benzo[g]indole-3-carboxylate
-
-
ethyl 2-[(3-chlorophenyl)-amino]-5-hydroxy-1H-indole-3-carboxylate
ethyl 2-[2-(3-chlorophenyl)ethyl]-5-hydroxy-1H-benzo[g]indole-3-carboxylate
-
-
ethyl 2-[2-(3-chlorophenyl)ethyl]-5-hydroxy-1H-indole-3-carboxylate
-
-
ethyl 2-[2-(4-chlorophenyl)ethyl]-5-hydroxy-1H-benzo[g]indole-3-carboxylate
-
-
ethyl 2-[2-(4-chlorophenyl)ethyl]-5-hydroxy-1H-indole-3-carboxylate
-
-
ethyl 2-[[4-chloro-6-(quinolin-6-ylamino)pyrimidin-2-yl]sulfanyl]octanoate
-
-
ethyl 5-benzoyloxy-2-(3-chlorobenzyl)-1H-benzo[g]indole-3-carboxylate
-
-
ethyl 5-hydroxy-1-methyl-2-((2-(trifluoromethyl)phenylthio)methyl)-1H-indole-3-carboxylate
-
ethyl 5-hydroxy-1-methyl-2-((4-(trifluoromethoxy)phenylthio)methyl)-1H-indole-3-carboxylate
-
ethyl 5-hydroxy-1-methyl-2-((4-(trifluoromethyl)phenylthio)methyl)-1H-indole-3-carboxylate
-
ethyl 5-hydroxy-1-methyl-2-(phenylthiomethyl)-1H-indole-3-carboxylate
-
ethyl 5-hydroxy-2-((2-methoxyphenylthio)methyl)-1-methyl-1H-indole-3-carboxylate
-
ethyl 5-hydroxy-2-((4-methoxyphenylthio)methyl)-1-methyl-1H-indole-3-carboxylate
-
ethyl 5-hydroxy-2-(mesitylthiomethyl)-1-methyl-1H-indole-3-carboxylate
-
ethyl 5-hydroxy-2-phenylethyl-1H-indole-3-carboxylate
-
-
ethyl 5-hydroxy-2-phenylpropyl-1H-benzo[g]indole-3-carboxylate
-
-
ethyl 6-biphenyl-4-yl-(3-chlorobenzyl)-5-hydroxy-1H-indole-3-carboxylate
-
-
ethyl [2-[(2-[1-[4-(2-methylpropyl)phenyl]ethyl]-1H-benzimidazol-1-yl)methyl]phenoxy]acetate
a BRP-7 derivative
eugenol
-
non-competitive, reversible inhibitor, IC50: 0.026 mM
eupatilin
-
IC50: 0.098 mM
ferrocenyl carboxylic acid
mixed type inhibitor. The compound shows better antioxidant activity than the antioxidant Trolox
-
fraxetin
-
polymorphonuclear leukocyte
genistein
-
noncompetitive
gingerdione
-
enzyme from polymorphonuclear leukocyte
helenalin
-
enzyme from polymorphonuclear leukocyte
indomethacin
-
IC50: 0.36 mM
iodoacetamide
-
0.01 mM, 20% inhibition
L-651,392
-
i.e. 4-bromo-2,7-dimethoxy-3H-phenothiazin-3-one, + 1 mM NADH, IV50: 0.0003-0.0005 mM
L-651,896
-
i.e. 2,3-dihydro-6-[3-(2-hydroxymethyl)-phenyl-2-propenyl]-5-benzofuranol, IC50: 0.0003-0.0004 mM
L-670,630
-
IC50: 0.0004 mM
L-689,065
-
IC50: 0.0003 mM
L-697,198
-
IC50: 0.00002 mM
L-702,701
-
IC50: 0.0015 mM
L705,302
-
IC50: 0.00002 mM
leucocyanidol
-
polymorphonuclear leukocyte
luteolin
inhibition of the 5-LO product formation of intact human polymorphonuclear leukocytes, IC50 value 0.0006 mM
methanol
-
complete inhibition at 50% v/v
methyl (4-[(5E)-5-(4-methoxybenzylidene)-4-oxo-4,5-dihydro-1,3-thiazol-2-yl]phenoxy)acetate
-
-
methyl 2-(allylamino)-1H-indole-3-carboxylate
-
-
methyl 2-(benzylamino)-1H-indole-3-carboxylate
-
-
methyl 2-(diallylamino)-1H-indole-3-carboxylate
-
-
methyl 2-[(2-chlorophenyl)amino]-1H-indole-3-carboxylate
-
-
methyl 2-[(3-bromophenyl)amino]-1H-indole-3-carboxylate
-
-
methyl 2-[(3-chlorophenyl)amino]-1H-indole-3-carboxylate
-
-
methyl 2-[(3-chlorophenyl)amino]-5-chloro-1H-indole-3-carboxylate
-
-
methyl 2-[(3-fluorophenyl)amino]-1H-indole-3-carboxylate
-
-
methyl 2-[(4-chlorophenyl)amino]-1H-indole-3-carboxylate
-
-
miogadial
-
potent inhibitor, IC50: 0.004 mM
miogatrial
-
potent inhibitor, IC50: 0.0075 mM
mithramycin
-
reduces endogenous 5-lipoxygenase in Mono Mac 6 cell, which blocks GC-boxes in the proximal part of the 5-lipoxygenase gene promoter
MK 886
-
i.e. CAS: 118414-82-7, inhibition of 5-lipoxygenase in prostate cancer cells blocks production of 5-hydroxyeicosatetraenoic acid and induces massive apoptosisin both hormone-responsive and hormone-nonresponsive prostate cancer cells
ML-3000
-
i.e. licofelone, ML-3000 has no effect on 5-LOX product synthesis in whole-blood assay, inhibition of COX pathways does not increase the transformation of arachidonic acid by the 5-LOX pathway
myrtol
-
enzyme from RBL-1 cell
-
myxochelin A
isolated from extracts of the predatory myxobacterium Pyxidicoccus fallax HKI 727, IC50 values for inhibition of proliferative cells K-562 and HeLa are 0.3052 mM and 0.0039 mM, respectively
myxochelin C
isolated from extracts of the predatory myxobacterium Pyxidicoccus fallax HKI 727, IC50 values for inhibition of proliferative cells K-562 and HeLa are 0.424 mM and 0.0535 mM, respectively
myxochelin D
isolated from extracts of the predatory myxobacterium Pyxidicoccus fallax HKI 727, IC50 values for inhibition of proliferative cells K-562 and HeLa are above 0.5 mM
N-(2,4-dimethylphenyl)-4-[(1E)-3-(2-hydroxy-4-methoxyphenyl)-3-oxoprop-1-en-1-yl]benzamide
-
-
N-(3,4-dimethoxyphenyl)-3,5-dinitrobenzamide
-
N-(3,5a,10-trimethyl-2-oxo-2,3,3a,4,5,5a,6,10,10a,10b-decahydrofuro[3',2':7,8]naphtho[2,3-d][1,3]thiazol-8-yl)-1,3-benzodioxole-5-carboxamide
-
-
N-(3,5a,10-trimethyl-2-oxo-2,3,3a,4,5,5a,6,10,10a,10b-decahydrofuro[3',2':7,8]naphtho[2,3-d][1,3]thiazol-8-yl)cyclopentanecarboxamide
-
-
N-(3-(4-chlorophenyl)-3-phenylpropyl)-3-(3-(1-hydroxyureido)-but-1-yn-1-yl)benzamide
dual 5-LOX/soluble epoxide hydrolase inhibitor
-
N-(3-bromobenzyl)-3,5-dinitrobenzamide
-
N-(3-bromophenyl)-3,5-dinitrobenzamide
-
N-(3-chlorophenyl)-3,5-dinitrobenzamide
-
N-(3-phenoxycinnamyl)-acetohydroxamic acid
-
-
N-(4-chlorophenyl)-N-hydroxy-N'-(3-chlorophenyl)urea
-
IC50: 0.0001 mM
N-(4-methoxyphenyl)-3,5-dinitrobenzamide
-
N-(biphenyl-3-yl)-3,5-dinitrobenzamide
-
N-(furan-2-ylmethyl)-2-(7-methoxy-5,8-dimethyl-1,2,3,4-tetrahydronaphthalen-2-yl)propanamide
-
-
N-(naphthalene-1-yl)-3,5-dinitrobenzamide
-
N-([(5R)-3-[3-fluoro-4-(morpholin-4-yl)phenyl]-2-oxo-1,3-oxazolidin-5-yl]methyl)-N-hydroxy-2-methylpropanamide
-
-
N-([(5R)-3-[3-fluoro-4-(morpholin-4-yl)phenyl]-2-oxo-1,3-oxazolidin-5-yl]methyl)-N-hydroxycyclopropanecarboxamide
-
-
N-([4-[(2E)-3-(2,4-dichlorophenyl)prop-2-enoyl]phenyl]carbamoyl)-4-methylbenzenesulfonamide
-
IC50: 0.00045 mM
N-3-tolyl-3,5-dinitrobenzamide
-
N-benzyl-4-[(1E)-3-(2-hydroxy-4-methoxyphenyl)-3-oxoprop-1-en-1-yl]benzamide
-
-
N-butyl-5-[[(2,5-dihydroxyphenyl)methyl]amino]-2-hydroxybenzamide
-
5-aminosalicylic acid derivative, additionally inhibits cyclooxygenases Cox-1 and Cox-2
-
N-cyclohexyl-5-[(E)-[(2,5-dihydroxyphenyl)methylidene]amino]-2-hydroxybenzamide
-
5-aminosalicylic acid derivative, additionally inhibits cyclooxygenases Cox-1 and Cox-2
-
N-cyclohexyl-5-[[(2,5-dihydroxyphenyl)methyl]amino]-2-hydroxybenzamide
-
5-aminosalicylic acid derivative, additionally inhibits cyclooxygenases Cox-1 and Cox-2. Compound shows 114% anti-inflammatory activity relative to reference drug indomethacin at 4 h interval
-
N-cyclopentyl-2-[7-(2-methoxyethoxy)-5,8-dimethyl-1,2,3,4-tetrahydronaphthalen-2-yl]propanamide
-
-
N-dodecyl-4-[(1E)-3-(2-hydroxy-4-methoxyphenyl)-3-oxoprop-1-en-1-yl]benzamide
-
-
N-hexyl-5-[[(2,5-dihydroxyphenyl)methyl]amino]-2-hydroxybenzamide
-
5-aminosalicylic acid derivative, additionally inhibits cyclooxygenases Cox-1 and Cox-2
-
N-hydroxy-N-[(2E)-3-(3-phenoxyphenyl)prop-2-en-1-yl]acetamide
N-hydroxy-N-[1-(1-methyl-1H-indol-2-yl)ethyl]acetamide
-
-
N-methyl-2[4-(2,4,6-trimethylphenyl)phenyl]-propenehydroxamic acid
-
IC50: 0.0005 mM
N-phenyl-3,5-dinitrobenzamide
-
N-tert-butyl-2-(7-methoxy-5,8-dimethyl-1,2,3,4-tetrahydronaphthalen-2-yl)propanamide
-
-
N-[2-(cyclohexyloxy)-4-nitrophenyl]methanesulfonamide
-
-
N-[5-(4-fluorophenoxy)thiophen-2-yl]methanesulfonamide
-
-
naphthalen-1-yl 3,5-dinitrobenzoate
JMC-4, identified from virtual inhibitor screening
naphthalene-1-yl 3-nitrobenzoate
-
NAPQI
compound reacts with catalytically relevant cysteine residues 416 and 418
-
NEM
-
0.01 mM, 75% inhibition
nordihydroguaiaretic acid
nordihydroguiaraetic acid
norepinephrine
-
IC50: 0.49 mM
ochnaflavone
-
IC50: 0.0656 mM
oroxindin
-
polymorphonuclear leukocyte
Phenidone
-
IC50: 0.005-0.01 mM
phenyl 3,5-dinitrobenzoate
-
piceid
-
polymorphonuclear leukocyte
Plumbagin
inhibition of the 5-LO product formation of intact human polymorphonuclear leukocytes, IC50 value 0.007 mM
polygodial
-
strong inhibitory activity, IC50: 0.0086 mM
primin
compound reacts with catalytically relevant cysteine residues 416 and 418, inhibition of the 5-LO product formation of intact human polymorphonuclear leukocytes, IC50 value 0.0028 mM
-
quercetagetin-7-O-beta-D-glucoside
-
polymorphonuclear leukocyte
resveratrol
-
polymorphonuclear leukocyte
Rev-5901
-
competitive 5-LO inhibitor
shikonin
inhibition of the 5-LO product formation of intact human polymorphonuclear leukocytes, IC50 value 0.0015 mM
sideritoflavone
-
polymorphonuclear leukocyte
tambuletin
-
polymorphonuclear leukocyte
tert-butyl 4-[4-(1-benzyl-1H-indol-3-yl)butanoyl]piperazine-1-carboxylate
38% inhibition at 0.005 mM
tert-butyl 4-[4-(1-benzyl-5-methoxy-2-methyl-1H-indol-3-yl)butanoyl]piperazine-1-carboxylate
51.5% inhibition at 0.005 mM
tert-butyl 4-[4-(1H-indol-3-yl)butanoyl]piperazine-1-carboxylate
84% inhibition at 0.005 mM
tert-butyl 4-[4-(5-methoxy-2-methyl-1H-indol-3-yl)butanoyl]piperazine-1-carboxylate
71% inhibition at 0.005 mM
thymoquinone
compound reacts with catalytically relevant cysteine residues 416 and 418, inhibition of the 5-LO product formation of intact human polymorphonuclear leukocytes, IC50 value 0.0015 mM
ZM 230,486
-
IC50: 0.00009 mM
[1-(2-cyclohexylethyl)-1H-1,2,3-triazol-4-yl]methyl (2E)-3-(3,4-dihydroxyphenyl)prop-2-enoate
compound is equipotent to zileuton. It forms pi-pi interactions with residues His367, Phe421 and coordinates iron
-
[1-(2-[[(2E)-3-(3,4-dihydroxyphenyl)prop-2-enoyl]oxy]ethyl)-1H-1,2,3-triazol-4-yl]methyl (2E)-3-(3,4-dihydroxyphenyl)prop-2-enoate
-
-
[1-(2-[[(2E)-3-phenylprop-2-enoyl]oxy]ethyl)-1H-1,2,3-triazol-4-yl]methyl (2E)-3-(3,4-dihydroxyphenyl)prop-2-enoate
-
-
[1-(2-[[(2E)-3-phenylprop-2-enoyl]oxy]ethyl)-1H-1,2,3-triazol-4-yl]methyl (2E)-3-phenylprop-2-enoate
-
shows less inhibitory activity than the corresponding clusters bearing the caffeic acid moiety
[1-(3-[4-([[(2E)-3-(3,4-dihydroxyphenyl)prop-2-enoyl]oxy]methyl)-1H-1,2,3-triazol-1-yl]-2-[(3-[4-([[(2E)-3-(3,4-dihydroxyphenyl)prop-2-enoyl]oxy]methyl)-1H-1,2,3-triazol-1-yl]-2,2-bis[[4-([[(2E)-3-(3,4-dihydroxyphenyl)prop-2-enoyl]oxy]methyl)-1H-1,2,3-triazol-1-yl]methyl]propoxy)methyl]-2-[[4-([[(2E)-3-(3,4-dihydroxyphenyl)prop-2-enoyl]oxy]methyl)-1H-1,2,3-triazol-1-yl]methyl]propyl)-1H-1,2,3-triazol-4-yl]methyl (2E)-3-(3,4-dihydroxyphenyl)prop-2-enoate
-
incorporation of additional caffeoyl units in hexamer results in less potent inhibition
[1-(3-[4-([[(2E)-3-phenylprop-2-enoyl]oxy]methyl)-1H-1,2,3-triazol-1-yl]-2-[(3-[4-([[(2E)-3-phenylprop-2-enoyl]oxy]methyl)-1H-1,2,3-triazol-1-yl]-2,2-bis[[4-([[(2E)-3-phenylprop-2-enoyl]oxy]methyl)-1H-1,2,3-triazol-1-yl]methyl]propoxy)methyl]-2-[[4-([[(2E)-3-phenylprop-2-enoyl]oxy]methyl)-1H-1,2,3-triazol-1-yl]methyl]propyl)-1H-1,2,3-triazol-4-yl]methyl (2E)-3-phenylprop-2-enoate
-
shows less inhibitory activity than the corresponding clusters bearing the caffeic acid moiety
[2-[(1S,8aR)-2-formyl-5,5,8a-trimethyldecahydronaphthalen-1-yl]ethylidene]propanedial
-
-
[2-[(2-methyl-1H-benzimidazol-1-yl)methyl]phenoxy]acetyl chloride
a BRP-7 derivative
[3-(1-[hydroxy[(3,4,5-trihydroxyphenyl)methyl]amino]ethyl)phenyl](morpholin-4-yl)methanone
-
[3-(1-[hydroxy[(4-hydroxyphenyl)methyl]amino]ethyl)phenyl](morpholin-4-yl)methanone
-
[3-(bromocarbonyl)phenyl](morpholin-4-yl)acetic acid
-
1-(3-hydroxyphenyl)-3-[4-(methylsulfonyl)phenyl]prop-2-yn-1-one
-
-
1-(3-hydroxyphenyl)-3-[4-(methylsulfonyl)phenyl]prop-2-yn-1-one
-
-
11,14,17-Eicosatrienoic acid
-
IC50: 0.015 mM
11,14,17-Eicosatrienoic acid
-
substrate inhibition
2-phenylethyl (2E)-3-(2,5-dihydroxyphenyl)prop-2-enoate
compound reduces the cell viability of renal cancer cells and is more selective toward RCC4 and 786.0 cells deficient for the Von Hippel-Lindau tumor suppressor gene. Compound induces apoptosis in Von Hippel-Lindau-deficient RCC4 cells and may block the autophagic flux in renal cancer cells
-
2-phenylethyl (2E)-3-(2,5-dihydroxyphenyl)prop-2-enoate
inhibits leukotriene biosynthesis in isolated human neutrophils and in whole blood
-
4-[5-(1H-indol-3-yl)-3-trifluoromethyl-4,5-dihydropyrazol-1-yl]-benzenesulfonamide
-
0.01 mM inhibits LOX-5 by 41%
4-[5-(1H-indol-3-yl)-3-trifluoromethyl-4,5-dihydropyrazol-1-yl]-benzenesulfonamide
-
0.01 mM inhibits LOX-15 by 31%
4-[5-(6-chloro-1H-indol-3-yl)-3-trifluoromethyl-4,5-dihydropyrazol-1-yl]-benzenesulfonamide
-
0.01 mM inhibits LOX-5 by 51%
4-[5-(6-chloro-1H-indol-3-yl)-3-trifluoromethyl-4,5-dihydropyrazol-1-yl]-benzenesulfonamide
-
0.01 mM inhibits LOX-15 by 36%
4-[5-(7-chloro-1H-indol-3-yl)-3-trifluoromethyl-4,5-dihydropyrazol-1-yl]-benzenesulfonamide
-
0.01 mM inhibits LOX-5 by 94%
4-[5-(7-chloro-1H-indol-3-yl)-3-trifluoromethyl-4,5-dihydropyrazol-1-yl]-benzenesulfonamide
-
0.01 mM inhibits LOX-15 by 36%
8,11,14-eicosatrienoic acid
-
IC50: 0.00219 mM
8,11,14-eicosatrienoic acid
-
substrate inhibition
AA-861
-
competitive 5-LO inhibitor
AA-861
compound reacts with catalytically relevant cysteine residues 416 and 418, inhibition of the 5-LO product formation of intact human polymorphonuclear leukocytes, IC50 value 0.0082 mM
AA861
-
specific inhibition
AA861
-
i.e. 2-(12-hydroxydodeca-5,10-diynyl)-3,5,6-trimethyl-1,4-benzoquinone, IC50: 0.004-0.01 mM
arachidonic acid
-
competitive inhibitor of linoleic acid oxidation
arachidonic acid
-
induces time-dependent enzyme inactivation at concentrations 100fold lower than the Km-value, IC50: 0.00023 mM; substrate inhibition
arachidonic acid
-
substrate inhibition above 0.045-0.05 mM
arachidonic acid
-
substrate inhibition
baicalein
inhibition of the 5-LO product formation of intact human polymorphonuclear leukocytes, IC50 value 0.0014 mM
baicalein
-
IC50: 0.0012 mM
BW755C
-
CAS: 66000-40-6; i.e. 3-amino-1-[3-(trifluoromethyl)phenyl]-2-pyrazoline, IC50: 0.013 mM
BW755C
-
CAS: 66000-40-6; IC50: 0.53 MM
BW755C
-
CAS: 66000-40-6; IC50: 0.004-0.015 mM
BWA4C
-
-
BWA4C
a direct inhibitor of 5-LO, treatment results not only in a suppression of leukotriene production, but in an almost complete inhibition of enzymatic
BWA4C
inhibition of the 5-LO product formation of intact human polymorphonuclear leukocytes, IC50 value 0.00015 mM
caffeic acid
-
-
caffeic acid
-
IC50: 0.046 mM
caffeic acid
-
micromolar 5-LOX inhibitory activity
caffeic acid phenethyl ester
IC50 value for inhibition of 5-Lox product synthesis in transfected HEK-293 cells is 0.00099 mM. Compound is a good radical scavenger
caffeic acid phenethyl ester
inhibits leukotriene biosynthesis in isolated human neutrophils and in whole blood
celecoxib
-
-
celecoxib
-
0.01 mM inhibits LOX-5 by 89%
celecoxib
-
0.01 mM inhibits LOX-15 by 22%
Cirsiliol
-
IC50: 0.098 mM
eicosapentaenoic acid
-
induces time-dependent enzyme inactivation at concentrations 100fold lower than the Km-value, IC50: 0.00065 mM; substrate inhibition
eicosapentaenoic acid
-
substrate inhibition
embelin
-
embelin
compound reacts with catalytically relevant cysteine residues 416 and 418, inhibition of the 5-LO product formation of intact human polymorphonuclear leukocytes, IC50 value 0.0035 mM
esculetin
-
IC50: 0.0045 mM
esculetin
-
polymorphonuclear leukocyte
ethyl 2-(3-chlorobenzyl)-5-hydroxy-1H-benzo[g]indole-3-carboxylate
-
-
ethyl 2-(3-chlorobenzyl)-5-hydroxy-1H-benzo[g]indole-3-carboxylate
-
prevents leukotriene B4 production in pleural exudates of carrageenan-treated rats, associated with reduced severity of pleurisy. Significantly reduces the inflammatory reaction measured as exudate volume (77%), inflammatory cell numbers (40%), and leukotriene B4 levels (49%) in the pleural exudates
ethyl 2-[(3-chlorophenyl)-amino]-5-hydroxy-1H-indole-3-carboxylate
-
-
ethyl 2-[(3-chlorophenyl)-amino]-5-hydroxy-1H-indole-3-carboxylate
-
forsythiaside
-
enzyme from polymorphonuclear leukocyte
forsythiaside
-
polymorphonuclear leukocyte
glutathione
-
inhibition is increased in presence of glutathione peroxidase
glutathione
efficiency of non-redox-type 5-LO inhibitors depends on the presence of glutathione peroxidase activity leading to low hydroperoxide concentration
glutathione
-
efficiency of non-redox-type 5-LO inhibitors depends on the presence of glutathione peroxidase activity leading to low hydroperoxide concentration
glutathione
-
efficiency of non-redox-type 5-LO inhibitors depends on the presence of glutathione peroxidase activity leading to low hydroperoxide concentration
L-656,224
-
i.e. 7-chloro-2-[(4-methoxyphenyl)-methyl]-3-methyl-5-propyl-4-benzofuranol, IC50: 0.0008 mM
L-656,224
-
IC50: 0.0003-0.0004 mM
licofelone
-
formerly termed ML-3000
licofelone
-
dual COX-2?5-LO inhibitor
MK-886
-
-
MK-886
-
competitive 5-LO inhibitor
MK886
-
a specific FLAP inhibitor
MK886
-
specific inhibitor of 5-hydroperoxyeicosatetraenoic acid synthesis by the enzyme
MK886
-
5-LOX activating protein inhibitor
N-hydroxy-N-[(2E)-3-(3-phenoxyphenyl)prop-2-en-1-yl]acetamide
-
-
N-hydroxy-N-[(2E)-3-(3-phenoxyphenyl)prop-2-en-1-yl]acetamide
-
-
nordihydroguaiaretic acid
-
-
nordihydroguaiaretic acid
-
-
nordihydroguaiaretic acid
-
IC50: 5 ppm
nordihydroguaiaretic acid
-
-
nordihydroguaiaretic acid
-
NDGA
nordihydroguaiaretic acid
redox-type inhibitor, is lodged in the 5-LOX active site, fully exposed by disordering of the helix that caps it in the apo-enzyme
nordihydroguaiaretic acid
-
reduces oxidative damage of erythrocytes in C57BL/6 Trypanosoma cruzi-infected mice but not in C57BL/6 iNOS-/- infected mice
nordihydroguaiaretic acid
-
IC50: 0.0023 mg/ml
nordihydroguaiaretic acid
-
is more potent inhibitor of 5-lipoxygenase than 1-(benzyloxy)hept-2-yn-4-ol
nordihydroguiaraetic acid
-
IC50: 0.00021 mM
nordihydroguiaraetic acid
-
IC50 for reaction with linoleic acid: 0.17 mM, IC50 for reaction with arachidonic acid: 0.0365 mM
quercetin
-
IC50: 0.0021 mM
quercetin
-
IC50: 0.0003-0.0005 mM
rofecoxib
-
-
rofecoxib
-
0.01 mM inhibits LOX-5 by 11%
rofecoxib
-
0.01 mM inhibits LOX-15 by 6%
shogaol
-
enzyme from polymorphonuclear leukocyte
shogaol
inhibition of the 5-LO product formation of intact human polymorphonuclear leukocytes, IC50 value 0.005 mM
sulindac sulfide
-
5-LO-selective inhibitor
suspensaside
-
enzyme from polymorphonuclear leukocyte
suspensaside
-
polymorphonuclear leukocyte
U73122
-
U73122
inhibition of the 5-LO product formation of intact human polymorphonuclear leukocytes, IC50 value 0.0069 mM
verbascoside
-
enzyme from polymorphonuclear leukocyte
verbascoside
-
polymorphonuclear leukocyte
ZD 2138
-
i.e. CAS: 140841-32-3, IC50: 0.0003 mM
ZD-2138
-
-
zileuton
-
IC50: 0.01
zileuton
-
IC50: 0.0038 mM with recombinant enzyme, IC50: 0.0011 mM with native enzyme
zileuton
IC50 value for inhibition of 5-Lox product synthesis in transfected HEK-293 cells is 0.003 mM. Compound is a good radical scavenger
zileuton
87% inhibition at 0.005 mM
zileuton
-
reduces exudate formation (77%), cell infiltration (41%), and leukotriene B4 exudate levels (66%)
additional information
-
plant extracts with inhibitory activity on arachidonate 5-lipoxygenase, inhibition of the 5-lipoxygenase pathway is considered to be interesting in the treatment of a variety of inflammatory diseases
-
additional information
-
docking and molecular modeling studies, overview
-
additional information
-
classes of 5-lipoxygenase inhibitors: 1. compounds that inhibit the enzyme via antioxidant mechanism - NGDA, BW755c, AA-861, ICI-207968, and A-53612. High toxicity, unacceptable for clinical development. 2. compounds that interact with the non-heme iron moiety of the enzyme - BW-A4A, and ABT-761 both effective in asthma and zileuton. 3. nonredox competitive inhibitors - ZD-2138 and L-697198
-
additional information
-
plant extracts with inhibitory activity on arachidonate 5-lipoxygenase, inhibition of the 5-lipoxygenase pathway is considered to be interesting in the treatment of a variety of inflammatory diseases.
-
additional information
-
plant extracts with inhibitory activity on arachidonate 5-lipoxygenase, inhibition of the 5-lipoxygenase pathway is considered to be interesting in the treatment of a variety of inflammatory diseases.
-
additional information
-
plant extracts with inhibitory activity on arachidonate 5-lipoxygenase, inhibition of the 5-lipoxygenase pathway is considered to be interesting in the treatment of a variety of inflammatory diseases.
-
additional information
-
classes of 5-lipoxygenase inhibitors: 1. compounds that inhibit the enzyme via antioxidant mechanism - NGDA, BW755c, AA-861, ICI-207968, and A-53612. High toxicity, unacceptable for clinical development. 2. compounds that interact with the non-heme iron moiety of the enzyme - BW-A4A, and ABT-761 both effective in asthma and zileuton. 3. nonredox competitive inhibitors - ZD-2138 and L-697198
-
additional information
-
overview: inhibitors and perspectives for future drug development
-
additional information
-
zinc inhibits leukotriene B4 formation due to a direct or indirect inhibitory effect on 5-lipoxygenase
-
additional information
-
selenium-induced apoptosis in prostate cancer cells may be mediated through inhibition of the activity of arachidonate 5-lipoxygenase. The anti-cancer effects of selenium may be substantially compromised by consumption of high-fat diets rich in arachidonic acid or its precursor fatty acids
-
additional information
-
no inhibition by galanal A, galanal B and 8beta(17)-epoxy-15-hydroxy-12(E)-labden-16-al
-
additional information
-
enzyme activity is inhibited by essential oil from Ballota africana (IC50: 29.99 ppm), methanol extract from Croton sylvaticus (IC50: 25.64 ppm), aqueous extract from Croton sylvaticus (IC50: 60.9 ppm), methanol extract from Melianthus comosus (IC50: 55.05 ppm), aqueous extract from Melianthus comosus (IC50: 13.84 ppm), methanol extract from Pentanisia prunelloides (IC50: 32.7 ppm), and methanol extract from Warburgia salutaris (IC50: 32.11 ppm)
-
additional information
-
isoflavones reduce active state iron to ferrous state and prevent the activation of the resting enzyme, model for the inhibition of lipoxygenase by isoflavones, overview
-
additional information
-
virtual inhibitor screening, structure-function relationship analysis, overview
-
additional information
-
class of dual microsomal PGE2 synthase-1/5-lipoxygenase inhibitors based on the structure of pirinixic acid. Target oriented structural modification of pirinixic acid, particularly R substitution with extended n-alkyl or bulky aryl substituents and concomitant replacement of the 2,3-dimethylaniline by a biphenyl-4-yl-methane-amino residue, results in potent suppression of mPGES-1 and 5-lipoxygenase activity. Is not inhibited by 3-(3-(tert-butylthio)-1-(4-chlorobenzyl)-5-isopropyl-1H-indol-2-yl)-2,2-dimethylpropanoic acid
-
additional information
-
5-lipoxygenase may be inhibited either by the direct interaction with an inhibitor or by the binding of an inhibitor to the 5-lipoxygenase activating protein (FLAP), e.g., the clinically effective MK-0591. Highly potent FLAP inhibitors are 2,2-bisaryl-bicycloheptanes
-
additional information
-
sulindac sulfone and sulindac do not inhibit 5-LO
-
additional information
molecular mechanism of 5-lipoxygenase inhibition by 2-aminothiazoles, overview. ST-1083 and ST-1905, but not the lead compounds, show covalent binding to 5-LO and the potency of ST-1083 and ST-1905, but not of the lead compounds is impaired for 5-LO cysteine mutants. Especially the cysteines 159, 300, 416, and 418, located in the substrate entry channel of 5-LO, are prone to be potential targets for inhibition. The lead compounds show no dependency on thiol level
-
additional information
-
molecular mechanism of 5-lipoxygenase inhibition by 2-aminothiazoles, overview. ST-1083 and ST-1905, but not the lead compounds, show covalent binding to 5-LO and the potency of ST-1083 and ST-1905, but not of the lead compounds is impaired for 5-LO cysteine mutants. Especially the cysteines 159, 300, 416, and 418, located in the substrate entry channel of 5-LO, are prone to be potential targets for inhibition. The lead compounds show no dependency on thiol level
-
additional information
synthesis and evaluation of inhibitors of 5-lipoxygenase catalytic activity based on 2-(3-methylphenyl)propanoic acid and 4-substituted morpholine derivatives, inhibitor molecular docking in the active site of 5-LOX, overview. 2-(3-benzoylphenyl)propanoic acid is an active component of the nonsteroidal antiinflammatory drug ketoprofen
-
additional information
treatement with FLAP inhibitor MK886 does not affect 5-H(p)ETE formation
-
additional information
-
treatement with FLAP inhibitor MK886 does not affect 5-H(p)ETE formation
-
additional information
development of 3,5-dinitrobenzoate-based 5-lipoxygenase inhibitors, structure-activity relationship study, overview
-
additional information
-
development of 3,5-dinitrobenzoate-based 5-lipoxygenase inhibitors, structure-activity relationship study, overview
-
additional information
immobilization of BRP-7 derivatives and pull-down assays, overview
-
additional information
high potency of 4,5-dimethoxy-3-alkyl-1,2-benzoquinones on 5-lipoxygenase inhibition is used for systematic structural optimization through accurate structure-based design of the compounds, improvement of the inhibitory potential in vitro and in vivo, overview. Binding patterns of the quinone- and hydroquinone-based 5-LO inhibitors are analyzed by molecular docking, and determination of the optimal alkyl chain pattern of quinones and corresponding hydroquinones
-
additional information
-
high potency of 4,5-dimethoxy-3-alkyl-1,2-benzoquinones on 5-lipoxygenase inhibition is used for systematic structural optimization through accurate structure-based design of the compounds, improvement of the inhibitory potential in vitro and in vivo, overview. Binding patterns of the quinone- and hydroquinone-based 5-LO inhibitors are analyzed by molecular docking, and determination of the optimal alkyl chain pattern of quinones and corresponding hydroquinones
-
additional information
design, synthesis, and evaluation of 2-phenylthiomethyl-indole derivatives from an ethyl 5-hydroxy-indole-3-carboxylate scaffold as efficient inhibitors of human 5-lipoxygenase, structure-activity relationships, overview. The potency of compounds is closely related to the positioning of the substituents at the phenylthiomethyl ring. The introduction of methyl or chlorine groups in ortho- and ortho/para-position of thiophenol represent the most favorable modifications. Among all tested compounds, ethyl 5-hydroxy-2-(mesitylthiomethyl)-1-methyl-1H-indole-3-carboxylate is the most potent derivative which blocks 5-LO activity in cell-free assays and suppresses 5-LO product synthesis in polymorphonuclear leukocytes. The compounds are not active against 12-LO and 15-LO, EC 1.13.11.31 and EC 1.13.11.33
-
additional information
-
design, synthesis, and evaluation of 2-phenylthiomethyl-indole derivatives from an ethyl 5-hydroxy-indole-3-carboxylate scaffold as efficient inhibitors of human 5-lipoxygenase, structure-activity relationships, overview. The potency of compounds is closely related to the positioning of the substituents at the phenylthiomethyl ring. The introduction of methyl or chlorine groups in ortho- and ortho/para-position of thiophenol represent the most favorable modifications. Among all tested compounds, ethyl 5-hydroxy-2-(mesitylthiomethyl)-1-methyl-1H-indole-3-carboxylate is the most potent derivative which blocks 5-LO activity in cell-free assays and suppresses 5-LO product synthesis in polymorphonuclear leukocytes. The compounds are not active against 12-LO and 15-LO, EC 1.13.11.31 and EC 1.13.11.33
-
additional information
human 5-lipoxygenase (5-LO) is a molecular target of the myxochelins that have antiproliferative effects on K-562 and HeLa cancer cells
-
additional information
-
human 5-lipoxygenase (5-LO) is a molecular target of the myxochelins that have antiproliferative effects on K-562 and HeLa cancer cells
-
additional information
outstanding anti-inflammatory potential of selected Asteraceae species through the potent dual inhibition of cyclooxygenase-1 and 5-lipoxygenase, evaluation of 57 Asteraceae extracts (EtOH:H2O - 7:3 v/v) for in vitro enzyme inhibition activity, e.g. from known anti-inflammatory herbs such as Solidago microglossa, Tithonia diversifolia, Vernonia polyanthes and Viguiera robusta, or food plants or previously uninvestigated species, such a Minasia scapigera, Piptolepis monticola, Prestelia eriopus, Sphagneticola trilobata, Vernonia herbacea, Vernonia platensis, Vernonia rubriramea, and Viguiera trichophylla, chemical profiles, detailed overview
-
additional information
naturally occurring or synthetic anti-inflammatory compounds carrying a Michael acceptor, such as thymoquinone, the paracetamol metabolite NAPQI, the 5-Lox inhibitor AA-861, and bardoxolone methyl (i.e. RTA 402 or CDDO-methyl ester) are direct covalent 5-Lox enzyme inhibitors that target the catalytically relevant cysteines 416 and 418
-
additional information
-
naturally occurring or synthetic anti-inflammatory compounds carrying a Michael acceptor, such as thymoquinone, the paracetamol metabolite NAPQI, the 5-Lox inhibitor AA-861, and bardoxolone methyl (i.e. RTA 402 or CDDO-methyl ester) are direct covalent 5-Lox enzyme inhibitors that target the catalytically relevant cysteines 416 and 418
-
additional information
synthesis of 5-(hydroxamic acid)methyl oxazolidinone derivatives as inhibitors. Increasing alkyl chain length on the hydroxamic acid moiety enhances activity and morpholinyl-containing derivatives are more active than N-acetyl-piperizinyl derivatives. The inhibitory effect of the compounds paralleles their effects in cell-based assays
-
additional information
-
synthesis of 5-(hydroxamic acid)methyl oxazolidinone derivatives as inhibitors. Increasing alkyl chain length on the hydroxamic acid moiety enhances activity and morpholinyl-containing derivatives are more active than N-acetyl-piperizinyl derivatives. The inhibitory effect of the compounds paralleles their effects in cell-based assays
-
additional information
-
plant extracts with inhibitory activity on arachidonate 5-lipoxygenase, inhibition of the 5-lipoxygenase pathway is considered to be interesting in the treatment of a variety of inflammatory diseases.
-
additional information
-
95% ethanol extract of Glycine tomentella inhibits tilapia thrombocyte 5-LOX with IC50 of 0.00043 mg/ml
-
additional information
-
classes of 5-lipoxygenase inhibitors: 1. compounds that inhibit the enzyme via antioxidant mechanism - NGDA, BW755c, AA-861, ICI-207968, and A-53612. High toxicity, unacceptable for clinical development. 2. compounds that interact with the non-heme iron moiety of the enzyme - BW-A4A, and ABT-761 both effective in asthma and zileuton. 3. nonredox competitive inhibitors - ZD-2138 and L-697198
-
additional information
-
-
-
additional information
-
plant extracts with inhibitory activity on arachidonate 5-lipoxygenase, inhibition of the 5-lipoxygenase pathway is considered to be interesting in the treatment of a variety of inflammatory diseases.
-
additional information
inhibitor design, synthesis, biological evaluation, and molecular modeling, overview
-
additional information
-
no inhibition by 1-linoleoyl lysophosphatidylcholine and (13S)-hydroperoxy-9,11-octadecadienoyl lysophosphatidylcholine
-
additional information
-
[(hept-2-yn-1-ylsulfanyl)methyl]benzene is no inhibitor, there are no strong interactions to stabilize the compound in the 5-lipoxygenase active site
-
additional information
-
class of 1-(4-methanesulfonylphenyl and 4-aminosulfonylphenyl)-5-[4-(1-difluoromethyl-1,2-dihydropyrid-2-one)]-3-trifluoromethyl-1H-pyrazoles as potent dual 5-LOX and COX-1/COX-2 isozyme inhibitors of inflammation
-
additional information
-
classes of 5-lipoxygenase inhibitors: 1. compounds that inhibit the enzyme via antioxidant mechanism - NGDA, BW755c, AA-861, ICI-207968, and A-53612. High toxicity, unacceptable for clinical development. 2. compounds that interact with the non-heme iron moiety of the enzyme - BW-A4A, and ABT-761 both effective in asthma and zileuton. 3. nonredox competitive inhibitors - ZD-2138 and L-697198
-
additional information
-
plant extracts with inhibitory activity on arachidonate 5-lipoxygenase, inhibition of the 5-lipoxygenase pathway is considered to be interesting in the treatment of a variety of inflammatory diseases.
-
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
0.00077
(1-difluoromethyl-2-oxo-1,2-dihydropyridin-3-yl)acetic acid
Solanum tuberosum
-
pH and temperature not specified in the publication
0.00044
(1-difluoromethyl-2-oxo-1,2-dihydropyridin-4-yl)acetic acid
Solanum tuberosum
-
pH and temperature not specified in the publication
0.005
(10E,12E)-octadeca-10,12-dien-8-ynoic acid
Rattus norvegicus
-
pH and temperature not specified in the publication
0.06
(11E)-octadec-11-en-9-ynoic acid
Rattus norvegicus
-
pH and temperature not specified in the publication
0.0241
(17S)-hydroperoxy-4,7,10,13,15,19-docosahexaenoyl lysophosphatidylcholine
Solanum tuberosum
-
pH 6.3, 25°C
0.0005
(1E)-1-((1-[(1Z)-prop-1-en-1-yldisulfanyl]propyl)sulfinyl)prop-1-ene
Rattus norvegicus
-
pH and temperature not specified in the publication
0.00051
(1E)-1-(2,5-dihydroxyphenyl)-5-phenylpent-1-en-3-one
Homo sapiens
inhibition of 5-Lox product biosynthesis in polymorphonuclear leukocyte, 37°C, pH not specified in the publication
-
0.00052
(1E)-1-(3,4-dihydroxyphenyl)-6-phenylhex-1-en-3-one
Homo sapiens
inhibition of 5-Lox product biosynthesis in polymorphonuclear leukocyte, 37°C, pH not specified in the publication
-
0.00041
(1E)-1-(4-hydroxy-3,5-dimethoxyphenyl)-5-phenylpent-1-en-3-one
Homo sapiens
inhibition of 5-Lox product biosynthesis in polymorphonuclear leukocyte, 37°C, pH not specified in the publication
-
0.0141
(2E)-1-(2-hydroxy-4-methoxyphenyl)-3-(2,4,5-trimethoxyphenyl)prop-2-en-1-one
Solanum tuberosum
-
pH 7.4, temperature not specified in the publication
0.0103
(2E)-1-(2-hydroxy-4-methoxyphenyl)-3-(3,4,5-trimethoxyphenyl)prop-2-en-1-one
Solanum tuberosum
-
pH 7.4, temperature not specified in the publication
0.03
(2E)-1-(2-hydroxy-4-methoxyphenyl)-3-(4-hydroxyphenyl)prop-2-en-1-one
Solanum tuberosum
-
pH 7.4, temperature not specified in the publication
0.0159 - 0.0358
(2E)-1-(2-hydroxy-4-methoxyphenyl)-3-(4-methoxyphenyl)prop-2-en-1-one
0.013
(2E)-1-(2-hydroxy-4-methoxyphenyl)-3-[3-methoxy-4-(3-phenoxypropoxy)phenyl]prop-2-en-1-one
Solanum tuberosum
-
pH 7.4, temperature not specified in the publication
0.0061
(2E)-1-(2-hydroxy-4-methoxyphenyl)-3-[4-(morpholin-4-ylcarbonyl)phenyl]prop-2-en-1-one
Solanum tuberosum
-
pH 7.4, temperature not specified in the publication
0.0068
(2E)-1-(2-hydroxy-4-methoxyphenyl)-3-[4-(piperidin-1-ylcarbonyl)phenyl]prop-2-en-1-one
Solanum tuberosum
-
pH 7.4, temperature not specified in the publication
0.0105
(2E)-1-(2-hydroxy-4-methoxyphenyl)-3-[4-(pyrrolidin-1-ylcarbonyl)phenyl]prop-2-en-1-one
Solanum tuberosum
-
pH 7.4, temperature not specified in the publication
0.0079
(2E)-1-(2-hydroxy-4-methoxyphenyl)-3-[4-[(4-methylpiperazin-1-yl)carbonyl]phenyl]prop-2-en-1-one
Solanum tuberosum
-
pH 7.4, temperature not specified in the publication
0.00004
(2E)-3-(3,4-dihydroxyphenyl)-1-(2,4-dimethoxyphenyl)prop-2-en-1-one
Solanum tuberosum
-
in 100 mM phosphate buffer, pH 6.3, 25°C
0.003
(2E)-3-(3,4-dihydroxyphenyl)prop-2-enoic acid
Rattus norvegicus
-
pH and temperature not specified in the publication
0.016
(2E)-3-[3-(2-ethoxyethoxy)phenyl]-1-(2-hydroxy-4-methoxyphenyl)prop-2-en-1-one
Solanum tuberosum
-
pH 7.4, temperature not specified in the publication
0.0097
(2E)-3-[4-(2-ethoxyethoxy)phenyl]-1-(2-hydroxy-4-methoxyphenyl)prop-2-en-1-one
Solanum tuberosum
-
pH 7.4, temperature not specified in the publication
0.0124
(2E)-3-[4-(3-ethoxypropoxy)-3-methoxyphenyl]-1-(2-hydroxy-4-methoxyphenyl)prop-2-en-1-one
Solanum tuberosum
-
pH 7.4, temperature not specified in the publication
0.011
(2E)-3-[4-(benzyloxy)-3-bromo-5-methoxyphenyl]-1-(2-hydroxy-4-methoxyphenyl)prop-2-en-1-one
Solanum tuberosum
-
pH 7.4, temperature not specified in the publication
0.0102
(2E)-3-[4-(benzyloxy)phenyl]-1-(2-hydroxy-4-methoxyphenyl)prop-2-en-1-one
Solanum tuberosum
-
pH 7.4, temperature not specified in the publication
0.00066 - 0.00246
(2E,2'E)-(1,1'-(2,2-bis((4-(((E)-3-(3,4-dihydroxyphenyl)acryloyloxy)methyl)-1H-1,2,3-triazol-1-yl)methyl)propane-1,3-diyl)bis(1H-1,2,3-triazole-4,1-diyl))bis(methylene) bis(3-(3,4-dihydroxyphenyl)acrylate)
0.00079 - 0.00237
(2E,2'E)-(1,1'-(2-((4-(((E)-3-(3,4-dihydroxyphenyl)acryloyloxy)methyl)-1H-1,2,3-triazol-1-yl)methyl)-2-(hydroxymethyl)propane-1,3-diyl)bis(1H-1,2,3-triazole-4,1-diyl))bis(methylene) bis(3-(3,4-dihydroxyphenyl)acrylate)
0.03
(2E,5E)-5-[(2E)-3-(furan-2-yl)prop-2-en-1-ylidene]-3-phenyl-2-(phenylimino)-1,3-thiazolidin-4-one
0.000572
(2E,6E,10E)-13-((R)-6-hydroxy-2,5,7,8-tetramethylchroman-2-yl)-N-(4-methoxybenzyl)-2,6,10-trimethyltrideca-2,6,10-trienamide
Homo sapiens
pH 7.4, 37°C
-
0.000094
(2E,6E,10E)-13-((R)-6-hydroxy-2,8-dimethylchroman-2-yl)-N-(4-methoxybenzyl)-2,6,10-trimethyltrideca-2,6,10-trienamide
Homo sapiens
pH 7.4, 37°C
-
0.000077
(2E,6E,10E)-13-(6-hydroxy-2,8-dimethylchroman-2-yl)-2,6,10-trimethyl-N-(pyridin-3-ylmethyl)trideca-2,6,10-trienamide
Homo sapiens
pH 7.4, 37°C
-
0.000595
(2E,6E,10E)-N-benzyl-13-((R)-6-hydroxy-2,5,7,8-tetramethylchroman-2-yl)-2,6,10-trimethyltrideca-2,6,10-trienamide
Homo sapiens
pH 7.4, 37°C
-
0.00005
(2E,6E,10E)-N-benzyl-13-((R)-6-hydroxy-2,8-dimethylchroman-2-yl)-2,6,10-trimethyltrideca-2,6,10-trienamide
Homo sapiens
pH 7.4, 37°C
-
0.00011
(2Z)-2-[4-(acetylamino)phenyl]-3-[4-(methylsulfonyl)phenyl]prop-2-enoic acid
Solanum tuberosum
-
in 100 mM phosphate buffer, pH 6.3, 25°C
0.00013 - 0.00038
(5E)-2-(3-acetylphenyl)-5-(4-methoxybenzylidene)-1,3-thiazol-4(5H)-one
0.00012 - 0.00024
(5E)-2-(3-fluorophenyl)-5-(4-methoxybenzylidene)-1,3-thiazol-4(5H)-one
0.00011 - 0.00055
(5E)-2-(4-acetylphenyl)-5-(4-methoxybenzylidene)-1,3-thiazol-4(5H)-one
0.00063 - 0.00193
(5E)-2-(4-aminophenyl)-5-(4-methoxybenzylidene)-1,3-thiazol-4(5H)-one
0.00011 - 0.0004
(5E)-2-(4-chlorophenyl)-5-(4-hydroxybenzylidene)-1,3-thiazol-4(5H)-one
0.00009 - 0.00028
(5E)-2-(4-chlorophenyl)-5-(4-methoxybenzylidene)-1,3-thiazol-4(5H)-one
0.00065 - 0.00169
(5E)-2-(4-hydroxyphenyl)-5-(4-methoxybenzylidene)-1,3-thiazol-4(5H)-one
0.0004 - 0.00245
(5E)-2-(4-methylphenyl)-5-(3,4,5-trimethoxybenzylidene)-1,3-thiazol-4(5H)-one
0.00098 - 0.00202
(5E)-5-(2,4-dimethoxybenzylidene)-2-(4-methylphenyl)-1,3-thiazol-4(5H)-one
0.0008 - 0.0013
(5E)-5-(2-hydroxy-3-methoxybenzylidene)-2-(4-methylphenyl)-1,3-thiazol-4(5H)-one
0.00048 - 0.00054
(5E)-5-(2-hydroxy-3-methoxybenzylidene)-2-phenyl-1,3-thiazol-4(5H)-one
0.00013 - 0.00035
(5E)-5-(3,5-dimethoxybenzylidene)-2-(4-methylphenyl)-1,3-thiazol-4(5H)-one
0.0027 - 0.01
(5E)-5-(3-chloro-4-hydroxy-5-methoxybenzylidene)-2-(4-methylphenyl)-1,3-thiazol-4(5H)-one
0.003 - 0.0095
(5E)-5-(3-chloro-4-hydroxy-5-methoxybenzylidene)-2-phenyl-1,3-thiazol-4(5H)-one
0.00125 - 0.0029
(5E)-5-(3-chloro-5-ethoxy-4-hydroxybenzylidene)-2-(4-methylphenyl)-1,3-thiazol-4(5H)-one
0.0003 - 0.00058
(5E)-5-(3-chlorobenzylidene)-2-(4-methylphenyl)-1,3-thiazol-4(5H)-one
0.003 - 0.0044
(5E)-5-(4-hydroxy-3-methoxy-5-nitrobenzylidene)-2-phenyl-1,3-thiazol-4(5H)-one
0.00032 - 0.004
(5E)-5-(4-methoxybenzylidene)-2-(4-methoxyphenyl)-1,3-thiazol-4(5H)-one
0.0003 - 0.00066
(5E)-5-(4-methoxybenzylidene)-2-(4-methylphenyl)-1,3-thiazol-4(5H)-one
0.00015 - 0.002
(5E)-5-(4-methoxybenzylidene)-2-phenyl-1,3-thiazol-4(5H)-one
0.0003 - 0.00091
(5E)-5-(4-tert-butylbenzylidene)-2-phenyl-1,3-thiazol-4(5H)-one
0.00019 - 0.00211
(5E)-5-(4-[(methylperoxy)acetyl]benzylidene)-2-(4-methylphenyl)-1,3-thiazol-4(5H)-one
0.0003 - 0.00065
(5E)-5-(5-chloro-2-hydroxy-3-methoxybenzylidene)-2-phenyl-1,3-thiazol-4(5H)-one
0.0003 - 0.004
(5E)-5-(anthracen-9-ylmethylidene)-2-phenyl-1,3-thiazol-4(5H)-one
0.00035 - 0.00073
(5E)-5-benzylidene-2-(4-methylphenyl)-1,3-thiazol-4(5H)-one
0.02 - 0.03
(5E)-5-[4-(dimethylamino)benzylidene]-2-(piperidin-1-yl)-1,3-thiazol-4(5H)-one
0.012 - 0.014
(5Z)-2-(cyclohexylamino)-5-(4-propoxybenzylidene)-1,3-thiazol-4(5H)-one
0.03
(5Z)-5-(4-methoxybenzylidene)-2-(pyrrolidin-1-yl)-1,3-thiazol-4(5H)-one
0.03
(5Z)-5-(4-methylbenzylidene)-2-(naphthalen-2-ylamino)-1,3-thiazol-4(5H)-one
0.03
(5Z)-5-benzylidene-2-(phenylamino)-1,3-thiazol-4(5H)-one
0.0019
(R)-N-((3-(3-fluoro-4-morpholinophenyl)-2-oxooxazolidin-5-yl) methyl)-N-hydroxyheptanamide
Homo sapiens
pH 7.5, 25°C
-
0.0016
(R)-N-((3-(3-fluoro-4-morpholinophenyl)-2-oxooxazolidin-5-yl) methyl)-N-hydroxyoctanamide
Homo sapiens
pH 7.5, 25°C
-
0.0033
(R)-N-((3-(3-fluoro-4-morpholinophenyl)-2-oxooxazolidin-5-yl)methyl)-N-hydroxypentanamide
Homo sapiens
pH 7.5, 25°C
-
0.00011
(R)-N-(2-(diphenylamino)ethyl)-3-(3-(1-hydroxyureido)but-1-yn-1-yl)benzamide, (R)-N-(3,3-bis(4-fluorophenyl)propyl)-3-(3-(1-hydroxyureido)but-1-yn-1-yl)benzamide
Homo sapiens
pH 7.4, 37°C
-
0.00011
(R)-N-(3,3-bis(4-fluorophenyl)propyl)-3-(3-(1-hydroxyureido)but-1-yn-1-yl)benzamide
Homo sapiens
-
pH 7.4, 37°C
-
0.0039
([3-chloro-5-(2,3-dihydro-1H-inden-4-ylamino)phenyl]sulfanyl)acetic acid
Rattus norvegicus
-
pH and temperature not specified in the publication
0.005
([4-chloro-6-[(2,3-dimethylphenyl)amino]pyrimidin-2-yl]sulfanyl)(naphthalen-1-yl)acetic acid
Homo sapiens
-
in intact polymorphonuclear leukocytes
0.029
1,4a-dimethyl-7-(propan-2-yl)-1-(prop-1-en-2-yl)-1,2,3,4,4a,4b,5,6,10,10a-decahydrophenanthrene (non-preferred name)
Rattus norvegicus
-
pH and temperature not specified in the publication
0.0006 - 0.007
1-(2,4-difluorophenyl)-3-(3,5a,10-trimethyl-2-oxo-2,3,3a,4,5,5a,6,10,10a,10b-decahydrofuro[3',2':7,8]naphtho[2,3-d][1,3]thiazol-8-yl)urea
0.0068 - 0.01
1-(2,4-dihydroxyphenyl)-2-(naphthalen-2-yl)ethanone
0.00087
1-(3,4-dichlorobenzyl)-3-(2-morpholin-4-yl-2-oxoethyl)-1H-indole
Rattus norvegicus
-
0.0028
1-(3,4-difluorophenyl)-1,2,4-triazinan-3-one
Rattus norvegicus
-
pH and temperature not specified in the publication
0.0021
1-(3-bromophenyl)-1,2,4-triazinan-3-one
Rattus norvegicus
-
pH and temperature not specified in the publication
0.0035
1-(3-chlorophenyl)-1,2,4-triazinan-3-one
Rattus norvegicus
-
pH and temperature not specified in the publication
0.0066
1-(3-ethylphenyl)-1,2,4-triazinan-3-one
Rattus norvegicus
-
pH and temperature not specified in the publication
0.0003 - 0.3
1-(3-hydroxyphenyl)-3-[4-(methylsulfonyl)phenyl]prop-2-yn-1-one
0.0013
1-(3-[5-(hydroxyureido)methyl-2-methoxyphenoxy]propyl)-3-[4-(trifluoromethoxy)phenyl]urea
Homo sapiens
pH 7.4, 37°C
0.00039
1-(4-aminosulfonylphenyl)-5-(2-chloropyridin-4-yl)-3-trifluoromethyl-1H-pyrazole
Solanum tuberosum
-
-
0.005
1-(4-aminosulfonylphenyl)-5-[4-(1-difluoromethyl-1,2-dihydropyrid-2-one)]-3-trifluoromethyl-1H-pyrazole
Solanum tuberosum
-
-
0.000016
1-(4-chlorobenzyl)-2-[2,2-dimethyl-3-(1H-tetrazol-5-yl)propyl]-4-methyl-6-[2-(5-phenylpyridin-2-yl)ethyl]-2,2a,4,5-tetrahydro-1H-thiopyrano[2,3,4-cd]indole
Solanum tuberosum
-
in 100 mM phosphate buffer, pH 6.3, 25°C
0.00225
1-(4-chlorophenoxy)-5-methoxy-2-methyl-3-(4-morpholin-4-yl-4-oxobutyl)-1H-indole
Rattus norvegicus
-
0.00047
1-(4-methanesulfonylphenyl)-5-(2-chloropyridin-4-yl)-3-trifluoromethyl-1H-pyrazole
Solanum tuberosum
-
-
0.0044
1-(4-methanesulfonylphenyl)-5-[4-(1-difluoromethyl-1,2-dihydropyrid-2-one)]-3-trifluoromethyl-1H-pyrazole
Solanum tuberosum
-
-
0.0039
1-(6-methylpyridin-2-yl)-1,2,4-triazinan-3-one
Rattus norvegicus
-
pH and temperature not specified in the publication
0.0085
1-(7-tert-butyl-3,3-dimethyl-2,3-dihydro-1-benzofuran-5-yl)butan-1-one
Solanum tuberosum
-
in 100 mM phosphate buffer, pH 6.3, 25°C
0.008
1-(8-tert-butyl-4,4-dimethyl-3,4-dihydro-2H-chromen-6-yl)-4-cyclopropylbutan-1-one
Solanum tuberosum
-
in 100 mM phosphate buffer, pH 6.3, 25°C
0.76
1-(benzyloxy)hept-2-yn-4-ol
Solanum tuberosum
-
-
0.0034
1-(difluoromethyl)-5-[[2-(methylsulfonyl)phenyl]ethynyl]pyridin-2(1H)-one
Solanum tuberosum
-
in 100 mM phosphate buffer, pH 6.3, 25°C
0.003 - 0.01
1-benzyl-3-(3,5a,10-trimethyl-2-oxo-2,3,3a,4,5,5a,6,10,10a,10b-decahydrofuro[3',2':7,8]naphtho[2,3-d][1,3]thiazol-8-yl)urea
0.00317
1-benzyl-3-(3-morpholin-4-yl-3-oxopropyl)-1H-indole
Rattus norvegicus
-
0.00085
1-benzyl-3-(4-oxo-4-piperazin-1-ylbutyl)-1H-indole
Rattus norvegicus
-
0.00095
1-benzyl-5-chloro-2-methyl-3-(4-morpholin-4-yl-4-oxobutyl)-1H-indole
Rattus norvegicus
-
0.0038
1-hydroxy-1-[1-(5-methoxy-1-methyl-1H-indol-2-yl)ethyl]urea
Rattus norvegicus
-
pH and temperature not specified in the publication
0.005
1-O-dodecyl 2,3-O-isopropylidene-5,6-dideoxy-5-N-[4-(2-hydroxy-2-oxoethyl) phenylaminocarbonyl] amino-beta-L-gulofuranoside sodium salt
Homo sapiens
-
competitive inhibitor, IC50: 0.0035 mM with recombinant enzyme, IC50: 0.005 mM with native enzyme
0.0039
1-phenyl-5-(propan-2-yl)-1,2,4-triazinan-3-one
Rattus norvegicus
-
pH and temperature not specified in the publication
0.045
1-[(4methylbenzyl)oxy]hept-2-yn-4-ol
Solanum tuberosum
-
-
0.0056
1-[1-(6-tert-butyl-1-benzothiophen-2-yl)ethyl]-1-hydroxyurea
Rattus norvegicus
-
pH and temperature not specified in the publication
0.0049
1-[3-(benzyloxy)phenyl]-1,2,4-triazinan-3-one
Rattus norvegicus
-
pH and temperature not specified in the publication
0.001 - 0.004
1-[3-(methylsulfanyl)phenyl]-3-(3,5a,10-trimethyl-2-oxo-2,3,3a,4,5,5a,6,10,10a,10b-decahydrofuro[3',2':7,8]naphtho[2,3-d][1,3]thiazol-8-yl)urea
0.00034
1-[4-([3-fluoro-5-[4-(methylsulfinyl)tetrahydro-2H-pyran-4-yl]phenoxy]methyl)phenyl]-2-methyl-1H-imidazole
Rattus norvegicus
-
pH and temperature not specified in the publication
0.000195
1-[4-([3-fluoro-5-[4-(methylsulfonyl)tetrahydro-2H-pyran-4-yl]phenoxy]methyl)phenyl]-2-methyl-1H-imidazole
Rattus norvegicus
-
pH and temperature not specified in the publication
0.017
10,17(S)-dihydroxydocosahexaenoic acid
Homo sapiens
-
IC50: 0.017 mM
0.0006
10-nitro-oleic acid
Homo sapiens
pH 7.4, 37°C
-
0.015
11,14,17-Eicosatrienoic acid
Rattus norvegicus
-
IC50: 0.015 mM
0.0048
15-hydroperoxy-6,8,11,13-eicosatetraenoic acid
Homo sapiens
-
IC50: 0.0048 mM
0.05
2,3-dichlorophenyl 3,5-dinitrobenzoate
Homo sapiens
pH 7.4, 37°C
0.00026
2,5-dimethoxy-3-tridecylbenzene-1,4-diol
Homo sapiens
pH 7.4, 37°C, cell-free enzyme extract
0.0037
2-(1-difluoromethyl-2-oxo-1,2-dihydropyridin-3-yl)propanoic acid
Solanum tuberosum
-
pH and temperature not specified in the publication
0.0002
2-(1-difluoromethyl-2-oxo-1,2-dihydropyridin-4-yl)phenylacetic acid
Solanum tuberosum
-
pH and temperature not specified in the publication
0.00025
2-(1-difluoromethyl-2-oxo-1,2-dihydropyridin-4-yl)propanoic acid
Solanum tuberosum
-
pH and temperature not specified in the publication
0.00046
2-(1-difluoromethyl-2-oxo-1,2-dihydropyridin-5-yl)acetic acid
Solanum tuberosum
-
pH and temperature not specified in the publication
0.003
2-(1-difluoromethyl-2-oxo-1,2-dihydropyridin-5-yl)propanoic acid
Solanum tuberosum
-
pH and temperature not specified in the publication
0.0015
2-(2,2-dimethyl-6-(4-nitrophenyl)-7-phenyl-2,3-dihydro-1H-pyrrolizin-5-yl)acetic acid
Homo sapiens
-
-
0.00031
2-(2,2-dimethyl-7-phenyl-6-(4-(trifluoromethyl)phenyl)-2,3-dihydro-1H-pyrrolizin-5-yl)acetic acid
Homo sapiens
-
-
0.1
2-(2,4-dihydroxyphenyl)-8,8-dimethyl-3-(3-methylbut-2-en-1-yl)-4H,8H-pyrano[2,3-f]chromen-4-one
Rattus norvegicus
-
pH and temperature not specified in the publication
0.004 - 0.01
2-(2-methoxyphenyl)-N-(3,5a,10-trimethyl-2-oxo-2,3,3a,4,5,5a,6,10,10a,10b-decahydrofuro[3',2':7,8]naphtho[2,3-d][1,3]thiazol-8-yl)acetamide
0.0055
2-(2-[ethyl(hydroxy)amino]ethyl)dibenzo[b,e]oxepin-11(6H)-one
Rattus norvegicus
-
pH and temperature not specified in the publication
0.03
2-(3,4,5-trihydroxyphenyl)-3,4-dihydro-2H-chromene-3,5,7-triol
Rattus norvegicus
-
pH and temperature not specified in the publication
0.02 - 2
2-(3,4-dihydroxyphenyl)-3,4-dihydro-2H-chromene-3,5,7-triol
Rattus norvegicus
-
pH and temperature not specified in the publication
0.0032
2-(3,4-dihydroxyphenyl)-3,5,7-trihydroxy-4H-chromen-4-one
Rattus norvegicus
-
pH and temperature not specified in the publication
0.0036
2-(3-methylbut-2-en-1-yl)-6H-[1]benzofuro[3,2-c]chromene-3,6,9-triol
Rattus norvegicus
-
pH and temperature not specified in the publication
0.0049
2-(3-[hydroxy(methyl)amino]propyl)dibenzo[b,e]oxepin-11(6H)-one
Rattus norvegicus
-
pH and temperature not specified in the publication
0.0007 - 0.0015
2-(4-(biphenyl-4-ylamino)-6-chloropyrimidine-2-ylthio)octanoic acid
0.001 - 0.002
2-(4-(biphenyl-4-ylmethylamino)-6-chloropyrimidin-2-ylthio)octanoic acid
0.0004 - 0.0015
2-(4-chloro-6-(4'-cyanobiphenyl-4-ylamino)pyrimidin-2-ylthio)octanoic acid
0.0005 - 0.002
2-(4-chloro-6-(5-methoxy-2-methylbiphenyl-4-ylamino)pyrimidin-2-ylthio)octanoic acid
0.00023 - 0.0004
2-(4-methylphenyl)-5-(2-phenylethenylidene)-1,3-thiazol-4(5H)-one
0.0008 - 0.001
2-(5,8-dimethyl-7-propoxy-1,2,3,4-tetrahydronaphthalen-2-yl)-N-(5-methyl-1,3-thiazol-2-yl)propanamide
0.0008 - 0.001
2-(5,8-dimethyl-7-propoxy-1,2,3,4-tetrahydronaphthalen-2-yl)-N-1,3-thiazol-2-ylpropanamide
0.0009 - 0.006
2-(5,8-dimethyl-7-propoxy-1,2,3,4-tetrahydronaphthalen-2-yl)-N-pyridin-2-ylpropanamide
0.003 - 0.008
2-(5,8-dimethyl-7-propoxy-1,2,3,4-tetrahydronaphthalen-2-yl)-N-thiophen-3-ylpropanamide
0.00023
2-(6-(4-chlorophenyl)-2,2-dimethyl-7-phenyl-2,3-dihydro-1H-pyrrolizin-5-yl)-N-(methylsulfonyl)acetamide
Homo sapiens
-
-
0.00025
2-(6-(4-chlorophenyl)-2,2-dimethyl-7-phenyl-2,3-dihydro-1H-pyrrolizin-5-yl)-N-(phenylsulfonyl)acetamide
Homo sapiens
-
-
0.00026
2-(6-(4-chlorophenyl)-2,2-dimethyl-7-phenyl-2,3-dihydro-1H-pyrrolizin-5-yl)-N-tosylacetamide
Homo sapiens
-
-
0.0016
2-(6-(4-chlorophenyl)-7-phenyl-2,3-dihydro-1H-pyrrolizin-5-yl)acetic acid
Homo sapiens
-
-
0.00018
2-(6-(4-tert-butylphenyl)-2,2-dimethyl-7-phenyl-2,3-dihydro-1H-pyrrolizin-5-yl)acetic acid
Homo sapiens
-
-
0.008 - 0.01
2-(7-methoxy-5,8-dimethyl-1,2,3,4-tetrahydronaphthalen-2-yl)-N-(thiophen-2-ylmethyl)propanamide
0.0008 - 0.005
2-(7-methoxy-5,8-dimethyl-1,2,3,4-tetrahydronaphthalen-2-yl)-N-pyridin-2-ylpropanamide
0.0008 - 0.01
2-(dibenzo[b,d]furan-3-yl)-5-hydroxycyclohexa-2,5-diene-1,4-dione
0.0041 - 0.0065
2-([4-chloro-6-[(2,3-dimethylphenyl)amino]pyrimidin-2-yl]sulfanyl)octanoic acid
0.01
2-benzyl-5-hydroxycyclohexa-2,5-diene-1,4-dione
0.0014 - 0.003
2-hexyl-5-hydroxycyclohexa-2,5-diene-1,4-dione
0.0046 - 0.01
2-hydroxy-5-(3-nitrophenyl)cyclohexa-2,5-diene-1,4-dione
0.00078 - 0.0023
2-hydroxy-5-(naphthalen-2-ylmethyl)cyclohexa-2,5-diene-1,4-dione
0.01
2-hydroxy-5-methoxy-3-(naphthalen-2-ylmethyl)cyclohexa-2,5-diene-1,4-dione
0.00028 - 0.0067
2-methoxy-5-(naphthalen-2-yloxy)cyclohexa-2,5-diene-1,4-dione
0.00032 - 0.00033
2-phenylethyl (2E)-3-(2,5-dihydroxyphenyl)prop-2-enoate
-
0.00029
2-phenylethyl (2E)-3-(4-hydroxy-3,5-dimethoxyphenyl)prop-2-enoate
Homo sapiens
inhibition of 5-Lox product biosynthesis in polymorphonuclear leukocyte, 37°C, pH not specified in the publication
-
0.01
2-[(1-hydroxy-6-oxo-1,6-dihydropyridin-3-yl)ethynyl]benzenesulfonamide
Solanum tuberosum
-
in 100 mM phosphate buffer, pH 6.3, 25°C
0.0015 - 0.003
2-[(4-[[3,5-bis(2,2,2-trifluoroethoxy)phenyl]amino]-6-chloropyrimidin-2-yl)sulfanyl]octanoic acid
0.002
2-[2-(1-difluoromethyl-2-oxo-1,2-dihydropyridin-4-yl)phenyl]propanoic acid
Solanum tuberosum
-
pH and temperature not specified in the publication
0.00037
2-[3-(1-difluoromethyl-2-oxo-1,2-dihydropyridin-4-yl)phenyl]propanoic acid
Solanum tuberosum
-
pH and temperature not specified in the publication
0.006
2-[4'-(iso-propylphenyl)-amino]-5,6-dimethyl-1,4-benzoquinone
Homo sapiens
-
potent inhibitor, IC50: 0.006 mM
0.003
2-[4-(1-difluoromethyl-2-oxo-1,2-dihydropyridin-4-yl)phenyl]propanoic acid
Solanum tuberosum
-
pH and temperature not specified in the publication
0.00068
2-[4-([[(2E)-3-phenylprop-2-enoyl]oxy]methyl)-1H-1,2,3-triazol-1-yl]ethyl (2E)-3-(3,4-dihydroxyphenyl)prop-2-enoate
0.00018
2-[6-(4-chlorophenyl)-2,2-dimethyl-7-phenyl-2,3-dihydro-1H-pyrrolizin-5-yl]acetic acid
Homo sapiens
-
-
0.001 - 0.01
2-[7-[2-(dimethylamino)ethoxy]-5,8-dimethyl-1,2,3,4-tetrahydronaphthalen-2-yl]-N-1,3-thiazol-2-ylpropanamide
0.005
2-[[5-fluoro-6-(4-fluorophenoxy)-1H-benzimidazol-2-yl]sulfanyl]-2-methylpropanoic acid
Glycine max
-
pH 7.0, 25°C
-
0.01
3'-nitrobiphenyl-2,4-diol
0.0009 - 0.01
3,4,5-trimethoxy-N-(3,5a,10-trimethyl-2-oxo-2,3,3a,4,5,5a,6,10,10a,10b-decahydrofuro[3',2':7,8]naphtho[2,3-d][1,3]thiazol-8-yl)benzamide
0.00031
3,4,6-trimethoxy-5-undecylcyclohexa-2,4-dien-1-one
Homo sapiens
pH 7.4, 37°C, cell-free enzyme extract
0.05
3-((naphthalene-1-yloxy)carbonyl)benzoic acid
Homo sapiens
pH 7.4, 37°C
0.00146
3-(1,10-dihydroxydecyl)-2,5-dimethoxycyclohexa-2,5-diene-1,4-dione
Homo sapiens
pH 7.4, 37°C, cell-free enzyme extract
0.00049
3-(1-acetoxy-10-hydroxydecyl)-2,5-dimethoxycyclohexa-2,5-diene-1,4-dione
Homo sapiens
pH 7.4, 37°C, cell-free enzyme extract
0.00037
3-(1-difluoromethyl-2-oxo-1,2-dihydropyridin-4-yl)phenylacetic acid
Solanum tuberosum
-
pH and temperature not specified in the publication
0.00175
3-(10-hydroxydecyl)-2,5-dimethoxycyclohexa-2,5-diene-1,4-dione
Homo sapiens
pH 7.4, 37°C, cell-free enzyme extract
0.00108
3-(10-hydroxydecyl)-4,5-dimethoxycyclohexa-3,5-diene-1,2-dione
Homo sapiens
pH 7.4, 37°C, cell-free enzyme extract
0.00151
3-(11-hydroxyundecyl)-2,5-dimethoxycyclohexa-2,5-diene-1,4-dione
Homo sapiens
pH 7.4, 37°C, cell-free enzyme extract
0.00196
3-(11-hydroxyundecyl)-4,5-dimethoxycyclohexa-3,5-diene-1,2-dione
Homo sapiens
pH 7.4, 37°C, cell-free enzyme extract
0.01
3-(2-(2-[(4-chlorophenyl)sulfanyl]ethoxy)-3-methoxy-5-[5-(3,4,5-trimethoxyphenyl)tetrahydrofuran-2-yl]benzyl)-1-hydroxy-1-methylurea
Rattus norvegicus
-
pH and temperature not specified in the publication
0.0007
3-(3-(1-hydroxyureido)but-1-yn-1-yl)-N-(2-(trifluoromethyl)-benzyl)benzamide
Homo sapiens
pH 7.4, 37°C
-
0.00011
3-(3-(1-hydroxyureido)but-1-yn-1-yl)-N-(3-phenyl-3-(4-(trifluoromethoxy)phenyl)propyl)benzamide
Homo sapiens
pH 7.4, 37°C
-
0.0017
3-(3-(1-hydroxyureido)but-1-yn-1-yl)-N-(4-methoxy-2-(trifluoromethyl)benzyl)-benzamide
Homo sapiens
pH 7.4, 37°C
-
0.0003
3-(3-(1-hydroxyureido)hex-1-yn-1-yl)-N-(2-(trifluoromethyl)-benzyl)benzamide
Homo sapiens
pH 7.4, 37°C
-
0.0042
3-(4,5-dihydroxy-2-methyl-9,10-dioxo-4a,9,9a,10-tetrahydroanthracen-1-yl)-2-hydroxy-4,6-dimethoxybenzoic acid
Rattus norvegicus
-
pH and temperature not specified in the publication
0.00206
3-(4-morpholin-4-yl-4-oxobutyl)-1H-indole
Rattus norvegicus
-
0.00184
3-(8-hydroxyoctyl)-2,5-dimethoxycyclohexa-2,5-diene-1,4-dione
Homo sapiens
pH 7.4, 37°C, cell-free enzyme extract
0.00022
3-(8-hydroxyoctyl)-4,5-dimethoxycyclohexa-3,5-diene-1,2-dione
Homo sapiens
pH 7.4, 37°C, cell-free enzyme extract
0.05
3-(benzyloxycarbonyl)benzoic acid
Homo sapiens
pH 7.4, 37°C
0.01
3-(cyclohexylmethyl)-2,5-dihydroxycyclohexa-2,5-diene-1,4-dione
0.00058 - 0.011
3-(decahydronaphthalen-2-ylmethyl)-2,5-dihydroxycyclohexa-2,5-diene-1,4-dione
0.05
3-(naphhthalen-1-ylcarbmoyl)benzoic acid
Homo sapiens
pH 7.4, 37°C
0.05
3-(phenylcarbamoyl)benzoic acid
Homo sapiens
pH 7.4, 37°C
0.01
3-benzyl-2-hydroxy-5-methoxycyclohexa-2,5-diene-1,4-dione
0.00024
3-dodecyl-4,5-dimethoxybenzene-1,2-diol
Homo sapiens
pH 7.4, 37°C, cell-free enzyme extract
0.00013
3-dodecyl-4,5-dimethoxycyclohexa-3,5-diene-1,2-dione
Homo sapiens
pH 7.4, 37°C, cell-free enzyme extract
0.0015
3-ethoxy-11-oxours-12-en-23-oic acid
Rattus norvegicus
-
pH and temperature not specified in the publication
0.00274
3-n-pentadecylcatechol
Homo sapiens
pH 7.5, temperature not specified in the publication
-
0.0065
3-propylphenyl 3,5-dinitrobenzoate
Homo sapiens
pH 7.4, 37°C
0.0005
3-tolyl 3,5-dinitrobenzoate
Homo sapiens
pH 7.4, 37°C
0.00006
3-tridecyl-4,5-dimethoxybenzene-1,2-diol
Homo sapiens
pH 7.4, 37°C, cell-free enzyme extract
0.0001
3-undecyl-4,5-dimethoxybenzene-1,2-diol
Homo sapiens
pH 7.4, 37°C, cell-free enzyme extract
0.00116
3-[(10E)-pentadec-10'-en-1-yl]-catechol
Homo sapiens
i.e. a catechol mixture from Lithrea caustica containing 65% of the compound, pH 7.5, temperature not specified in the publication
-
0.00209
3-[(10Z)-pentadec-10'-en-1-yl]-catechol
Homo sapiens
pH 7.5, temperature not specified in the publication
-
0.00238
3-[2-[3-fluoro-5-(4-methoxytetrahydro-2H-pyran-4-yl)phenoxy]ethyl]-1H-indole
Rattus norvegicus
-
0.32
3-[4-(methylsulfonyl)phenyl]-1-[4-(propan-2-yl)phenyl]prop-2-yn-1-one
Rattus norvegicus
-
pH and temperature not specified in the publication
0.0005
3-[5-[(2E)-3,7-dimethylocta-2,6-dien-1-yl]-2,4-dihydroxyphenyl]-5,7-dihydroxy-2,3-dihydro-4H-chromen-4-one
Rattus norvegicus
-
pH and temperature not specified in the publication
0.000003
3-[[3-fluoro-5-(4-methoxytetrahydro-2H-pyran-4-yl)phenoxy]methyl]-1-[4-(methylsulfonyl)phenyl]-5-phenyl-1H-pyrazole
Solanum tuberosum
-
in 100 mM phosphate buffer, pH 6.3, 25°C
0.00008
4,5-dimethoxy-3-tridecylcyclohexa-3,5-diene-1,2-dione
Homo sapiens
pH 7.4, 37°C, cell-free enzyme extract
0.00009
4,5-dimethoxy-3-undecylcyclohexa-3,5-diene-1,2-dione
Homo sapiens
pH 7.4, 37°C, cell-free enzyme extract
0.0013
4,7,10,13,16,19-docosahexaenoic acid
Rattus norvegicus
-
IC50: 0.0013 mM
0.0085
4,9-dimethoxy-3-methyl-9,10-dihydrophenanthrene-2,7-diol
Rattus norvegicus
-
pH and temperature not specified in the publication
0.01
4-(1-benzothiophen-3-yl)benzene-1,3-diol
0.074
4-(1-benzyl-1H-indol-3-yl)-1-morpholinobutan-1-one
Rattus norvegicus
-
0.00347
4-(1-difluoromethyl-2-oxo-1,2-dihydropyridin-4-yl)phenylacetic acid
Solanum tuberosum
-
pH and temperature not specified in the publication
0.001
4-(3-(1-hydroxyureido)but-1-yn-1-yl)-N-(2-(trifluoromethyl)-benzyl)benzamide
Homo sapiens
pH 7.4, 37°C
-
0.0068
4-(3-fluoro-5-[[4-(2-methyl-1H-imidazol-1-yl)benzyl]oxy]phenyl)-N-methyltetrahydro-2H-pyran-4-carboxamide
Rattus norvegicus
-
pH and temperature not specified in the publication
0.0006
4-(3-fluoro-5-[[4-(2-methyl-1H-imidazol-1-yl)benzyl]oxy]phenyl)tetrahydro-2H-pyran-4-ol
Rattus norvegicus
-
pH and temperature not specified in the publication
0.00054
4-(3-fluoro-5[[4-(2-methyl-1H-imidazol-1-yl)benzyl]oxy]phenyl)tetrahydro-2H-pyran-4-carboxylic acid
Rattus norvegicus
-
pH and temperature not specified in the publication
0.00004
4-(4-(4-chlorophenyl)thiazol-2-ylimino)cyclohexa-2,5-dienone
Homo sapiens
pH 7.4, 37°C, recombinant enzyme
0.00018
4-(4-chlorophenyl)-7-([3-fluoro-5-[2,2,2-trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]phenyl]sulfanyl)-2H-chromen-2-one
Homo sapiens
-
IC50: 180 nM
0.008
4-(4-fluorophenyl)-5-(4-(methylsulfonyl)phenyl)-1,2-selenazole
Bos taurus
-
-
0.000055
4-(4-fluorophenyl)-7-([3-fluoro-5-[2,2,2-trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]phenoxy]methyl)-2H-chromen-2-one
Homo sapiens
-
IC50: 55 nM
0.000027
4-(4-fluorophenyl)-7-([3-fluoro-5-[2,2,2-trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]phenyl]sulfanyl)-2H-chromen-2-one
Homo sapiens
-
IC50: 27 nM
0.003
4-(6-methoxynaphthalen-2-yl)butan-2-one
Rattus norvegicus
-
value above, pH and temperature not specified in the publication
0.0077
4-(acetyloxy)-2-[4-(acetyloxy)-6-methylhept-5-en-2-yl]cyclohexyl (2Z)-2-methylbut-2-enoate
Rattus norvegicus
-
pH and temperature not specified in the publication
0.0063 - 0.01
4-(dibenzo[b,d]furan-3-yl)benzene-1,3-diol
0.0055
4-(furan-3-yl)-7-[[2-(tetrahydro-2H-pyran-4-yl)pyridin-4-yl]methoxy]naphthalene-2-carbonitrile
Rattus norvegicus
-
pH and temperature not specified in the publication
0.000015
4-(furan-3-yl)-7-[[6-(4-hydroxytetrahydro-2H-pyran-4-yl)pyridin-2-yl]methoxy]naphthalene-2-carbonitrile
Solanum tuberosum
-
in 100 mM phosphate buffer, pH 6.3, 25°C
0.0038
4-(furan-3-yl)-7-[[7-(tetrahydro-2H-pyran-4-yl)-1,2,3,4-tetrahydroquinolin-2-yl]oxy]naphthalene-2-carbonitrile
Rattus norvegicus
-
pH and temperature not specified in the publication
0.0023 - 0.0074
4-(naphthalen-2-ylmethyl)benzene-1,3-diol
0.0021 - 0.0032
4-(thianthren-2-yl)benzene-1,3-diol
0.035
4-([[5-fluoro-6-(1H-1,2,4-triazol-1-yl)-1H-benzimidazol-2-yl]sulfanyl]methyl)benzoic acid
Glycine max
-
pH 7.0, 25°C
-
0.0009
4-([[5-fluoro-6-(4-fluorophenoxy)-1H-benzimidazol-2-yl]sulfanyl]methyl)benzoic acid
Glycine max
-
pH 7.0, 25°C
-
0.003
4-([[6-(4-chlorophenoxy)-5-fluoro-1H-benzimidazol-2-yl]sulfanyl]methyl)benzoic acid
Glycine max
-
pH 7.0, 25°C
-
0.009 - 0.01
4-benzylbenzene-1,3-diol
0.00042
4-chloro-N-([4-[(2E)-3-(2,4-dichlorophenyl)prop-2-enoyl]phenyl]carbamoyl)benzenesulfonamide
Homo sapiens
-
IC50: 0.00042 mM
0.00083
4-chloro-N-([4-[(2E)-3-phenylprop-2-enoyl]phenyl]carbamoyl)benzenesulfonamide
Homo sapiens
-
IC50: 0.00083 mM
0.0028 - 0.0046
4-hexylbenzene-1,3-diol
0.00001
4-methoxy-4-[3-(naphthalen-2-ylmethoxy)phenyl]tetrahydro-2H-pyran
Solanum tuberosum
-
in 100 mM phosphate buffer, pH 6.3, 25°C
0.006 - 0.01
4-methoxy-N-(3,5a,10-trimethyl-2-oxo-2,3,3a,4,5,5a,6,10,10a,10b-decahydrofuro[3',2':7,8]naphtho[2,3-d][1,3]thiazol-8-yl)benzamide
0.01
4-methyl-N-(3,5a,10-trimethyl-2-oxo-2,3,3a,4,5,5a,6,10,10a,10b-decahydrofuro[3',2':7,8]naphtho[2,3-d][1,3]thiazol-8-yl)-1,2,3-thiadiazole-5-carboxamide
0.00045
4-methyl-N-([4-[(2E)-3-(2,3,4-trimethylphenyl)prop-2 enoyl]phenyl]carbamoyl)benzenesulfonamide
Homo sapiens
-
IC50: 0.00045 mM
0.00089
4-methyl-N-([4-[(2E)-3-phenylprop-2-enoyl]phenyl]carbamoyl)benzenesulfonamide
Homo sapiens
-
IC50: 0.00089 mM
0.0114
4-[(1E)-3-(2-hydroxy-4-methoxyphenyl)-3-oxoprop-1-en-1-yl]-N-(2-hydroxy-5-nitrophenyl)benzamide
Solanum tuberosum
-
pH 7.4, temperature not specified in the publication
0.0165
4-[(1E)-3-(2-hydroxy-4-methoxyphenyl)-3-oxoprop-1-en-1-yl]-N-(2-hydroxyphenyl)benzamide
Solanum tuberosum
-
pH 7.4, temperature not specified in the publication
0.0249
4-[(1E)-3-(2-hydroxy-4-methoxyphenyl)-3-oxoprop-1-en-1-yl]-N-(2-methoxyphenyl)benzamide
Solanum tuberosum
-
pH 7.4, temperature not specified in the publication
0.0142
4-[(1E)-3-(2-hydroxy-4-methoxyphenyl)-3-oxoprop-1-en-1-yl]-N-(2-phenylethyl)benzamide
Solanum tuberosum
-
pH 7.4, temperature not specified in the publication
0.0221
4-[(1E)-3-(2-hydroxy-4-methoxyphenyl)-3-oxoprop-1-en-1-yl]-N-(propan-2-yl)benzamide
Solanum tuberosum
-
pH 7.4, temperature not specified in the publication
0.0204
4-[(1E)-3-(2-hydroxy-4-methoxyphenyl)-3-oxoprop-1-en-1-yl]-N-methyl-N-phenylbenzamide
Solanum tuberosum
-
pH 7.4, temperature not specified in the publication
0.0129
4-[(1E)-3-(2-hydroxy-4-methoxyphenyl)-3-oxoprop-1-en-1-yl]-N-propylbenzamide
Solanum tuberosum
-
pH 7.4, temperature not specified in the publication
0.03
4-[([5-fluoro-6-[4-(1H-imidazol-1-yl)phenoxy]-1H-benzimidazol-2-yl]sulfanyl)methyl]benzoic acid
Glycine max
-
pH 7.0, 25°C
-
0.000036
4-[1-(4-chlorobenzyl)-4-methyl-6-[(5-phenylpyridin-2-yl)methoxy]-2,2a,4,5-tetrahydro-1H-thiopyrano[2,3,4-cd]indol-2-yl]-3,3-dimethyl-N-(methylsulfonyl)butanamide
Solanum tuberosum
-
in 100 mM phosphate buffer, pH 6.3, 25°C
0.00007
4-[4-(4-fluoro-phenyl)-thiazol-2-ylamino]-2,6-dimethylphenol
Rattus norvegicus
-
in 50 mM Tris-HCl buffer (pH 7.4) containing 0.4 mM CaCl2+ , 0.024 mg/ml alpha-phosphatidylcholine and 0.02 mM ATP, at 22°C
0.041
4-[5-(1H-indol-3-yl)-3-(trifluoromethyl)-4,5-dihydro-1H-pyrazol-1-yl]benzenesulfonamide
Solanum tuberosum
-
in 100 mM phosphate buffer, pH 6.3, 25°C
0.01
4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide
Solanum tuberosum
-
in 100 mM phosphate buffer, pH 6.3, 25°C
0.00003
4-[[4-(4-chlorophenyl)-1,3-thiazol-2-yl]amino]phenol
Homo sapiens
pH 7.4, 37°C, recombinant enzyme
0.002
5,5'-di(prop-2-en-1-yl)biphenyl-2,2'-diol
Rattus norvegicus
-
pH and temperature not specified in the publication
0.0048
5,5-dimethyl-1-phenyl-1,2,4-triazinan-3-one
Rattus norvegicus
-
pH and temperature not specified in the publication
0.028
5,8,11,13-eicosatetraynoic acid
Rattus norvegicus
-
IC50: 0.028 mM
0.00077
5-(2-[[3-(trifluoromethyl)phenyl]amino]phenyl)-1,3,4-oxadiazole-2(3H)-thione
Solanum tuberosum
-
in 100 mM phosphate buffer, pH 6.3, 25°C
0.003
5-(4-fluorophenyl)-1-[4-(methylsulfonyl)phenyl]-3-(trifluoromethyl)-1H-pyrazole
Rattus norvegicus
-
value above, pH and temperature not specified in the publication
0.006
5-(7-tert-butyl-3,3-dimethyl-2,3-dihydro-1-benzofuran-5-yl)-5-oxopentanenitrile
Solanum tuberosum
-
in 100 mM phosphate buffer, pH 6.3, 25°C
0.00341
5-amino-2-hydroxy-N-(propan-2-yl)benzamide
Solanum tuberosum
-
pH 7.4, temperature not specified in the publication
-
0.00765
5-amino-N-cyclohexyl-2-hydroxybenzamide
Solanum tuberosum
-
pH 7.4, temperature not specified in the publication
-
0.00841
5-amino-N-hexyl-2-hydroxybenzamide
Solanum tuberosum
-
pH 7.4, temperature not specified in the publication
-
0.0084
5-butyl-1-phenyl-1,2,4-triazinan-3-one
Rattus norvegicus
-
pH and temperature not specified in the publication
0.00133
5-chloro-2-methyl-3-(4-morpholin-4-yl-4-oxobutyl)-1H-indole
Rattus norvegicus
-
0.006
5-ethyl-1-phenyl-1,2,4-triazinan-3-one
Rattus norvegicus
-
pH and temperature not specified in the publication
0.00316
5-methoxy-2-methyl-3-(4-morpholin-4-yl-4-oxobutyl)-1H-indole
Rattus norvegicus
-
0.00029
5-methoxy-3-tridecylbenzene-1,2,4-triol
Homo sapiens
pH 7.4, 37°C, cell-free enzyme extract
0.00137
5-[(E)-2-(4-hydroxyphenyl)ethenyl]benzene-1,3-diol
Rattus norvegicus
-
pH and temperature not specified in the publication
0.00796
5-[[(2,5-dihydroxyphenyl)methyl]amino]-2-hydroxy-N-(4-methylphenyl)benzamide
Solanum tuberosum
-
pH 7.4, temperature not specified in the publication
-
0.00092
6-hydroxy-3,4-dimethoxy-5-undecylcyclohexa-2,4-dien-1-one
Homo sapiens
pH 7.4, 37°C, cell-free enzyme extract
0.009 - 0.01
6-[(4-hydroxy-3,6-dioxocyclohexa-1,4-dien-1-yl)methyl]naphthalene-2-carboxylic acid
0.00033
6-[[3-fluoro-5-(4-methoxytetrahydro-2H-pyran-4-yl)phenoxy]methyl]-1-methylquinolin-2(1H)-one
Solanum tuberosum
-
in 100 mM phosphate buffer, pH 6.3, 25°C
0.007
7,17(S)-dihydroxydocosahexaenoic acid
Homo sapiens
-
IC50: 0.007 mM
0.0069
7,8-dihydroxy-2H-chromen-2-one
Rattus norvegicus
-
pH and temperature not specified in the publication
0.01
7-(4-methylphenyl)-6-[4-(methylsulfonyl)phenyl]-2,3-dihydro-1H-pyrrolizine
Solanum tuberosum
-
in 100 mM phosphate buffer, pH 6.3, 25°C
0.000175
7-([3-fluoro-5-[(1R)-1-hydroxy-1-pyridin-2-ylpropyl]phenoxy]methyl)-4-furan-3-yl-2H-chromen-2-one
Homo sapiens
-
IC50: 175 nM
0.0002
7-([3-fluoro-5-[(1R,3R,5S)-3-hydroxy-6,8-dioxabicyclo[3.2.1]oct-3-yl]phenoxy]methyl)-4-furan-3-yl-2H-chromen-2-one
Homo sapiens
-
IC50: 200 nM
0.0003
7-([3-fluoro-5-[(1R,3R,5S)-3-hydroxy-6,8-dioxabicyclo[3.2.1]oct-3-yl]phenoxy]methyl)-4-phenyl-2H-chromen-2-one
Homo sapiens
-
IC50: 300 nM
0.000175
7-([3-fluoro-5-[(1S)-1-hydroxy-1-(1,3-thiazol-2-yl)propyl]phenoxy]methyl)-4-(4-fluorophenyl)-2H-chromen-2-one
Homo sapiens
-
IC50: 175 nM
0.000009
7-([3-fluoro-5-[2,2,2-trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]phenyl]sulfanyl)-4-furan-3-yl-2H-chromen-2-one
Homo sapiens
-
IC50: 9 nM
0.000026
7-([3-fluoro-5-[2,2,2-trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]phenyl]sulfanyl)-4-phenyl-2H-chromen-2-one
Homo sapiens
-
IC50: 26 nM
0.022
7-tert-butyl-N-ethyl-N,3,3-trimethyl-2,3-dihydro-1-benzofuran-5-carboxamide
Solanum tuberosum
-
in 100 mM phosphate buffer, pH 6.3, 25°C
0.000015
7-[[3-(1-ethyl-1-hydroxypropyl)-5-fluorophenoxy]methyl]-4-furan-3-yl-2H-chromen-2-one
Homo sapiens
-
IC50: 15 nM
0.000014
7-[[3-(4-methoxytetrahydro-2H-pyran-4-yl)benzyl]oxy]-4-phenylnaphtho[2,3-c]furan-1(3H)-one
Solanum tuberosum
-
in 100 mM phosphate buffer, pH 6.3, 25°C
0.000027
7-[[3-fluoro-5-(3-hydroxy-6,8-dioxabicyclo[3.2.1]oct-3-yl)phenoxy]methyl]-4-(furan-3-yl)quinoline-2-carbonitrile
Solanum tuberosum
-
in 100 mM phosphate buffer, pH 6.3, 25°C
0.00219
8,11,14-eicosatrienoic acid
Rattus norvegicus
-
IC50: 0.00219 mM
0.0038
AA-861
Homo sapiens
pH 7.4, 37°C
0.0039
acetonylacetone bisphenylhydrazone
Solanum tuberosum
-
IC50 for reaction with linoleic acid: 0.015 mM, IC50 for reaction with arachidonic acid: 0.0039 mM
0.00023
arachidonic acid
Rattus norvegicus
-
induces time-dependent enzyme inactivation at concentrations 100fold lower than the Km-value, IC50: 0.00023 mM
0.0166
arachidonoyl lysophosphatidylcholine
Solanum tuberosum
-
pH 6.3, 25°C
0.00029 - 0.0012
baicalein
0.0014
benzaldehyde phenylhydrazone
Solanum tuberosum
-
IC50 for reaction with linoleic acid: 0.0345 mM, IC50 for reaction with arachidonic acid: 0.0014 mM
0.00013 - 0.00035
benzyl 2-(3-chlorobenzyl)-5-hydroxy-1H-benzo[g]indole-3-carboxylate
0.00017 - 0.00048
benzyl 2-(4-chlorobenzyl)-5-hydroxy-1H-benzo[g]indole-3-carboxylate
0.0028 - 0.0042
biphenyl-2,4-diol
0.038
biphenyl-3-yl 3,5-dinitrobenzoate
Homo sapiens
pH 7.4, 37°C
0.05
biphenyl-4-yl 3,5-dinitrobenzoate
Homo sapiens
pH 7.4, 37°C
0.0048
BRP-7
Homo sapiens
pH 7.4, 37°C
0.0002
BWA4C
Homo sapiens
pH 7.4, 37°C
0.004 - 0.046
caffeic acid
0.00097
caffeic acid phenethyl ester
Homo sapiens
inhibition of 5-Lox product biosynthesis in polymorphonuclear leukocyte, 37°C, pH not specified in the publication
0.062
catechol
Rattus norvegicus
-
IC50: 0.062 mM
0.0195
celecoxib
Homo sapiens
-
37°C, whole blood assay
0.0007
chalcone
Homo sapiens
pH 7.4, 37°C
0.098
Cirsiliol
Rattus norvegicus
-
IC50: 0.098 mM
0.00115 - 0.00155
CJ-13610
Homo sapiens
-
pH 7.5, 37°C, dependent on assay method via fluorescence or UV measurement, kinetics, overview
0.0014
curcumin
Homo sapiens
pH 7.4, 37°C
0.05
cyrhetrenyl carboxylic acid
Homo sapiens
above 0.050 mM, pH 7.5, 23°C
-
0.157
daidzein
Homo sapiens
-
pH 7.4, 27°C
0.0069
delphinidin 3-O-galactoside
Homo sapiens
-
-
0.00215
delphinidin 3-O-glucoside
Homo sapiens
-
-
0.000057
delta-garcinoic acid
Homo sapiens
pH 7.4, 37°C
-
0.002 - 0.005
diphenyldisulfide
Sus scrofa
-
IC50: 0.002-0.005 mM
0.00065
eicosapentaenoic acid
Rattus norvegicus
-
induces time-dependent enzyme inactivation at concentrations 100fold lower than the Km-value, IC50: 0.00065 mM
0.00023
embelin
Homo sapiens
pH 7.4, 37°C
0.98
epinephrine
Rattus norvegicus
-
IC50: 0.98 mM
0.0045
esculetin
Rattus norvegicus
-
IC50: 0.0045 mM
0.00065 - 0.0018
ethyl 1-benzyl-2-(4-chlorobenzyl)-5-hydroxy-1H-benzo[g]indole-3-carboxylate
0.0032
ethyl 2-((2,4-difluorophenylthio)methyl)-5-hydroxy-1-methyl-1H-indole-3-carboxylate
Homo sapiens
pH 7.4, 37°C, cell-free enzyme extract
0.0008
ethyl 2-((2,6-dichlorophenylthio)methyl)-5-hydroxy-1-methyl-1H-indole-3-carboxylate
Homo sapiens
pH 7.4, 37°C, cell-free enzyme extract
0.0008
ethyl 2-((2,6-dimethylphenylthio)methyl)-5-hydroxy-1-methyl-1H-indole-3-carboxylate
Homo sapiens
pH 7.4, 37°C, cell-free enzyme extract
0.0018
ethyl 2-((3,5-dimethylphenylthio)methyl)-5-hydroxy-1-methyl-1H-indole-3-carboxylate
Homo sapiens
pH 7.4, 37°C, cell-free enzyme extract
0.0038
ethyl 2-((3-chlorophenylthio)methyl)-5-hydroxy-1-methyl-1H-indole-3-carboxylate
Homo sapiens
pH 7.4, 37°C, cell-free enzyme extract
0.005
ethyl 2-((4-fluorophenylthio)methyl)-5-hydroxy-1-methyl-1H-indole-3-carboxylate
Homo sapiens
pH 7.4, 37°C, cell-free enzyme extract
0.000097 - 0.0012
ethyl 2-(2-chlorobenzyl)-5-hydroxy-1H-benzo[g]indole-3-carboxylate
0.0016 - 0.0017
ethyl 2-(2-chlorobenzyl)-5-hydroxy-1H-indole-3-carboxylate
0.00015 - 0.00045
ethyl 2-(3-bromobenzyl)-5-hydroxy-1H-benzo[g]indole-3-carboxylate
0.000086 - 0.00023
ethyl 2-(3-chlorobenzyl)-5-hydroxy-1H-benzo[g]indole-3-carboxylate
0.0017 - 0.002
ethyl 2-(3-chlorobenzyl)-5-hydroxy-1H-indole-3-carboxylate
0.00058 - 0.0043
ethyl 2-(3-chlorobenzyl)-5-hydroxy-1H-pyrrolo[2,3-f]quinoline-3-carboxylate
0.0012 - 0.0057
ethyl 2-(3-chlorobenzyl)-5-hydroxy-6-phenyl-1H-indole-3-carboxylate
0.01 - 0.03
ethyl 2-(3-chlorobenzyl)-5-methoxy-1-methyl-1H-benzo[g]-indole-3-carboxylate
0.03
ethyl 2-(3-chlorobenzyl)-5-phenyl-1H-benzo[g]indole-3-carboxylate
0.007 - 0.01
ethyl 2-(3-chlorobenzyl)-7,8-dimethoxy-5-hydroxy-1H-benzo[g]indole-3-carboxylate
0.000045 - 0.00052
ethyl 2-(3-chlorophenyl)-5-hydroxy-1H-benzo[g]indole-3-carboxylate
0.0033 - 0.0048
ethyl 2-(3-chlorophenyl)-5-hydroxy-1H-indole-3-carboxylate
0.00014 - 0.00034
ethyl 2-(3-fluorobenzyl)-5-hydroxy-1H-benzo[g]indole-3-carboxylate
0.00013 - 0.00052
ethyl 2-(3-methoxybenzyl)-5-hydroxy-1H-benzo[g]indole-3-carboxylate
0.000095 - 0.0006
ethyl 2-(4-bromobenzyl)-5-hydroxy-1H-benzo[g]indole-3-carboxylate
0.000084 - 0.0012
ethyl 2-(4-chlorobenzyl)-5-hydroxy-1H-benzo[g]indole-3-carboxylate
0.0007 - 0.0012
ethyl 2-(4-chlorobenzyl)-5-hydroxy-1H-indole-3-carboxylate
0.000067 - 0.00032
ethyl 2-(4-chlorophenyl)-5-hydroxy-1H-benzo[g]indole-3-carboxylate
0.002 - 0.0021
ethyl 2-(4-chlorophenyl)-5-hydroxy-1H-indole-3-carboxylate
0.000096 - 0.0005
ethyl 2-(4-fluorobenzyl)-5-hydroxy-1H-benzo[g]indole-3-carboxylate
0.00015 - 0.00065
ethyl 2-(4-methoxybenzyl)-5-hydroxy-1H-benzo[g]indole-3-carboxylate
0.00025 - 0.0017
ethyl 2-(4-trifluoromethylbenzyl)-5-hydroxy-1H-benzo[g]indole-3-carboxylate
0.0003 - 0.0024
ethyl 2-[(3-chlorophenyl)-amino]-5-hydroxy-1H-indole-3-carboxylate
0.000031 - 0.00049
ethyl 2-[2-(3-chlorophenyl)ethyl]-5-hydroxy-1H-benzo[g]indole-3-carboxylate
0.0017 - 0.0028
ethyl 2-[2-(3-chlorophenyl)ethyl]-5-hydroxy-1H-indole-3-carboxylate
0.000049 - 0.0028
ethyl 2-[2-(4-chlorophenyl)ethyl]-5-hydroxy-1H-benzo[g]indole-3-carboxylate
0.0007 - 0.0039
ethyl 2-[2-(4-chlorophenyl)ethyl]-5-hydroxy-1H-indole-3-carboxylate
0.0006 - 0.019
ethyl 2-[[4-chloro-6-(quinolin-6-ylamino)pyrimidin-2-yl]sulfanyl]octanoate
0.0034 - 0.01
ethyl 5-benzoyloxy-2-(3-chlorobenzyl)-1H-benzo[g]indole-3-carboxylate
0.0008
ethyl 5-hydroxy-1-methyl-2-((2-(trifluoromethyl)phenylthio)methyl)-1H-indole-3-carboxylate
Homo sapiens
pH 7.4, 37°C, cell-free enzyme extract
0.0009
ethyl 5-hydroxy-1-methyl-2-((4-(trifluoromethoxy)phenylthio)methyl)-1H-indole-3-carboxylate
Homo sapiens
pH 7.4, 37°C, cell-free enzyme extract
0.0042
ethyl 5-hydroxy-1-methyl-2-((4-(trifluoromethyl)phenylthio)methyl)-1H-indole-3-carboxylate
Homo sapiens
pH 7.4, 37°C, cell-free enzyme extract
0.0057
ethyl 5-hydroxy-1-methyl-2-(phenylthiomethyl)-1H-indole-3-carboxylate
Homo sapiens
pH 7.4, 37°C, cell-free enzyme extract
0.0029
ethyl 5-hydroxy-2-((2-methoxyphenylthio)methyl)-1-methyl-1H-indole-3-carboxylate
Homo sapiens
pH 7.4, 37°C, cell-free enzyme extract
0.0023
ethyl 5-hydroxy-2-((4-methoxyphenylthio)methyl)-1-methyl-1H-indole-3-carboxylate
Homo sapiens
pH 7.4, 37°C, cell-free enzyme extract
0.0007
ethyl 5-hydroxy-2-(mesitylthiomethyl)-1-methyl-1H-indole-3-carboxylate
Homo sapiens
pH 7.4, 37°C, cell-free enzyme extract
0.0055 - 0.0073
ethyl 5-hydroxy-2-phenylethyl-1H-indole-3-carboxylate
0.00013 - 0.00044
ethyl 5-hydroxy-2-phenylpropyl-1H-benzo[g]indole-3-carboxylate
0.00033 - 0.0028
ethyl 6-biphenyl-4-yl-(3-chlorobenzyl)-5-hydroxy-1H-indole-3-carboxylate
0.026
eugenol
Homo sapiens
-
non-competitive, reversible inhibitor, IC50: 0.026 mM
0.098
eupatilin
Rattus norvegicus
-
IC50: 0.098 mM
0.0025
ferrocenyl carboxylic acid
Homo sapiens
pH 7.5, 23°C
-
0.125
genistein
Homo sapiens
-
pH 7.4, 27°C
0.36
indomethacin
Rattus norvegicus
-
IC50: 0.36 mM
0.0003 - 0.0004
L-651,896
Sus scrofa
-
i.e. 2,3-dihydro-6-[3-(2-hydroxymethyl)-phenyl-2-propenyl]-5-benzofuranol, IC50: 0.0003-0.0004 mM
0.0003 - 0.0008
L-656,224
0.0004
L-670,630
Homo sapiens
-
IC50: 0.0004 mM
0.0003
L-689,065
Homo sapiens
-
IC50: 0.0003 mM
0.00002
L-697,198
Homo sapiens
-
IC50: 0.00002 mM
0.0015
L-702,701
Homo sapiens
-
IC50: 0.0015 mM
0.000027
L-746,530
Homo sapiens
-
IC50: 27 nM
0.00002
L705,302
Homo sapiens
-
IC50: 0.00002 mM
0.00006
luteolin
Homo sapiens
pH 7.4, 37°C
0.00058 - 0.00086
methyl (4-[(5E)-5-(4-methoxybenzylidene)-4-oxo-4,5-dihydro-1,3-thiazol-2-yl]phenoxy)acetate
0.03
methyl 2-(allylamino)-1H-indole-3-carboxylate
0.0034 - 0.004
methyl 2-(benzylamino)-1H-indole-3-carboxylate
0.0069 - 0.0125
methyl 2-(diallylamino)-1H-indole-3-carboxylate
0.0098 - 0.0102
methyl 2-[(2-chlorophenyl)amino]-1H-indole-3-carboxylate
0.0035 - 0.0083
methyl 2-[(3-bromophenyl)amino]-1H-indole-3-carboxylate
0.0065 - 0.0081
methyl 2-[(3-chlorophenyl)amino]-1H-indole-3-carboxylate
0.0035 - 0.0055
methyl 2-[(3-chlorophenyl)amino]-5-chloro-1H-indole-3-carboxylate
0.0079 - 0.0134
methyl 2-[(3-fluorophenyl)amino]-1H-indole-3-carboxylate
0.0072 - 0.0098
methyl 2-[(4-chlorophenyl)amino]-1H-indole-3-carboxylate
0.004
miogadial
Homo sapiens
-
potent inhibitor, IC50: 0.004 mM
0.0075
miogatrial
Homo sapiens
-
potent inhibitor, IC50: 0.0075 mM
0.0032
MK-886
Homo sapiens
-
37°C, whole blood assay
0.0011
MK886
Homo sapiens
pH 7.4, 37°C
0.1
ML-3000
Homo sapiens
-
above, 37°C, whole blood assay
0.0163
N-(2,4-dimethylphenyl)-4-[(1E)-3-(2-hydroxy-4-methoxyphenyl)-3-oxoprop-1-en-1-yl]benzamide
Solanum tuberosum
-
pH 7.4, temperature not specified in the publication
0.05
N-(3,4-dimethoxyphenyl)-3,5-dinitrobenzamide
Homo sapiens
pH 7.4, 37°C
0.002 - 0.01
N-(3,5a,10-trimethyl-2-oxo-2,3,3a,4,5,5a,6,10,10a,10b-decahydrofuro[3',2':7,8]naphtho[2,3-d][1,3]thiazol-8-yl)-1,3-benzodioxole-5-carboxamide
0.008 - 0.01
N-(3,5a,10-trimethyl-2-oxo-2,3,3a,4,5,5a,6,10,10a,10b-decahydrofuro[3',2':7,8]naphtho[2,3-d][1,3]thiazol-8-yl)cyclopentanecarboxamide
0.00012
N-(3-(4-chlorophenyl)-3-phenylpropyl)-3-(3-(1-hydroxyureido)-but-1-yn-1-yl)benzamide
Homo sapiens
pH 7.4, 37°C
-
0.0144
N-(3-bromobenzyl)-3,5-dinitrobenzamide
Homo sapiens
pH 7.4, 37°C
0.05
N-(3-bromophenyl)-3,5-dinitrobenzamide
Homo sapiens
pH 7.4, 37°C
0.05
N-(3-chlorophenyl)-3,5-dinitrobenzamide
Homo sapiens
pH 7.4, 37°C
0.000038 - 0.00016
N-(3-phenoxycinnamyl)-acetohydroxamic acid
0.0001
N-(4-chlorophenyl)-N-hydroxy-N'-(3-chlorophenyl)urea
Homo sapiens
-
IC50: 0.0001 mM
0.0027
N-(4-methoxyphenyl)-3,5-dinitrobenzamide
Homo sapiens
pH 7.4, 37°C
0.05
N-(biphenyl-3-yl)-3,5-dinitrobenzamide
Homo sapiens
pH 7.4, 37°C
0.0009 - 0.01
N-(furan-2-ylmethyl)-2-(7-methoxy-5,8-dimethyl-1,2,3,4-tetrahydronaphthalen-2-yl)propanamide
0.05
N-(naphthalene-1-yl)-3,5-dinitrobenzamide
Homo sapiens
pH 7.4, 37°C
0.0039
N-([(5R)-3-[3-fluoro-4-(morpholin-4-yl)phenyl]-2-oxo-1,3-oxazolidin-5-yl]methyl)-N-hydroxy-2-methylpropanamide
Homo sapiens
pH 7.5, 25°C
-
0.0035
N-([(5R)-3-[3-fluoro-4-(morpholin-4-yl)phenyl]-2-oxo-1,3-oxazolidin-5-yl]methyl)-N-hydroxycyclopropanecarboxamide
Homo sapiens
pH 7.5, 25°C
-
0.00045
N-([4-[(2E)-3-(2,4-dichlorophenyl)prop-2-enoyl]phenyl]carbamoyl)-4-methylbenzenesulfonamide
Homo sapiens
-
IC50: 0.00045 mM
0.05
N-3-tolyl-3,5-dinitrobenzamide
Homo sapiens
pH 7.4, 37°C
0.018
N-benzyl-4-[(1E)-3-(2-hydroxy-4-methoxyphenyl)-3-oxoprop-1-en-1-yl]benzamide
Solanum tuberosum
-
pH 7.4, temperature not specified in the publication
0.0105
N-butyl-5-[[(2,5-dihydroxyphenyl)methyl]amino]-2-hydroxybenzamide
Solanum tuberosum
-
pH 7.4, temperature not specified in the publication
-
0.0113
N-cyclohexyl-5-[(E)-[(2,5-dihydroxyphenyl)methylidene]amino]-2-hydroxybenzamide
Solanum tuberosum
-
pH 7.4, temperature not specified in the publication
-
0.0123
N-cyclohexyl-5-[[(2,5-dihydroxyphenyl)methyl]amino]-2-hydroxybenzamide
Solanum tuberosum
-
pH 7.4, temperature not specified in the publication
-
0.01
N-cyclopentyl-2-[7-(2-methoxyethoxy)-5,8-dimethyl-1,2,3,4-tetrahydronaphthalen-2-yl]propanamide
0.0157
N-dodecyl-4-[(1E)-3-(2-hydroxy-4-methoxyphenyl)-3-oxoprop-1-en-1-yl]benzamide
Solanum tuberosum
-
pH 7.4, temperature not specified in the publication
0.0119
N-hexyl-5-[[(2,5-dihydroxyphenyl)methyl]amino]-2-hydroxybenzamide
Solanum tuberosum
-
pH 7.4, temperature not specified in the publication
-
0.00005 - 0.15
N-hydroxy-N-[(2E)-3-(3-phenoxyphenyl)prop-2-en-1-yl]acetamide
0.00119
N-hydroxy-N-[1-(1-methyl-1H-indol-2-yl)ethyl]acetamide
Rattus norvegicus
-
pH and temperature not specified in the publication
0.0005
N-methyl-2[4-(2,4,6-trimethylphenyl)phenyl]-propenehydroxamic acid
Sus scrofa
-
IC50: 0.0005 mM
0.0152
N-phenyl-3,5-dinitrobenzamide
Homo sapiens
pH 7.4, 37°C
0.004 - 0.01
N-tert-butyl-2-(7-methoxy-5,8-dimethyl-1,2,3,4-tetrahydronaphthalen-2-yl)propanamide
0.01
N-[2-(cyclohexyloxy)-4-nitrophenyl]methanesulfonamide
Solanum tuberosum
-
in 100 mM phosphate buffer, pH 6.3, 25°C
0.00013
N-[5-(4-fluorophenoxy)thiophen-2-yl]methanesulfonamide
Solanum tuberosum
-
in 100 mM phosphate buffer, pH 6.3, 25°C
0.0246
naphthalene-1-yl 3-nitrobenzoate
Homo sapiens
pH 7.4, 37°C
0.003
NAPQI
Homo sapiens
pH 7.4, 37°C
-
0.00009 - 0.0125
nordihydroguaiaretic acid
0.00021 - 0.0365
nordihydroguiaraetic acid
0.49
norepinephrine
Rattus norvegicus
-
IC50: 0.49 mM
0.0656
ochnaflavone
Mus musculus
-
IC50: 0.0656 mM
0.005 - 0.01
Phenidone
Sus scrofa
-
IC50: 0.005-0.01 mM
0.0158
phenyl 3,5-dinitrobenzoate
Homo sapiens
pH 7.4, 37°C
0.00143
Plumbagin
Homo sapiens
pH 7.4, 37°C
0.0086
polygodial
Homo sapiens
-
strong inhibitory activity, IC50: 0.0086 mM
0.0006
primin
Homo sapiens
pH 7.4, 37°C
-
0.0003 - 0.0021
quercetin
0.033
rutin
Rattus norvegicus
-
IC50: 0.033 mM
0.00013
SC-756
Homo sapiens
-
pH 7.5, 37°C, assay method via fluorescence measurement
0.0005
shikonin
Homo sapiens
pH 7.4, 37°C
0.0006
shogaol
Homo sapiens
pH 7.4, 37°C
0.02
sulindac sulfide
Homo sapiens
-
pH and temperature not specified in the publication
0.00074
tert-butyl 4-[4-(1H-indol-3-yl)butanoyl]piperazine-1-carboxylate
Rattus norvegicus
-
0.00017
U73122
Homo sapiens
pH 7.4, 37°C
0.0003
ZD 2138
Homo sapiens
-
i.e. CAS: 140841-32-3, IC50: 0.0003 mM
0.00011 - 0.00012
ZD-2138
Homo sapiens
-
pH 7.5, 37°C, dependent on assay method via fluorescence or UV measurement
0.00012 - 0.0156
zileuton
0.00009
ZM 230,486
Homo sapiens
-
IC50: 0.00009 mM
0.00074 - 0.00148
[1-(2-[[(2E)-3-phenylprop-2-enoyl]oxy]ethyl)-1H-1,2,3-triazol-4-yl]methyl (2E)-3-(3,4-dihydroxyphenyl)prop-2-enoate
0.0075
[2-[(1S,8aR)-2-formyl-5,5,8a-trimethyldecahydronaphthalen-1-yl]ethylidene]propanedial
Solanum tuberosum
-
in 100 mM phosphate buffer, pH 6.3, 25°C
additional information
additional information
-
0.0159
(2E)-1-(2-hydroxy-4-methoxyphenyl)-3-(4-methoxyphenyl)prop-2-en-1-one
Solanum tuberosum
-
pH 7.4, temperature not specified in the publication
0.0358
(2E)-1-(2-hydroxy-4-methoxyphenyl)-3-(4-methoxyphenyl)prop-2-en-1-one
Solanum tuberosum
-
pH 7.4, temperature not specified in the publication
0.00066
(2E,2'E)-(1,1'-(2,2-bis((4-(((E)-3-(3,4-dihydroxyphenyl)acryloyloxy)methyl)-1H-1,2,3-triazol-1-yl)methyl)propane-1,3-diyl)bis(1H-1,2,3-triazole-4,1-diyl))bis(methylene) bis(3-(3,4-dihydroxyphenyl)acrylate)
Homo sapiens
-
-
0.00246
(2E,2'E)-(1,1'-(2,2-bis((4-(((E)-3-(3,4-dihydroxyphenyl)acryloyloxy)methyl)-1H-1,2,3-triazol-1-yl)methyl)propane-1,3-diyl)bis(1H-1,2,3-triazole-4,1-diyl))bis(methylene) bis(3-(3,4-dihydroxyphenyl)acrylate)
Homo sapiens
-
per number of caffeic acid moieties
0.00079
(2E,2'E)-(1,1'-(2-((4-(((E)-3-(3,4-dihydroxyphenyl)acryloyloxy)methyl)-1H-1,2,3-triazol-1-yl)methyl)-2-(hydroxymethyl)propane-1,3-diyl)bis(1H-1,2,3-triazole-4,1-diyl))bis(methylene) bis(3-(3,4-dihydroxyphenyl)acrylate)
Homo sapiens
-
-
0.00237
(2E,2'E)-(1,1'-(2-((4-(((E)-3-(3,4-dihydroxyphenyl)acryloyloxy)methyl)-1H-1,2,3-triazol-1-yl)methyl)-2-(hydroxymethyl)propane-1,3-diyl)bis(1H-1,2,3-triazole-4,1-diyl))bis(methylene) bis(3-(3,4-dihydroxyphenyl)acrylate)
Homo sapiens
-
per number of caffeic acid moieties
0.03
(2E,5E)-5-[(2E)-3-(furan-2-yl)prop-2-en-1-ylidene]-3-phenyl-2-(phenylimino)-1,3-thiazolidin-4-one
Homo sapiens
-
a cell-based test system using isolated human polymorphonuclear leukocytes is applied, pH and temperature not specified in the publication
0.03
(2E,5E)-5-[(2E)-3-(furan-2-yl)prop-2-en-1-ylidene]-3-phenyl-2-(phenylimino)-1,3-thiazolidin-4-one
Homo sapiens
-
a cell-free assay utilizing the 100000g supernatant (S100) of human polymorphonuclear leukocytes (PMNL) homogenates is applied, pH and temperature not specified in the publication
0.00013
(5E)-2-(3-acetylphenyl)-5-(4-methoxybenzylidene)-1,3-thiazol-4(5H)-one
Homo sapiens
-
a cell-free assay utilizing the 100000g supernatant (S100) of human polymorphonuclear leukocytes (PMNL) homogenates is applied, pH and temperature not specified in the publication
0.00038
(5E)-2-(3-acetylphenyl)-5-(4-methoxybenzylidene)-1,3-thiazol-4(5H)-one
Homo sapiens
-
a cell-based test system using isolated human polymorphonuclear leukocytes is applied, pH and temperature not specified in the publication
0.00012
(5E)-2-(3-fluorophenyl)-5-(4-methoxybenzylidene)-1,3-thiazol-4(5H)-one
Homo sapiens
-
a cell-free assay utilizing the 100000g supernatant (S100) of human polymorphonuclear leukocytes (PMNL) homogenates is applied, pH and temperature not specified in the publication
0.00024
(5E)-2-(3-fluorophenyl)-5-(4-methoxybenzylidene)-1,3-thiazol-4(5H)-one
Homo sapiens
-
a cell-based test system using isolated human polymorphonuclear leukocytes is applied, pH and temperature not specified in the publication
0.00011
(5E)-2-(4-acetylphenyl)-5-(4-methoxybenzylidene)-1,3-thiazol-4(5H)-one
Homo sapiens
-
a cell-free assay utilizing the 100000g supernatant (S100) of human polymorphonuclear leukocytes (PMNL) homogenates is applied, pH and temperature not specified in the publication
0.00055
(5E)-2-(4-acetylphenyl)-5-(4-methoxybenzylidene)-1,3-thiazol-4(5H)-one
Homo sapiens
-
a cell-based test system using isolated human polymorphonuclear leukocytes is applied, pH and temperature not specified in the publication
0.00063
(5E)-2-(4-aminophenyl)-5-(4-methoxybenzylidene)-1,3-thiazol-4(5H)-one
Homo sapiens
-
a cell-free assay utilizing the 100000g supernatant (S100) of human polymorphonuclear leukocytes (PMNL) homogenates is applied, pH and temperature not specified in the publication
0.00193
(5E)-2-(4-aminophenyl)-5-(4-methoxybenzylidene)-1,3-thiazol-4(5H)-one
Homo sapiens
-
a cell-based test system using isolated human polymorphonuclear leukocytes is applied, pH and temperature not specified in the publication
0.00011
(5E)-2-(4-chlorophenyl)-5-(4-hydroxybenzylidene)-1,3-thiazol-4(5H)-one
Homo sapiens
-
a cell-free assay utilizing the 100000g supernatant (S100) of human polymorphonuclear leukocytes (PMNL) homogenates is applied, pH and temperature not specified in the publication
0.0004
(5E)-2-(4-chlorophenyl)-5-(4-hydroxybenzylidene)-1,3-thiazol-4(5H)-one
Homo sapiens
-
a cell-based test system using isolated human polymorphonuclear leukocytes is applied, pH and temperature not specified in the publication
0.00009
(5E)-2-(4-chlorophenyl)-5-(4-methoxybenzylidene)-1,3-thiazol-4(5H)-one
Homo sapiens
-
a cell-free assay utilizing the 100000g supernatant (S100) of human polymorphonuclear leukocytes (PMNL) homogenates is applied, pH and temperature not specified in the publication
0.00028
(5E)-2-(4-chlorophenyl)-5-(4-methoxybenzylidene)-1,3-thiazol-4(5H)-one
Homo sapiens
-
a cell-based test system using isolated human polymorphonuclear leukocytes is applied, pH and temperature not specified in the publication
0.00065
(5E)-2-(4-hydroxyphenyl)-5-(4-methoxybenzylidene)-1,3-thiazol-4(5H)-one
Homo sapiens
-
a cell-free assay utilizing the 100000g supernatant (S100) of human polymorphonuclear leukocytes (PMNL) homogenates is applied, pH and temperature not specified in the publication
0.00169
(5E)-2-(4-hydroxyphenyl)-5-(4-methoxybenzylidene)-1,3-thiazol-4(5H)-one
Homo sapiens
-
a cell-based test system using isolated human polymorphonuclear leukocytes is applied, pH and temperature not specified in the publication
0.0004
(5E)-2-(4-methylphenyl)-5-(3,4,5-trimethoxybenzylidene)-1,3-thiazol-4(5H)-one
Homo sapiens
-
a cell-free assay utilizing the 100000g supernatant (S100) of human polymorphonuclear leukocytes (PMNL) homogenates is applied, pH and temperature not specified in the publication
0.00245
(5E)-2-(4-methylphenyl)-5-(3,4,5-trimethoxybenzylidene)-1,3-thiazol-4(5H)-one
Homo sapiens
-
a cell-based test system using isolated human polymorphonuclear leukocytes is applied, pH and temperature not specified in the publication
0.00098
(5E)-5-(2,4-dimethoxybenzylidene)-2-(4-methylphenyl)-1,3-thiazol-4(5H)-one
Homo sapiens
-
a cell-free assay utilizing the 100000g supernatant (S100) of human polymorphonuclear leukocytes (PMNL) homogenates is applied, pH and temperature not specified in the publication
0.00202
(5E)-5-(2,4-dimethoxybenzylidene)-2-(4-methylphenyl)-1,3-thiazol-4(5H)-one
Homo sapiens
-
a cell-based test system using isolated human polymorphonuclear leukocytes is applied, pH and temperature not specified in the publication
0.0008
(5E)-5-(2-hydroxy-3-methoxybenzylidene)-2-(4-methylphenyl)-1,3-thiazol-4(5H)-one
Homo sapiens
-
a cell-based test system using isolated human polymorphonuclear leukocytes is applied, pH and temperature not specified in the publication
0.0013
(5E)-5-(2-hydroxy-3-methoxybenzylidene)-2-(4-methylphenyl)-1,3-thiazol-4(5H)-one
Homo sapiens
-
a cell-free assay utilizing the 100000g supernatant (S100) of human polymorphonuclear leukocytes (PMNL) homogenates is applied, pH and temperature not specified in the publication
0.00048
(5E)-5-(2-hydroxy-3-methoxybenzylidene)-2-phenyl-1,3-thiazol-4(5H)-one
Homo sapiens
-
a cell-based test system using isolated human polymorphonuclear leukocytes is applied, pH and temperature not specified in the publication
0.00054
(5E)-5-(2-hydroxy-3-methoxybenzylidene)-2-phenyl-1,3-thiazol-4(5H)-one
Homo sapiens
-
a cell-free assay utilizing the 100000g supernatant (S100) of human polymorphonuclear leukocytes (PMNL) homogenates is applied, pH and temperature not specified in the publication
0.00013
(5E)-5-(3,5-dimethoxybenzylidene)-2-(4-methylphenyl)-1,3-thiazol-4(5H)-one
Homo sapiens
-
a cell-free assay utilizing the 100000g supernatant (S100) of human polymorphonuclear leukocytes (PMNL) homogenates is applied, pH and temperature not specified in the publication
0.00035
(5E)-5-(3,5-dimethoxybenzylidene)-2-(4-methylphenyl)-1,3-thiazol-4(5H)-one
Homo sapiens
-
a cell-based test system using isolated human polymorphonuclear leukocytes is applied, pH and temperature not specified in the publication
0.0027
(5E)-5-(3-chloro-4-hydroxy-5-methoxybenzylidene)-2-(4-methylphenyl)-1,3-thiazol-4(5H)-one
Homo sapiens
-
a cell-free assay utilizing the 100000g supernatant (S100) of human polymorphonuclear leukocytes (PMNL) homogenates is applied, pH and temperature not specified in the publication
0.01
(5E)-5-(3-chloro-4-hydroxy-5-methoxybenzylidene)-2-(4-methylphenyl)-1,3-thiazol-4(5H)-one
Homo sapiens
-
a cell-based test system using isolated human polymorphonuclear leukocytes is applied, pH and temperature not specified in the publication
0.003
(5E)-5-(3-chloro-4-hydroxy-5-methoxybenzylidene)-2-phenyl-1,3-thiazol-4(5H)-one
Homo sapiens
-
a cell-free assay utilizing the 100000g supernatant (S100) of human polymorphonuclear leukocytes (PMNL) homogenates is applied, pH and temperature not specified in the publication
0.0095
(5E)-5-(3-chloro-4-hydroxy-5-methoxybenzylidene)-2-phenyl-1,3-thiazol-4(5H)-one
Homo sapiens
-
a cell-based test system using isolated human polymorphonuclear leukocytes is applied, pH and temperature not specified in the publication
0.00125
(5E)-5-(3-chloro-5-ethoxy-4-hydroxybenzylidene)-2-(4-methylphenyl)-1,3-thiazol-4(5H)-one
Homo sapiens
-
a cell-free assay utilizing the 100000g supernatant (S100) of human polymorphonuclear leukocytes (PMNL) homogenates is applied, pH and temperature not specified in the publication
0.0029
(5E)-5-(3-chloro-5-ethoxy-4-hydroxybenzylidene)-2-(4-methylphenyl)-1,3-thiazol-4(5H)-one
Homo sapiens
-
a cell-based test system using isolated human polymorphonuclear leukocytes is applied, pH and temperature not specified in the publication
0.0003
(5E)-5-(3-chlorobenzylidene)-2-(4-methylphenyl)-1,3-thiazol-4(5H)-one
Homo sapiens
-
a cell-free assay utilizing the 100000g supernatant (S100) of human polymorphonuclear leukocytes (PMNL) homogenates is applied, pH and temperature not specified in the publication
0.00058
(5E)-5-(3-chlorobenzylidene)-2-(4-methylphenyl)-1,3-thiazol-4(5H)-one
Homo sapiens
-
a cell-based test system using isolated human polymorphonuclear leukocytes is applied, pH and temperature not specified in the publication
0.003
(5E)-5-(4-hydroxy-3-methoxy-5-nitrobenzylidene)-2-phenyl-1,3-thiazol-4(5H)-one
Homo sapiens
-
a cell-free assay utilizing the 100000g supernatant (S100) of human polymorphonuclear leukocytes (PMNL) homogenates is applied, pH and temperature not specified in the publication
0.0044
(5E)-5-(4-hydroxy-3-methoxy-5-nitrobenzylidene)-2-phenyl-1,3-thiazol-4(5H)-one
Homo sapiens
-
a cell-based test system using isolated human polymorphonuclear leukocytes is applied, pH and temperature not specified in the publication
0.00032
(5E)-5-(4-methoxybenzylidene)-2-(4-methoxyphenyl)-1,3-thiazol-4(5H)-one
Homo sapiens
-
a cell-based test system using isolated human polymorphonuclear leukocytes is applied, pH and temperature not specified in the publication
0.004
(5E)-5-(4-methoxybenzylidene)-2-(4-methoxyphenyl)-1,3-thiazol-4(5H)-one
Homo sapiens
-
a cell-free assay utilizing the 100000g supernatant (S100) of human polymorphonuclear leukocytes (PMNL) homogenates is applied, pH and temperature not specified in the publication
0.0003
(5E)-5-(4-methoxybenzylidene)-2-(4-methylphenyl)-1,3-thiazol-4(5H)-one
Homo sapiens
-
a cell-free assay utilizing the 100000g supernatant (S100) of human polymorphonuclear leukocytes (PMNL) homogenates is applied, pH and temperature not specified in the publication
0.00066
(5E)-5-(4-methoxybenzylidene)-2-(4-methylphenyl)-1,3-thiazol-4(5H)-one
Homo sapiens
-
a cell-based test system using isolated human polymorphonuclear leukocytes is applied, pH and temperature not specified in the publication
0.00015
(5E)-5-(4-methoxybenzylidene)-2-phenyl-1,3-thiazol-4(5H)-one
Homo sapiens
-
a cell-free assay utilizing the 100000g supernatant (S100) of human polymorphonuclear leukocytes (PMNL) homogenates is applied, pH and temperature not specified in the publication
0.0005
(5E)-5-(4-methoxybenzylidene)-2-phenyl-1,3-thiazol-4(5H)-one
Homo sapiens
-
a cell-free assay utilizing the 100000g supernatant (S100) of human polymorphonuclear leukocytes (PMNL) homogenates is applied, pH and temperature not specified in the publication
0.00053
(5E)-5-(4-methoxybenzylidene)-2-phenyl-1,3-thiazol-4(5H)-one
Homo sapiens
-
a cell-based test system using isolated human polymorphonuclear leukocytes is applied, pH and temperature not specified in the publication
0.002
(5E)-5-(4-methoxybenzylidene)-2-phenyl-1,3-thiazol-4(5H)-one
Homo sapiens
-
a cell-based test system using isolated human polymorphonuclear leukocytes is applied, pH and temperature not specified in the publication
0.0003
(5E)-5-(4-tert-butylbenzylidene)-2-phenyl-1,3-thiazol-4(5H)-one
Homo sapiens
-
a cell-free assay utilizing the 100000g supernatant (S100) of human polymorphonuclear leukocytes (PMNL) homogenates is applied, pH and temperature not specified in the publication
0.00091
(5E)-5-(4-tert-butylbenzylidene)-2-phenyl-1,3-thiazol-4(5H)-one
Homo sapiens
-
a cell-based test system using isolated human polymorphonuclear leukocytes is applied, pH and temperature not specified in the publication
0.00019
(5E)-5-(4-[(methylperoxy)acetyl]benzylidene)-2-(4-methylphenyl)-1,3-thiazol-4(5H)-one
Homo sapiens
-
a cell-free assay utilizing the 100000g supernatant (S100) of human polymorphonuclear leukocytes (PMNL) homogenates is applied, pH and temperature not specified in the publication
0.00211
(5E)-5-(4-[(methylperoxy)acetyl]benzylidene)-2-(4-methylphenyl)-1,3-thiazol-4(5H)-one
Homo sapiens
-
a cell-based test system using isolated human polymorphonuclear leukocytes is applied, pH and temperature not specified in the publication
0.0003
(5E)-5-(5-chloro-2-hydroxy-3-methoxybenzylidene)-2-phenyl-1,3-thiazol-4(5H)-one
Homo sapiens
-
a cell-free assay utilizing the 100000g supernatant (S100) of human polymorphonuclear leukocytes (PMNL) homogenates is applied, pH and temperature not specified in the publication
0.00065
(5E)-5-(5-chloro-2-hydroxy-3-methoxybenzylidene)-2-phenyl-1,3-thiazol-4(5H)-one
Homo sapiens
-
a cell-based test system using isolated human polymorphonuclear leukocytes is applied, pH and temperature not specified in the publication
0.0003
(5E)-5-(anthracen-9-ylmethylidene)-2-phenyl-1,3-thiazol-4(5H)-one
Homo sapiens
-
a cell-free assay utilizing the 100000g supernatant (S100) of human polymorphonuclear leukocytes (PMNL) homogenates is applied, pH and temperature not specified in the publication
0.004
(5E)-5-(anthracen-9-ylmethylidene)-2-phenyl-1,3-thiazol-4(5H)-one
Homo sapiens
-
a cell-based test system using isolated human polymorphonuclear leukocytes is applied, pH and temperature not specified in the publication
0.00035
(5E)-5-benzylidene-2-(4-methylphenyl)-1,3-thiazol-4(5H)-one
Homo sapiens
-
a cell-free assay utilizing the 100000g supernatant (S100) of human polymorphonuclear leukocytes (PMNL) homogenates is applied, pH and temperature not specified in the publication
0.00073
(5E)-5-benzylidene-2-(4-methylphenyl)-1,3-thiazol-4(5H)-one
Homo sapiens
-
a cell-based test system using isolated human polymorphonuclear leukocytes is applied, pH and temperature not specified in the publication
0.02
(5E)-5-[4-(dimethylamino)benzylidene]-2-(piperidin-1-yl)-1,3-thiazol-4(5H)-one
Homo sapiens
-
a cell-based test system using isolated human polymorphonuclear leukocytes is applied, pH and temperature not specified in the publication
0.03
(5E)-5-[4-(dimethylamino)benzylidene]-2-(piperidin-1-yl)-1,3-thiazol-4(5H)-one
Homo sapiens
-
a cell-free assay utilizing the 100000g supernatant (S100) of human polymorphonuclear leukocytes (PMNL) homogenates is applied, pH and temperature not specified in the publication
0.012
(5Z)-2-(cyclohexylamino)-5-(4-propoxybenzylidene)-1,3-thiazol-4(5H)-one
Homo sapiens
-
a cell-based test system using isolated human polymorphonuclear leukocytes is applied, pH and temperature not specified in the publication
0.014
(5Z)-2-(cyclohexylamino)-5-(4-propoxybenzylidene)-1,3-thiazol-4(5H)-one
Homo sapiens
-
a cell-free assay utilizing the 100000g supernatant (S100) of human polymorphonuclear leukocytes (PMNL) homogenates is applied, pH and temperature not specified in the publication
0.03
(5Z)-5-(4-methoxybenzylidene)-2-(pyrrolidin-1-yl)-1,3-thiazol-4(5H)-one
Homo sapiens
-
a cell-based test system using isolated human polymorphonuclear leukocytes is applied, pH and temperature not specified in the publication
0.03
(5Z)-5-(4-methoxybenzylidene)-2-(pyrrolidin-1-yl)-1,3-thiazol-4(5H)-one
Homo sapiens
-
a cell-free assay utilizing the 100000g supernatant (S100) of human polymorphonuclear leukocytes (PMNL) homogenates is applied, pH and temperature not specified in the publication
0.03
(5Z)-5-(4-methylbenzylidene)-2-(naphthalen-2-ylamino)-1,3-thiazol-4(5H)-one
Homo sapiens
-
a cell-based test system using isolated human polymorphonuclear leukocytes is applied, pH and temperature not specified in the publication
0.03
(5Z)-5-(4-methylbenzylidene)-2-(naphthalen-2-ylamino)-1,3-thiazol-4(5H)-one
Homo sapiens
-
a cell-free assay utilizing the 100000g supernatant (S100) of human polymorphonuclear leukocytes (PMNL) homogenates is applied, pH and temperature not specified in the publication
0.03
(5Z)-5-benzylidene-2-(phenylamino)-1,3-thiazol-4(5H)-one
Homo sapiens
-
a cell-based test system using isolated human polymorphonuclear leukocytes is applied, pH and temperature not specified in the publication
0.03
(5Z)-5-benzylidene-2-(phenylamino)-1,3-thiazol-4(5H)-one
Homo sapiens
-
a cell-free assay utilizing the 100000g supernatant (S100) of human polymorphonuclear leukocytes (PMNL) homogenates is applied, pH and temperature not specified in the publication
0.0006
1-(2,4-difluorophenyl)-3-(3,5a,10-trimethyl-2-oxo-2,3,3a,4,5,5a,6,10,10a,10b-decahydrofuro[3',2':7,8]naphtho[2,3-d][1,3]thiazol-8-yl)urea
Homo sapiens
-
37°C, partially purified enzyme
0.007
1-(2,4-difluorophenyl)-3-(3,5a,10-trimethyl-2-oxo-2,3,3a,4,5,5a,6,10,10a,10b-decahydrofuro[3',2':7,8]naphtho[2,3-d][1,3]thiazol-8-yl)urea
Homo sapiens
-
37°C, intact polymorphonuclear leukocytes
0.0068
1-(2,4-dihydroxyphenyl)-2-(naphthalen-2-yl)ethanone
Homo sapiens
-
pH not specified in the publication, 37°C, cell-based test system
0.01
1-(2,4-dihydroxyphenyl)-2-(naphthalen-2-yl)ethanone
Homo sapiens
-
value above, pH not specified in the publication, 37°C, cell-free based test system
0.0003
1-(3-hydroxyphenyl)-3-[4-(methylsulfonyl)phenyl]prop-2-yn-1-one
Solanum tuberosum
-
in 100 mM phosphate buffer, pH 6.3, 25°C
0.3
1-(3-hydroxyphenyl)-3-[4-(methylsulfonyl)phenyl]prop-2-yn-1-one
Rattus norvegicus
-
pH and temperature not specified in the publication
0.003
1-benzyl-3-(3,5a,10-trimethyl-2-oxo-2,3,3a,4,5,5a,6,10,10a,10b-decahydrofuro[3',2':7,8]naphtho[2,3-d][1,3]thiazol-8-yl)urea
Homo sapiens
-
37°C, intact polymorphonuclear leukocytes
0.01
1-benzyl-3-(3,5a,10-trimethyl-2-oxo-2,3,3a,4,5,5a,6,10,10a,10b-decahydrofuro[3',2':7,8]naphtho[2,3-d][1,3]thiazol-8-yl)urea
Homo sapiens
-
above, 37°C, partially purified enzyme
0.001
1-[3-(methylsulfanyl)phenyl]-3-(3,5a,10-trimethyl-2-oxo-2,3,3a,4,5,5a,6,10,10a,10b-decahydrofuro[3',2':7,8]naphtho[2,3-d][1,3]thiazol-8-yl)urea
Homo sapiens
-
37°C, partially purified enzyme
0.004
1-[3-(methylsulfanyl)phenyl]-3-(3,5a,10-trimethyl-2-oxo-2,3,3a,4,5,5a,6,10,10a,10b-decahydrofuro[3',2':7,8]naphtho[2,3-d][1,3]thiazol-8-yl)urea
Homo sapiens
-
37°C, intact polymorphonuclear leukocytes
0.004
2-(2-methoxyphenyl)-N-(3,5a,10-trimethyl-2-oxo-2,3,3a,4,5,5a,6,10,10a,10b-decahydrofuro[3',2':7,8]naphtho[2,3-d][1,3]thiazol-8-yl)acetamide
Homo sapiens
-
37°C, intact polymorphonuclear leukocytes
0.01
2-(2-methoxyphenyl)-N-(3,5a,10-trimethyl-2-oxo-2,3,3a,4,5,5a,6,10,10a,10b-decahydrofuro[3',2':7,8]naphtho[2,3-d][1,3]thiazol-8-yl)acetamide
Homo sapiens
-
above, 37°C, partially purified enzyme
0.0007
2-(4-(biphenyl-4-ylamino)-6-chloropyrimidine-2-ylthio)octanoic acid
Homo sapiens
-
in intact polymorphonuclear leukocytes
0.0015
2-(4-(biphenyl-4-ylamino)-6-chloropyrimidine-2-ylthio)octanoic acid
Homo sapiens
-
purified 5-lipoxygenase
0.001
2-(4-(biphenyl-4-ylmethylamino)-6-chloropyrimidin-2-ylthio)octanoic acid
Homo sapiens
-
in intact polymorphonuclear leukocytes
0.002
2-(4-(biphenyl-4-ylmethylamino)-6-chloropyrimidin-2-ylthio)octanoic acid
Homo sapiens
-
purified 5-lipoxygenase
0.0004
2-(4-chloro-6-(4'-cyanobiphenyl-4-ylamino)pyrimidin-2-ylthio)octanoic acid
Homo sapiens
-
in intact polymorphonuclear leukocytes
0.0015
2-(4-chloro-6-(4'-cyanobiphenyl-4-ylamino)pyrimidin-2-ylthio)octanoic acid
Homo sapiens
-
purified 5-lipoxygenase
0.0005
2-(4-chloro-6-(5-methoxy-2-methylbiphenyl-4-ylamino)pyrimidin-2-ylthio)octanoic acid
Homo sapiens
-
in intact polymorphonuclear leukocytes
0.002
2-(4-chloro-6-(5-methoxy-2-methylbiphenyl-4-ylamino)pyrimidin-2-ylthio)octanoic acid
Homo sapiens
-
purified 5-lipoxygenase
0.00023
2-(4-methylphenyl)-5-(2-phenylethenylidene)-1,3-thiazol-4(5H)-one
Homo sapiens
-
a cell-free assay utilizing the 100000g supernatant (S100) of human polymorphonuclear leukocytes (PMNL) homogenates is applied, pH and temperature not specified in the publication
0.0004
2-(4-methylphenyl)-5-(2-phenylethenylidene)-1,3-thiazol-4(5H)-one
Homo sapiens
-
a cell-based test system using isolated human polymorphonuclear leukocytes is applied, pH and temperature not specified in the publication
0.0008
2-(5,8-dimethyl-7-propoxy-1,2,3,4-tetrahydronaphthalen-2-yl)-N-(5-methyl-1,3-thiazol-2-yl)propanamide
Homo sapiens
-
37°C, partially purified enzyme
0.001
2-(5,8-dimethyl-7-propoxy-1,2,3,4-tetrahydronaphthalen-2-yl)-N-(5-methyl-1,3-thiazol-2-yl)propanamide
Homo sapiens
-
37°C, intact polymorphonuclear leukocytes
0.0008
2-(5,8-dimethyl-7-propoxy-1,2,3,4-tetrahydronaphthalen-2-yl)-N-1,3-thiazol-2-ylpropanamide
Homo sapiens
-
37°C, in intact polymorphonuclear leukocytes
0.001
2-(5,8-dimethyl-7-propoxy-1,2,3,4-tetrahydronaphthalen-2-yl)-N-1,3-thiazol-2-ylpropanamide
Homo sapiens
-
37°C, partially purified enzyme
0.0009
2-(5,8-dimethyl-7-propoxy-1,2,3,4-tetrahydronaphthalen-2-yl)-N-pyridin-2-ylpropanamide
Homo sapiens
-
37°C, intact polymorphonuclear leukocytes
0.006
2-(5,8-dimethyl-7-propoxy-1,2,3,4-tetrahydronaphthalen-2-yl)-N-pyridin-2-ylpropanamide
Homo sapiens
-
37°C, partially purified enzyme
0.003
2-(5,8-dimethyl-7-propoxy-1,2,3,4-tetrahydronaphthalen-2-yl)-N-thiophen-3-ylpropanamide
Homo sapiens
-
37°C, partially purified enzyme
0.008
2-(5,8-dimethyl-7-propoxy-1,2,3,4-tetrahydronaphthalen-2-yl)-N-thiophen-3-ylpropanamide
Homo sapiens
-
37°C, intact polymorphonuclear leukocytes
0.008
2-(7-methoxy-5,8-dimethyl-1,2,3,4-tetrahydronaphthalen-2-yl)-N-(thiophen-2-ylmethyl)propanamide
Homo sapiens
-
37°C, intact polymorphonuclear leukocytes
0.01
2-(7-methoxy-5,8-dimethyl-1,2,3,4-tetrahydronaphthalen-2-yl)-N-(thiophen-2-ylmethyl)propanamide
Homo sapiens
-
37°C, partially purified enzyme
0.0008
2-(7-methoxy-5,8-dimethyl-1,2,3,4-tetrahydronaphthalen-2-yl)-N-pyridin-2-ylpropanamide
Homo sapiens
-
37°C, partially purified enzyme
0.005
2-(7-methoxy-5,8-dimethyl-1,2,3,4-tetrahydronaphthalen-2-yl)-N-pyridin-2-ylpropanamide
Homo sapiens
-
37°C, intact polymorphonuclear leukocytes
0.0008
2-(dibenzo[b,d]furan-3-yl)-5-hydroxycyclohexa-2,5-diene-1,4-dione
Homo sapiens
-
pH not specified in the publication, 37°C, cell-free based test system
0.01
2-(dibenzo[b,d]furan-3-yl)-5-hydroxycyclohexa-2,5-diene-1,4-dione
Homo sapiens
-
value above, pH not specified in the publication, 37°C, cell-based test system
0.0041
2-([4-chloro-6-[(2,3-dimethylphenyl)amino]pyrimidin-2-yl]sulfanyl)octanoic acid
Homo sapiens
-
in intact polymorphonuclear leukocytes
0.0065
2-([4-chloro-6-[(2,3-dimethylphenyl)amino]pyrimidin-2-yl]sulfanyl)octanoic acid
Homo sapiens
-
purified 5-lipoxygenase
0.01
2-benzyl-5-hydroxycyclohexa-2,5-diene-1,4-dione
Homo sapiens
-
value above, pH not specified in the publication, 37°C, cell-based test system
0.01
2-benzyl-5-hydroxycyclohexa-2,5-diene-1,4-dione
Homo sapiens
-
value above, pH not specified in the publication, 37°C, cell-free based test system
0.0014
2-hexyl-5-hydroxycyclohexa-2,5-diene-1,4-dione
Homo sapiens
-
pH not specified in the publication, 37°C, cell-free based test system
0.003
2-hexyl-5-hydroxycyclohexa-2,5-diene-1,4-dione
Homo sapiens
-
pH not specified in the publication, 37°C, cell-based test system
0.0046
2-hydroxy-5-(3-nitrophenyl)cyclohexa-2,5-diene-1,4-dione
Homo sapiens
-
pH not specified in the publication, 37°C, cell-free based test system
0.01
2-hydroxy-5-(3-nitrophenyl)cyclohexa-2,5-diene-1,4-dione
Homo sapiens
-
value above, pH not specified in the publication, 37°C, cell-based test system
0.00078
2-hydroxy-5-(naphthalen-2-ylmethyl)cyclohexa-2,5-diene-1,4-dione
Homo sapiens
-
pH not specified in the publication, 37°C, cell-free based test system
0.0023
2-hydroxy-5-(naphthalen-2-ylmethyl)cyclohexa-2,5-diene-1,4-dione
Homo sapiens
-
value above, pH not specified in the publication, 37°C, cell-based test system
0.01
2-hydroxy-5-methoxy-3-(naphthalen-2-ylmethyl)cyclohexa-2,5-diene-1,4-dione
Homo sapiens
-
value above, pH not specified in the publication, 37°C, cell-based test system
0.01
2-hydroxy-5-methoxy-3-(naphthalen-2-ylmethyl)cyclohexa-2,5-diene-1,4-dione
Homo sapiens
-
value above, pH not specified in the publication, 37°C, cell-free based test system
0.00028
2-methoxy-5-(naphthalen-2-yloxy)cyclohexa-2,5-diene-1,4-dione
Homo sapiens
-
pH not specified in the publication, 37°C, cell-free based test system
0.0067
2-methoxy-5-(naphthalen-2-yloxy)cyclohexa-2,5-diene-1,4-dione
Homo sapiens
-
pH not specified in the publication, 37°C, cell-based test system
0.00032
2-phenylethyl (2E)-3-(2,5-dihydroxyphenyl)prop-2-enoate
Homo sapiens
inhibition of 5-Lox product biosynthesis in polymorphonuclear leukocyte, 37°C, pH not specified in the publication
-
0.00033
2-phenylethyl (2E)-3-(2,5-dihydroxyphenyl)prop-2-enoate
Homo sapiens
5-Lox products biosynthesis assay, 37°C, pH not specified in the publication
-
0.0015
2-[(4-[[3,5-bis(2,2,2-trifluoroethoxy)phenyl]amino]-6-chloropyrimidin-2-yl)sulfanyl]octanoic acid
Homo sapiens
-
in intact polymorphonuclear leukocytes
0.003
2-[(4-[[3,5-bis(2,2,2-trifluoroethoxy)phenyl]amino]-6-chloropyrimidin-2-yl)sulfanyl]octanoic acid
Homo sapiens
-
purified 5-lipoxygenase
0.00068
2-[4-([[(2E)-3-phenylprop-2-enoyl]oxy]methyl)-1H-1,2,3-triazol-1-yl]ethyl (2E)-3-(3,4-dihydroxyphenyl)prop-2-enoate
Homo sapiens
-
-
0.00068
2-[4-([[(2E)-3-phenylprop-2-enoyl]oxy]methyl)-1H-1,2,3-triazol-1-yl]ethyl (2E)-3-(3,4-dihydroxyphenyl)prop-2-enoate
Homo sapiens
-
per number of caffeic acid moieties
0.001
2-[7-[2-(dimethylamino)ethoxy]-5,8-dimethyl-1,2,3,4-tetrahydronaphthalen-2-yl]-N-1,3-thiazol-2-ylpropanamide
Homo sapiens
-
37°C, partially purified enzyme
0.01
2-[7-[2-(dimethylamino)ethoxy]-5,8-dimethyl-1,2,3,4-tetrahydronaphthalen-2-yl]-N-1,3-thiazol-2-ylpropanamide
Homo sapiens
-
above, 37°C, intact polymorphonuclear leukocytes
0.01
3'-nitrobiphenyl-2,4-diol
Homo sapiens
-
value above, pH not specified in the publication, 37°C, cell-free based test system
0.01
3'-nitrobiphenyl-2,4-diol
Homo sapiens
-
value above,pH not specified in the publication, 37°C, cell-based test system
0.0009
3,4,5-trimethoxy-N-(3,5a,10-trimethyl-2-oxo-2,3,3a,4,5,5a,6,10,10a,10b-decahydrofuro[3',2':7,8]naphtho[2,3-d][1,3]thiazol-8-yl)benzamide
Homo sapiens
-
37°C, in intact polymorphonuclear leukocytes
0.01
3,4,5-trimethoxy-N-(3,5a,10-trimethyl-2-oxo-2,3,3a,4,5,5a,6,10,10a,10b-decahydrofuro[3',2':7,8]naphtho[2,3-d][1,3]thiazol-8-yl)benzamide
Homo sapiens
-
above, 37°C, partially purified enzyme
0.01
3-(cyclohexylmethyl)-2,5-dihydroxycyclohexa-2,5-diene-1,4-dione
Homo sapiens
-
value above, pH not specified in the publication, 37°C, cell-based test system
0.01
3-(cyclohexylmethyl)-2,5-dihydroxycyclohexa-2,5-diene-1,4-dione
Homo sapiens
-
value above, pH not specified in the publication, 37°C, cell-free based test system
0.00058
3-(decahydronaphthalen-2-ylmethyl)-2,5-dihydroxycyclohexa-2,5-diene-1,4-dione
Homo sapiens
-
pH not specified in the publication, 37°C, cell-based test system
0.011
3-(decahydronaphthalen-2-ylmethyl)-2,5-dihydroxycyclohexa-2,5-diene-1,4-dione
Homo sapiens
-
pH not specified in the publication, 37°C, cell-free based test system
0.01
3-benzyl-2-hydroxy-5-methoxycyclohexa-2,5-diene-1,4-dione
Homo sapiens
-
value above, pH not specified in the publication, 37°C, cell-based test system
0.01
3-benzyl-2-hydroxy-5-methoxycyclohexa-2,5-diene-1,4-dione
Homo sapiens
-
value above, pH not specified in the publication, 37°C, cell-free based test system
0.01
4-(1-benzothiophen-3-yl)benzene-1,3-diol
Homo sapiens
-
value above, pH not specified in the publication, 37°C, cell-based test system
0.01
4-(1-benzothiophen-3-yl)benzene-1,3-diol
Homo sapiens
-
value above, pH not specified in the publication, 37°C, cell-free based test system
0.0063
4-(dibenzo[b,d]furan-3-yl)benzene-1,3-diol
Homo sapiens
-
pH not specified in the publication, 37°C, cell-free based test system
0.01
4-(dibenzo[b,d]furan-3-yl)benzene-1,3-diol
Homo sapiens
-
value above, pH not specified in the publication, 37°C, cell-based test system
0.0023
4-(naphthalen-2-ylmethyl)benzene-1,3-diol
Homo sapiens
-
value above, pH not specified in the publication, 37°C, cell-based test system
0.0074
4-(naphthalen-2-ylmethyl)benzene-1,3-diol
Homo sapiens
-
pH not specified in the publication, 37°C, cell-free based test system
0.0021
4-(thianthren-2-yl)benzene-1,3-diol
Homo sapiens
-
pH not specified in the publication, 37°C, cell-based test system
0.0032
4-(thianthren-2-yl)benzene-1,3-diol
Homo sapiens
-
pH not specified in the publication, 37°C, cell-free based test system
0.009
4-benzylbenzene-1,3-diol
Homo sapiens
-
pH not specified in the publication, 37°C, cell-free based test system
0.01
4-benzylbenzene-1,3-diol
Homo sapiens
-
value above, pH not specified in the publication, 37°C, cell-based test system
0.0028
4-hexylbenzene-1,3-diol
Homo sapiens
-
value above, pH not specified in the publication, 37°C, cell-based test system
0.0046
4-hexylbenzene-1,3-diol
Homo sapiens
-
pH not specified in the publication, 37°C, cell-free based test system
0.006
4-methoxy-N-(3,5a,10-trimethyl-2-oxo-2,3,3a,4,5,5a,6,10,10a,10b-decahydrofuro[3',2':7,8]naphtho[2,3-d][1,3]thiazol-8-yl)benzamide
Homo sapiens
-
37°C, intact polymorphonuclear leukocytes
0.01
4-methoxy-N-(3,5a,10-trimethyl-2-oxo-2,3,3a,4,5,5a,6,10,10a,10b-decahydrofuro[3',2':7,8]naphtho[2,3-d][1,3]thiazol-8-yl)benzamide
Homo sapiens
-
above, 37°C, partially purified enzyme
0.01
4-methyl-N-(3,5a,10-trimethyl-2-oxo-2,3,3a,4,5,5a,6,10,10a,10b-decahydrofuro[3',2':7,8]naphtho[2,3-d][1,3]thiazol-8-yl)-1,2,3-thiadiazole-5-carboxamide
Homo sapiens
-
37°C, intact polymorphonuclear leukocytes
0.01
4-methyl-N-(3,5a,10-trimethyl-2-oxo-2,3,3a,4,5,5a,6,10,10a,10b-decahydrofuro[3',2':7,8]naphtho[2,3-d][1,3]thiazol-8-yl)-1,2,3-thiadiazole-5-carboxamide
Homo sapiens
-
above, 37°C, partially purified enzyme
0.009
6-[(4-hydroxy-3,6-dioxocyclohexa-1,4-dien-1-yl)methyl]naphthalene-2-carboxylic acid
Homo sapiens
-
pH not specified in the publication, 37°C, cell-free based test system
0.01
6-[(4-hydroxy-3,6-dioxocyclohexa-1,4-dien-1-yl)methyl]naphthalene-2-carboxylic acid
Homo sapiens
-
value above, pH not specified in the publication, 37°C, cell-based test system
0.0026
AA861
Rattus norvegicus
-
IC50: 0.0026 mM
0.004 - 0.01
AA861
Sus scrofa
-
i.e. 2-(12-hydroxydodeca-5,10-diynyl)-3,5,6-trimethyl-1,4-benzoquinone, IC50: 0.004-0.01 mM
0.00029
baicalein
Homo sapiens
pH 7.4, 37°C
0.0012
baicalein
Rattus norvegicus
-
IC50: 0.0012 mM
0.00013
benzyl 2-(3-chlorobenzyl)-5-hydroxy-1H-benzo[g]indole-3-carboxylate
Homo sapiens
-
recombinant 5-lipoxygenase
0.00035
benzyl 2-(3-chlorobenzyl)-5-hydroxy-1H-benzo[g]indole-3-carboxylate
Homo sapiens
-
5-lipoxygenase inhibited in neutrophils
0.00017
benzyl 2-(4-chlorobenzyl)-5-hydroxy-1H-benzo[g]indole-3-carboxylate
Homo sapiens
-
recombinant 5-lipoxygenase
0.00048
benzyl 2-(4-chlorobenzyl)-5-hydroxy-1H-benzo[g]indole-3-carboxylate
Homo sapiens
-
5-lipoxygenase inhibited in neutrophils
0.0028
biphenyl-2,4-diol
Homo sapiens
-
pH not specified in the publication, 37°C, cell-free based test system
0.0042
biphenyl-2,4-diol
Homo sapiens
-
pH not specified in the publication, 37°C, cell-based test system
0.004 - 0.015
BW755C
Sus scrofa
-
IC50: 0.004-0.015 mM
0.013
BW755C
Homo sapiens
-
i.e. 3-amino-1-[3-(trifluoromethyl)phenyl]-2-pyrazoline, IC50: 0.013 mM
0.53
BW755C
Rattus norvegicus
-
IC50: 0.53 mM
0.004
caffeic acid
Solanum tuberosum
-
-
0.004
caffeic acid
Solanum tuberosum
-
pH and temperature not specified in the publication
0.025
caffeic acid
Homo sapiens
-
-
0.046
caffeic acid
Rattus norvegicus
-
IC50: 0.046 mM
0.00065
ethyl 1-benzyl-2-(4-chlorobenzyl)-5-hydroxy-1H-benzo[g]indole-3-carboxylate
Homo sapiens
-
recombinant 5-lipoxygenase
0.0018
ethyl 1-benzyl-2-(4-chlorobenzyl)-5-hydroxy-1H-benzo[g]indole-3-carboxylate
Homo sapiens
-
5-lipoxygenase inhibited in neutrophils
0.000097
ethyl 2-(2-chlorobenzyl)-5-hydroxy-1H-benzo[g]indole-3-carboxylate
Homo sapiens
-
recombinant 5-lipoxygenase
0.0012
ethyl 2-(2-chlorobenzyl)-5-hydroxy-1H-benzo[g]indole-3-carboxylate
Homo sapiens
-
5-lipoxygenase inhibited in neutrophils
0.0016
ethyl 2-(2-chlorobenzyl)-5-hydroxy-1H-indole-3-carboxylate
Homo sapiens
-
recombinant 5-lipoxygenase
0.0017
ethyl 2-(2-chlorobenzyl)-5-hydroxy-1H-indole-3-carboxylate
Homo sapiens
-
5-lipoxygenase inhibited in neutrophils
0.00015
ethyl 2-(3-bromobenzyl)-5-hydroxy-1H-benzo[g]indole-3-carboxylate
Homo sapiens
-
recombinant 5-lipoxygenase
0.00045
ethyl 2-(3-bromobenzyl)-5-hydroxy-1H-benzo[g]indole-3-carboxylate
Homo sapiens
-
5-lipoxygenase inhibited in neutrophils
0.000086
ethyl 2-(3-chlorobenzyl)-5-hydroxy-1H-benzo[g]indole-3-carboxylate
Homo sapiens
-
recombinant 5-lipoxygenase
0.00023
ethyl 2-(3-chlorobenzyl)-5-hydroxy-1H-benzo[g]indole-3-carboxylate
Homo sapiens
-
5-lipoxygenase inhibited in neutrophils
0.0017
ethyl 2-(3-chlorobenzyl)-5-hydroxy-1H-indole-3-carboxylate
Homo sapiens
-
5-lipoxygenase inhibited in neutrophils
0.002
ethyl 2-(3-chlorobenzyl)-5-hydroxy-1H-indole-3-carboxylate
Homo sapiens
-
recombinant 5-lipoxygenase
0.00058
ethyl 2-(3-chlorobenzyl)-5-hydroxy-1H-pyrrolo[2,3-f]quinoline-3-carboxylate
Homo sapiens
-
recombinant 5-lipoxygenase
0.0043
ethyl 2-(3-chlorobenzyl)-5-hydroxy-1H-pyrrolo[2,3-f]quinoline-3-carboxylate
Homo sapiens
-
5-lipoxygenase inhibited in neutrophils
0.0012
ethyl 2-(3-chlorobenzyl)-5-hydroxy-6-phenyl-1H-indole-3-carboxylate
Homo sapiens
-
recombinant 5-lipoxygenase
0.0057
ethyl 2-(3-chlorobenzyl)-5-hydroxy-6-phenyl-1H-indole-3-carboxylate
Homo sapiens
-
5-lipoxygenase inhibited in neutrophils
0.01
ethyl 2-(3-chlorobenzyl)-5-methoxy-1-methyl-1H-benzo[g]-indole-3-carboxylate
Homo sapiens
-
recombinant 5-lipoxygenase
0.03
ethyl 2-(3-chlorobenzyl)-5-methoxy-1-methyl-1H-benzo[g]-indole-3-carboxylate
Homo sapiens
-
5-lipoxygenase inhibited in neutrophils
0.03
ethyl 2-(3-chlorobenzyl)-5-phenyl-1H-benzo[g]indole-3-carboxylate
Homo sapiens
-
5-lipoxygenase inhibited in neutrophils
0.03
ethyl 2-(3-chlorobenzyl)-5-phenyl-1H-benzo[g]indole-3-carboxylate
Homo sapiens
-
recombinant 5-lipoxygenase
0.007
ethyl 2-(3-chlorobenzyl)-7,8-dimethoxy-5-hydroxy-1H-benzo[g]indole-3-carboxylate
Homo sapiens
-
5-lipoxygenase inhibited in neutrophils
0.01
ethyl 2-(3-chlorobenzyl)-7,8-dimethoxy-5-hydroxy-1H-benzo[g]indole-3-carboxylate
Homo sapiens
-
recombinant 5-lipoxygenase
0.000045
ethyl 2-(3-chlorophenyl)-5-hydroxy-1H-benzo[g]indole-3-carboxylate
Homo sapiens
-
recombinant 5-lipoxygenase
0.00052
ethyl 2-(3-chlorophenyl)-5-hydroxy-1H-benzo[g]indole-3-carboxylate
Homo sapiens
-
5-lipoxygenase inhibited in neutrophils
0.0033
ethyl 2-(3-chlorophenyl)-5-hydroxy-1H-indole-3-carboxylate
Homo sapiens
-
5-lipoxygenase inhibited in neutrophils
0.0048
ethyl 2-(3-chlorophenyl)-5-hydroxy-1H-indole-3-carboxylate
Homo sapiens
-
recombinant 5-lipoxygenase
0.00014
ethyl 2-(3-fluorobenzyl)-5-hydroxy-1H-benzo[g]indole-3-carboxylate
Homo sapiens
-
recombinant 5-lipoxygenase
0.00034
ethyl 2-(3-fluorobenzyl)-5-hydroxy-1H-benzo[g]indole-3-carboxylate
Homo sapiens
-
5-lipoxygenase inhibited in neutrophils
0.00013
ethyl 2-(3-methoxybenzyl)-5-hydroxy-1H-benzo[g]indole-3-carboxylate
Homo sapiens
-
recombinant 5-lipoxygenase
0.00052
ethyl 2-(3-methoxybenzyl)-5-hydroxy-1H-benzo[g]indole-3-carboxylate
Homo sapiens
-
5-lipoxygenase inhibited in neutrophils
0.000095
ethyl 2-(4-bromobenzyl)-5-hydroxy-1H-benzo[g]indole-3-carboxylate
Homo sapiens
-
recombinant 5-lipoxygenase
0.0006
ethyl 2-(4-bromobenzyl)-5-hydroxy-1H-benzo[g]indole-3-carboxylate
Homo sapiens
-
5-lipoxygenase inhibited in neutrophils
0.000084
ethyl 2-(4-chlorobenzyl)-5-hydroxy-1H-benzo[g]indole-3-carboxylate
Homo sapiens
-
recombinant 5-lipoxygenase
0.0012
ethyl 2-(4-chlorobenzyl)-5-hydroxy-1H-benzo[g]indole-3-carboxylate
Homo sapiens
-
5-lipoxygenase inhibited in neutrophils
0.0007
ethyl 2-(4-chlorobenzyl)-5-hydroxy-1H-indole-3-carboxylate
Homo sapiens
-
5-lipoxygenase inhibited in neutrophils
0.0012
ethyl 2-(4-chlorobenzyl)-5-hydroxy-1H-indole-3-carboxylate
Homo sapiens
-
recombinant 5-lipoxygenase
0.000067
ethyl 2-(4-chlorophenyl)-5-hydroxy-1H-benzo[g]indole-3-carboxylate
Homo sapiens
-
recombinant 5-lipoxygenase
0.00032
ethyl 2-(4-chlorophenyl)-5-hydroxy-1H-benzo[g]indole-3-carboxylate
Homo sapiens
-
5-lipoxygenase inhibited in neutrophils
0.002
ethyl 2-(4-chlorophenyl)-5-hydroxy-1H-indole-3-carboxylate
Homo sapiens
-
5-lipoxygenase inhibited in neutrophils
0.0021
ethyl 2-(4-chlorophenyl)-5-hydroxy-1H-indole-3-carboxylate
Homo sapiens
-
recombinant 5-lipoxygenase
0.000096
ethyl 2-(4-fluorobenzyl)-5-hydroxy-1H-benzo[g]indole-3-carboxylate
Homo sapiens
-
recombinant 5-lipoxygenase
0.0005
ethyl 2-(4-fluorobenzyl)-5-hydroxy-1H-benzo[g]indole-3-carboxylate
Homo sapiens
-
5-lipoxygenase inhibited in neutrophils
0.00015
ethyl 2-(4-methoxybenzyl)-5-hydroxy-1H-benzo[g]indole-3-carboxylate
Homo sapiens
-
recombinant 5-lipoxygenase
0.00065
ethyl 2-(4-methoxybenzyl)-5-hydroxy-1H-benzo[g]indole-3-carboxylate
Homo sapiens
-
5-lipoxygenase inhibited in neutrophils
0.00025
ethyl 2-(4-trifluoromethylbenzyl)-5-hydroxy-1H-benzo[g]indole-3-carboxylate
Homo sapiens
-
recombinant 5-lipoxygenase
0.0017
ethyl 2-(4-trifluoromethylbenzyl)-5-hydroxy-1H-benzo[g]indole-3-carboxylate
Homo sapiens
-
5-lipoxygenase inhibited in neutrophils
0.0003
ethyl 2-[(3-chlorophenyl)-amino]-5-hydroxy-1H-indole-3-carboxylate
Homo sapiens
-
recombinant 5-lipoxygenase
0.0003
ethyl 2-[(3-chlorophenyl)-amino]-5-hydroxy-1H-indole-3-carboxylate
Homo sapiens
pH 7.4, 37°C, cell-free enzyme extract
0.0024
ethyl 2-[(3-chlorophenyl)-amino]-5-hydroxy-1H-indole-3-carboxylate
Homo sapiens
-
5-lipoxygenase inhibited in neutrophils
0.000031
ethyl 2-[2-(3-chlorophenyl)ethyl]-5-hydroxy-1H-benzo[g]indole-3-carboxylate
Homo sapiens
-
recombinant 5-lipoxygenase
0.00049
ethyl 2-[2-(3-chlorophenyl)ethyl]-5-hydroxy-1H-benzo[g]indole-3-carboxylate
Homo sapiens
-
5-lipoxygenase inhibited in neutrophils
0.0017
ethyl 2-[2-(3-chlorophenyl)ethyl]-5-hydroxy-1H-indole-3-carboxylate
Homo sapiens
-
recombinant 5-lipoxygenase
0.0028
ethyl 2-[2-(3-chlorophenyl)ethyl]-5-hydroxy-1H-indole-3-carboxylate
Homo sapiens
-
5-lipoxygenase inhibited in neutrophils
0.000049
ethyl 2-[2-(4-chlorophenyl)ethyl]-5-hydroxy-1H-benzo[g]indole-3-carboxylate
Homo sapiens
-
recombinant 5-lipoxygenase
0.0028
ethyl 2-[2-(4-chlorophenyl)ethyl]-5-hydroxy-1H-benzo[g]indole-3-carboxylate
Homo sapiens
-
5-lipoxygenase inhibited in neutrophils
0.0007
ethyl 2-[2-(4-chlorophenyl)ethyl]-5-hydroxy-1H-indole-3-carboxylate
Homo sapiens
-
recombinant 5-lipoxygenase
0.0039
ethyl 2-[2-(4-chlorophenyl)ethyl]-5-hydroxy-1H-indole-3-carboxylate
Homo sapiens
-
5-lipoxygenase inhibited in neutrophils
0.0006
ethyl 2-[[4-chloro-6-(quinolin-6-ylamino)pyrimidin-2-yl]sulfanyl]octanoate
Homo sapiens
-
in intact polymorphonuclear leukocytes
0.019
ethyl 2-[[4-chloro-6-(quinolin-6-ylamino)pyrimidin-2-yl]sulfanyl]octanoate
Homo sapiens
-
purified 5-lipoxygenase
0.0034
ethyl 5-benzoyloxy-2-(3-chlorobenzyl)-1H-benzo[g]indole-3-carboxylate
Homo sapiens
-
recombinant 5-lipoxygenase
0.01
ethyl 5-benzoyloxy-2-(3-chlorobenzyl)-1H-benzo[g]indole-3-carboxylate
Homo sapiens
-
5-lipoxygenase inhibited in neutrophils
0.0055
ethyl 5-hydroxy-2-phenylethyl-1H-indole-3-carboxylate
Homo sapiens
-
5-lipoxygenase inhibited in neutrophils
0.0073
ethyl 5-hydroxy-2-phenylethyl-1H-indole-3-carboxylate
Homo sapiens
-
recombinant 5-lipoxygenase
0.00013
ethyl 5-hydroxy-2-phenylpropyl-1H-benzo[g]indole-3-carboxylate
Homo sapiens
-
recombinant 5-lipoxygenase
0.00044
ethyl 5-hydroxy-2-phenylpropyl-1H-benzo[g]indole-3-carboxylate
Homo sapiens
-
5-lipoxygenase inhibited in neutrophils
0.00033
ethyl 6-biphenyl-4-yl-(3-chlorobenzyl)-5-hydroxy-1H-indole-3-carboxylate
Homo sapiens
-
recombinant 5-lipoxygenase
0.0028
ethyl 6-biphenyl-4-yl-(3-chlorobenzyl)-5-hydroxy-1H-indole-3-carboxylate
Homo sapiens
-
5-lipoxygenase inhibited in neutrophils
0.0003 - 0.0004
L-656,224
Sus scrofa
-
IC50: 0.0003-0.0004 mM
0.0008
L-656,224
Homo sapiens
-
i.e. 7-chloro-2-[(4-methoxyphenyl)-methyl]-3-methyl-5-propyl-4-benzofuranol, IC50: 0.0008 mM
0.00058
methyl (4-[(5E)-5-(4-methoxybenzylidene)-4-oxo-4,5-dihydro-1,3-thiazol-2-yl]phenoxy)acetate
Homo sapiens
-
a cell-free assay utilizing the 100000g supernatant (S100) of human polymorphonuclear leukocytes (PMNL) homogenates is applied, pH and temperature not specified in the publication
0.00086
methyl (4-[(5E)-5-(4-methoxybenzylidene)-4-oxo-4,5-dihydro-1,3-thiazol-2-yl]phenoxy)acetate
Homo sapiens
-
a cell-based test system using isolated human polymorphonuclear leukocytes is applied, pH and temperature not specified in the publication
0.03
methyl 2-(allylamino)-1H-indole-3-carboxylate
Homo sapiens
-
5-lipoxygenase inhibited in neutrophils
0.03
methyl 2-(allylamino)-1H-indole-3-carboxylate
Homo sapiens
-
recombinant 5-lipoxygenase
0.0034
methyl 2-(benzylamino)-1H-indole-3-carboxylate
Homo sapiens
-
recombinant 5-lipoxygenase
0.004
methyl 2-(benzylamino)-1H-indole-3-carboxylate
Homo sapiens
-
5-lipoxygenase inhibited in neutrophils
0.0069
methyl 2-(diallylamino)-1H-indole-3-carboxylate
Homo sapiens
-
recombinant 5-lipoxygenase
0.0125
methyl 2-(diallylamino)-1H-indole-3-carboxylate
Homo sapiens
-
5-lipoxygenase inhibited in neutrophils
0.0098
methyl 2-[(2-chlorophenyl)amino]-1H-indole-3-carboxylate
Homo sapiens
-
5-lipoxygenase inhibited in neutrophils
0.0102
methyl 2-[(2-chlorophenyl)amino]-1H-indole-3-carboxylate
Homo sapiens
-
recombinant 5-lipoxygenase
0.0035
methyl 2-[(3-bromophenyl)amino]-1H-indole-3-carboxylate
Homo sapiens
-
5-lipoxygenase inhibited in neutrophils
0.0083
methyl 2-[(3-bromophenyl)amino]-1H-indole-3-carboxylate
Homo sapiens
-
recombinant 5-lipoxygenase
0.0065
methyl 2-[(3-chlorophenyl)amino]-1H-indole-3-carboxylate
Homo sapiens
-
5-lipoxygenase inhibited in neutrophils
0.0081
methyl 2-[(3-chlorophenyl)amino]-1H-indole-3-carboxylate
Homo sapiens
-
recombinant 5-lipoxygenase
0.0035
methyl 2-[(3-chlorophenyl)amino]-5-chloro-1H-indole-3-carboxylate
Homo sapiens
-
recombinant 5-lipoxygenase
0.0055
methyl 2-[(3-chlorophenyl)amino]-5-chloro-1H-indole-3-carboxylate
Homo sapiens
-
5-lipoxygenase inhibited in neutrophils
0.0079
methyl 2-[(3-fluorophenyl)amino]-1H-indole-3-carboxylate
Homo sapiens
-
5-lipoxygenase inhibited in neutrophils
0.0134
methyl 2-[(3-fluorophenyl)amino]-1H-indole-3-carboxylate
Homo sapiens
-
recombinant 5-lipoxygenase
0.0072
methyl 2-[(4-chlorophenyl)amino]-1H-indole-3-carboxylate
Homo sapiens
-
5-lipoxygenase inhibited in neutrophils
0.0098
methyl 2-[(4-chlorophenyl)amino]-1H-indole-3-carboxylate
Homo sapiens
-
recombinant 5-lipoxygenase
0.002
N-(3,5a,10-trimethyl-2-oxo-2,3,3a,4,5,5a,6,10,10a,10b-decahydrofuro[3',2':7,8]naphtho[2,3-d][1,3]thiazol-8-yl)-1,3-benzodioxole-5-carboxamide
Homo sapiens
-
37°C, intact polymorphonuclear leukocytes
0.01
N-(3,5a,10-trimethyl-2-oxo-2,3,3a,4,5,5a,6,10,10a,10b-decahydrofuro[3',2':7,8]naphtho[2,3-d][1,3]thiazol-8-yl)-1,3-benzodioxole-5-carboxamide
Homo sapiens
-
above, 37°C, partially purified enzyme
0.008
N-(3,5a,10-trimethyl-2-oxo-2,3,3a,4,5,5a,6,10,10a,10b-decahydrofuro[3',2':7,8]naphtho[2,3-d][1,3]thiazol-8-yl)cyclopentanecarboxamide
Homo sapiens
-
37°C, intact polymorphonuclear leukocytes
0.01
N-(3,5a,10-trimethyl-2-oxo-2,3,3a,4,5,5a,6,10,10a,10b-decahydrofuro[3',2':7,8]naphtho[2,3-d][1,3]thiazol-8-yl)cyclopentanecarboxamide
Homo sapiens
-
37°C, partially purified enzyme
0.000038
N-(3-phenoxycinnamyl)-acetohydroxamic acid
Homo sapiens
-
recombinant 5-lipoxygenase
0.00016
N-(3-phenoxycinnamyl)-acetohydroxamic acid
Homo sapiens
-
5-lipoxygenase inhibited in neutrophils
0.0009
N-(furan-2-ylmethyl)-2-(7-methoxy-5,8-dimethyl-1,2,3,4-tetrahydronaphthalen-2-yl)propanamide
Homo sapiens
-
37°C, partially purified enzyme
0.01
N-(furan-2-ylmethyl)-2-(7-methoxy-5,8-dimethyl-1,2,3,4-tetrahydronaphthalen-2-yl)propanamide
Homo sapiens
-
above, 37°C, intact polymorphonuclear leukocytes
0.01
N-cyclopentyl-2-[7-(2-methoxyethoxy)-5,8-dimethyl-1,2,3,4-tetrahydronaphthalen-2-yl]propanamide
Homo sapiens
-
above, 37°C, intact polymorphonuclear leukocytes
0.01
N-cyclopentyl-2-[7-(2-methoxyethoxy)-5,8-dimethyl-1,2,3,4-tetrahydronaphthalen-2-yl]propanamide
Homo sapiens
-
above, 37°C, partially purified enzyme
0.00005
N-hydroxy-N-[(2E)-3-(3-phenoxyphenyl)prop-2-en-1-yl]acetamide
Homo sapiens
-
a cell-free assay utilizing the 100000g supernatant (S100) of human polymorphonuclear leukocytes (PMNL) homogenates is applied, pH and temperature not specified in the publication
0.00008
N-hydroxy-N-[(2E)-3-(3-phenoxyphenyl)prop-2-en-1-yl]acetamide
Homo sapiens
-
a cell-based test system using isolated human polymorphonuclear leukocytes is applied, pH and temperature not specified in the publication
0.00011
N-hydroxy-N-[(2E)-3-(3-phenoxyphenyl)prop-2-en-1-yl]acetamide
Homo sapiens
-
in intact polymorphonuclear leukocytes
0.00016
N-hydroxy-N-[(2E)-3-(3-phenoxyphenyl)prop-2-en-1-yl]acetamide
Homo sapiens
-
purified 5-lipoxygenase
0.15
N-hydroxy-N-[(2E)-3-(3-phenoxyphenyl)prop-2-en-1-yl]acetamide
Rattus norvegicus
-
pH and temperature not specified in the publication
0.004
N-tert-butyl-2-(7-methoxy-5,8-dimethyl-1,2,3,4-tetrahydronaphthalen-2-yl)propanamide
Homo sapiens
-
37°C, partially purified enzyme
0.01
N-tert-butyl-2-(7-methoxy-5,8-dimethyl-1,2,3,4-tetrahydronaphthalen-2-yl)propanamide
Homo sapiens
-
above, 37°C, intact polymorphonuclear leukocytes
0.00009
nordihydroguaiaretic acid
Homo sapiens
-
pH 7.5, 37°C, assay method via fluorescence measurement
0.001
nordihydroguaiaretic acid
Bos taurus
-
-
0.0015
nordihydroguaiaretic acid
Solanum tuberosum
-
-
0.0125
nordihydroguaiaretic acid
Glycine max
-
pH 7.0, 25°C
0.00021
nordihydroguiaraetic acid
Rattus norvegicus
-
IC50: 0.00021 mM
0.0365
nordihydroguiaraetic acid
Solanum tuberosum
-
IC50 for reaction with linoleic acid: 0.17 mM, IC50 for reaction with arachidonic acid: 0.0365 mM
0.0003 - 0.0005
quercetin
Sus scrofa
-
IC50: 0.0003-0.0005 mM
0.0021
quercetin
Rattus norvegicus
-
IC50: 0.0021 mM
0.00012 - 0.00092
zileuton
Homo sapiens
-
pH 7.5, 37°C, dependent on assay method via fluorescence or UV measurement
0.00028
zileuton
Rattus norvegicus
-
in 50 mM Tris-HCl buffer (pH 7.4) containing 0.4 mM CaCl2+ , 0.024 mg/ml alpha-phosphatidylcholine and 0.02 mM ATP, at 22°C
0.0008
zileuton
Homo sapiens
pH 7.5, 25°C
0.0008
zileuton
Homo sapiens
-
recombinant 5-lipoxygenase
0.00083
zileuton
Rattus norvegicus
-
0.0009
zileuton
Homo sapiens
-
5-lipoxygenase inhibited in neutrophils
0.0011
zileuton
Homo sapiens
-
IC50: 0.0038 mM with recombinant enzyme, IC50: 0.0011 mM with native enzyme
0.0023
zileuton
Homo sapiens
inhibition of 5-Lox product biosynthesis in polymorphonuclear leukocyte, 37°C, pH not specified in the publication
0.01
zileuton
Homo sapiens
-
IC50: 0.01 mM
0.0156
zileuton
Solanum tuberosum
-
pH 7.4, temperature not specified in the publication
0.00074
[1-(2-[[(2E)-3-phenylprop-2-enoyl]oxy]ethyl)-1H-1,2,3-triazol-4-yl]methyl (2E)-3-(3,4-dihydroxyphenyl)prop-2-enoate
Homo sapiens
-
-
0.00148
[1-(2-[[(2E)-3-phenylprop-2-enoyl]oxy]ethyl)-1H-1,2,3-triazol-4-yl]methyl (2E)-3-(3,4-dihydroxyphenyl)prop-2-enoate
Homo sapiens
-
per number of caffeic acid moieties
additional information
additional information
Homo sapiens
-
enzyme inhibition in presence of inhibitor and glutathione peroxidase, overview
-
additional information
additional information
Homo sapiens
-
inhibitory activity in polymorphonuclear leukocytes, overview
-
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.